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ABSTRACT
Saccharomyces cerevisiae stimulates dendritic cells and represents a promising candidate
for cancer immunotherapy development. Effective cross-presentation of antigen delivered to
dendritic cells is necessary for successful induction of cellular immunity. Using a yeast vaccine
model, we investigated the phagosome-to-cytosol pathway of cross-presentation. We
demonstrate that the rate of antigen release from phagocytosed yeast directly affects cross-
presentation efficiency, with an apparent time limit of about 25 min post-phagocytosis for
antigen release to be productive. Antigen expressed on the yeast surface is cross-presented much
more efficiently than antigen trapped in the yeast cytosol by the cell wall. The cross-presentation
efficiency of yeast surface-displayed antigen can be increased by the insertion of linkers
susceptible to cleavage in the early phagosome. Antigens indirectly attached to yeast through
antibody fragments are less efficiently cross-presented when the antibody dissociation rate is
extremely slow.
Next, we present a yeast-based cancer vaccine approach that is independent of yeast's
ability to express the chosen antigen, which is instead produced separately and conjugated to the
yeast cell wall. The conjugation method is site-specific (based on the SNAP-tag) and designed to
facilitate antigen release in the dendritic cell phagosome and subsequent translocation for cross-
presentation. Phagosomal antigen release was further expedited through the insertion of the
invariant chain ectodomain as a linker, which is rapidly cleaved by Cathepsin S. The dose of
delivered antigen was increased in several ways: by using yeast strains with higher surface amine
densities, by using yeast cell wall fragments instead of whole cells, and by conjugating multiple
layers of antigen. The novel multi-layer conjugation scheme is site-specific and takes advantage
of Sfp phosphopantetheinyl transferase, enabling the antigen dose to grow linearly. We show that
whole yeast cells coated with one layer of the cancer-testis antigen NY-ESO-1 and yeast hulls
bearing three layers were able to cross-prime na've CD8 + T cells in vitro, with the latter resulting
in higher frequencies of antigen-specific cells after ten days. This cross-presentation-efficient
antigen conjugation scheme is not limited to yeast and can readily be applied towards the
development of other particulate vaccines.
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Chapter 1
Introduction
1.1 Cancer Immunotherapy
The idea that the immune system defends the body from not just infections but also
cancer is almost one century old (1). Since then, extensive data has been collected showing that
immunodeficient mice are particularly susceptible to both carcinogen-induced and spontaneous
tumors (2). Three lines of evidence support the role of cancer immunosurveillance in humans
(reviewed in (3)). First, the incidence of cancer is elevated in immunodeficient individuals and in
immunosuppressed transplant recipients. Second, some cancer patients have developed
detectable humoral or cellular responses against their own tumors, demonstrating that the
immune system can differentiate between normal and transformed cells and leading to the
discovery of hundreds of tumor-associated antigens (TAAs). Third, numerous studies have
demonstrated a positive correlation between the presence of tumor-infiltrating lymphocytes and
patient prognosis, suggesting that anti-tumor immune responses are not merely incidental but can
be protective. The growing field of cancer immunotherapy addresses the challenge of harnessing
the immune system to treat cancer.
Cancer immunotherapy may be classified into passive and active strategies. In passive
immunotherapy, the effectors of immunity-antibodies, cytokines, or even T cells-are
generated outside the body for introduction into the patient. The goal of active immunotherapy,
or cancer vaccination, is to stimulate the body into mounting an adaptive immune response
against one or more TAAs. While passive immunotherapy technology is more mature, with
multiple monoclonal antibodies and cytokines already on the market, the elusive allure of cancer
vaccines lies in their potential ability to confer long-lasting protection against tumor recurrence.
Amongst the immune system's arsenal, cytotoxic T lymphocytes (CTLs) are the most direct
weapon against tumor cells. Humoral immunity is limited to cell membrane-expressed targets
and the therapeutic effects mediated by growth inhibition, antibody-dependent cytotoxicity and
complement-dependent cytotoxicity vary considerably between antibodies (4). Therefore,
understanding how professional antigen-presenting cells (APCs) trigger T cell activation is
critical to cancer vaccine development.
Dendritic cells (DCs) have been described as "nature's best APCs" (5) and until recently
were thought to be the only APCs known to activate naive T cells (6). Since the immune system
often appears to be ignorant of tumor antigens, especially in early stage solid tumors (7), DCs are
crucial to the success of cancer vaccines. In their immature state, DCs reside in the blood and
peripheral tissues, constantly sampling the microenvironment for antigens. In the absence of
infection or inflammation, small numbers of these resting DCs travel to secondary lymphoid
organs to contribute towards peripheral tolerance of self-antigens. In the presence of an infection,
DCs mature in response to inflammatory stimuli and pathogen-associated "danger signals". They
migrate to the draining lymph nodes to present foreign antigen, thus stimulating lymphocyte
proliferation. The two-signal model of lymphocyte activation explains how such different
outcomes can arise from DC-T cell interaction. In this model, mature DCs presenting both
peptide-MHC complexes (signal 1) and costimulatory molecules (signal 2) to T cells stimulate
proliferation, whereas immature DCs presenting signal 1 without signal 2 induce T cell anergy.
This model has been refined over time but it remains the prevailing paradigm. In a striking
demonstration by Dhodapkar et al., injection of immature DCs pulsed with influenza matrix
peptide inhibited CTL function in human volunteers, whereas mature DCs pulsed with the same
antigen boosted the number of specific CTLs (8). Therefore, DC maturation status and the choice
of adjuvants warrant special consideration in cancer vaccine design, particularly when pre-
existing immune tolerance to tumors has to be overcome (9).
1.2 The Cancer Vaccine Landscape
Historically, non-specific stimulators of the immune system have been reported to be
beneficial in treating cancer, beginning with Coley's toxins in the 1890s. William Coley
developed a mixture of two heat-killed bacterial strains to treat bone sarcoma, which was widely
used until radiation therapy and chemotherapy emerged (10). Bacillus Calmette-Guerin (BCG,
inactivated tuberculosis bacteria) is still part of the standard of care for superficial bladder cancer.
The cytokines IFN-a and IL-2 are FDA-approved treatments for specific types of cancers. While
all these treatments are thought to boost the immune response against cancer, they are not true
cancer vaccines in that they are not targeted against TAAs. Gardasil® is sometimes described as
the first cancer vaccine on the market, but it is really a vaccine preventing infection by certain
strains of human papillomavirus and will neither prevent nor treat cervical cancer in individuals
already infected. Despite intense research and optimism, no cancer vaccines have been approved
until very recently, and none by the FDA. In April 2008, Oncophage@, peptide-heat shock
protein complexes isolated from each patient's tumor cells, was approved to treat renal cell
carcinoma in Russia. In May, OncoVAX®, a preparation made from irradiated autologous tumor
cells, was licensed to be commercialized in Switzerland followed by seven Eastern European
countries.
Many different strategies for cancer vaccination are under investigation. Before TAAs
were identified, whole tumor cells (often irradiated) and tumor cell lysates were used. Early
efforts to increase their immunogenicity centered on genetic engineering of the tumor cells to
express cytokines, MHC molecules and costimulatory molecules (11, 12). Vaccines made from
autologous tumor cells remain attractive because they are personalized and contain a wider
variety of antigens (including unidentified antigens and those bearing unique mutations);
however, obtaining enough cells can be difficult and the risk of an autoimmune response may be
higher than when only defined TAAs are present (13).
SEREX (serological identification of antigens by recombinant expression cloning (14))
and other methods to discover TAAs opened up the floodgates for the development of a new
generation of cancer vaccines. Synthetic peptides representing T cell epitopes are relatively easy
to produce and thus have been widely studied in clinical trials. To increase immunogenicity,
peptide vaccines are frequently co-administered with cytokines, "classical" adjuvants (e.g. alum,
incomplete Freund's adjuvant) or Toll-like receptor ligands mimicking danger signals from
pathogens. Although peptide vaccination frequently results in marked expansion of specific
CD8+ T cells, up to 5-10% of circulating CD8+ T cells in some cases, clinical responses have
been disappointing (15). Often, the expanded T cells have low avidity and recognize peptide-
pulsed target cells but not unmodified tumor cells with lower surface levels of the peptide-MHC;
this problem is thought to arise because peptide vaccination results in APCs with unusually high
surface levels of peptide-MHC complexes that then activate these "low quality" CTLs (16).
Ironically, the fact that minimal peptide-epitope vaccines do not need to be processed by APCs
may turn out to be problematic rather than advantageous. Other issues with peptide vaccines
include the narrow immune response (easily evaded by tumors) and the lack of helper epitopes.
Recombinant proteins representing full-length TAAs or parts thereof partially address these
problems. Like peptides, they do not inherently mature DCs and have to be combined with one
or more adjuvants. Recombinant proteins may also be produced as fusions to sequences with a
variety of functions, such as antibodies against DC receptors (17), heat shock proteins (18),
protein transduction domains (19), the bacterial danger signal flagellin (20) and chemokines (21).
Another tactic to increase the efficacy of protein vaccines is to mix them with antibodies to form
immune complexes that both mature DCs and enhance uptake by interaction with Fc receptors
(22, 23); this is also applicable to whole cell vaccines (24).
Recombinant proteins can be expensive to produce and purify and have a limited shelf-
life. DNA vaccination is a cheaper and more stable alternative, whereby genes encoding TAAs
are introduced into the body, usually in the form of plasmids. The TAAs may be expressed and
processed directly in DCs or they may be expressed or secreted by other cell types prior to
uptake by DCs. Much of the research in DNA vaccine development focuses on ways to increase
transfection efficiency and transgene expression levels, in particular, by using different delivery
methods such as injection, electroporation or particle bombardment of naked DNA or the
delivery of DNA complexed with polymers or lipids (25). Molecular adjuvants such as cytokines
and chemokines may be encoded on the same or separate plasmid.
Viral vaccines are another way to deliver TAA genes, typically with much higher
transfection rates than those achieved by non-viral methods. Although recombinant viruses are
much more difficult to manufacture than plasmid DNA, they by nature contain or induce danger
signals and are adept at entering cells. The advantages and disadvantages of various viral vectors,
including vaccinia, fowlpox and adenovirus, are beyond the scope of this overview and are
discussed in recent reviews (26-29). Although viral vectors used for cancer immunotherapy are
generally replication-defective, safety issues and regulatory hurdles remain significant concerns.
Pre-existing immunity to some viral vectors can limit the potential patient pool and neutralizing
antibody responses may prevent the same viral vector from being used twice in the same patient.
Like viral vectors, recombinant microorganisms share the appeal of being "self-
adjuvented". The microorganisms may be dead, functioning as APC-targeted carriers of danger
signals and antigen expressed recombinantly (30, 31) or in plasmid form (32). Certain strains of
bacteria possessing functions that can be exploited for antigen delivery are delivered live, such as
Listeria monocytogenes that can inhabit the cytosol of APCs (33, 34) and Salmonella
typhimurium that can inject proteins into the host cell cytosol (35, 36). Yeast-based vaccines will
be discussed in more detail later. Many of the same strategies used by the drug delivery field are
being explored to package antigen (and sometimes adjuvant) into nano- or microparticles, such
as liposomes and other lipid-based carriers (37) and encapsulation by biodegradable (38, 39) or
pH-sensitive polymers (40, 41).
Finally, with DC vaccines, DCs or their precursors (e.g. monocytes, CD34 + progenitors)
are isolated from the patient, cultured, loaded with antigen and matured ex vivo, and re-
administered into the body. Any of the above cancer vaccine strategies can be used to deliver
TAAs directly to the DCs. In addition, DCs may be transfected with mRNA isolated from tumors
(42), or even fused with tumor cells (43). The stand-out advantage of DC vaccines is the ability
to control and monitor antigen loading and DC maturation state, whereas the obvious drawbacks
are the high cost and difficulty of scaling up the approach.
1.3 Cross-presentation
To provide the first signal required to activate CTLs, APCs need. to process and present
antigen as peptide-MHC class I complexes. This presents a challenge for cancer vaccine
development because MHC class I molecules are conventionally loaded with endogenous
antigens generated within the cell, for example, during viral infections. The mechanisms by
which exogenous antigens can be processed and presented on MHC class I molecules, i.e cross-
presented, are not as well characterized. The requirement for cross-presentation can be
circumvented by vaccinating with peptides that represent defined epitopes, such that no antigen
processing is required. This approach requires knowledge of these epitopes and is limited to
patients with corresponding HLA haplotypes. Alternatively, viral or non-viral vectors can be
used to transfect APCs with TAA genes; however, outside of an ex vivo approach, the difficulty
lies in targeting gene transfer to rare APC cells. Therefore, cross-presentation is likely to remain
key to cancer vaccine development, especially as it has turned out to be unexpectedly efficient
(44-46). Teleologically, cross-presentation needs to be effective because uptake and processing
of virus-infected cells would be critical for protection against viruses that either do not infect
APCs or that block antigen presentation in infected APCs (47).
Exogenous proteins may be taken up by APCs by a number of mechanisms, including
receptor-mediated endocytosis and macropinocytosis, but we will focus on phagocytosis as the
mechanism relevant to yeast-based vaccines. Early reports of cross-presentation at times
disagreed as to whether proteasomes and TAP were required, leading to the elucidation of two
distinct pathways. In the phagosome-to-cytosol route, internalized antigens are transported to the
cytosol surrounding the phagosome through a size-selective but as yet unidentified "pore" (48).
The proteins are thought to be polyubiquitinated and thus targeted for proteasomal cleavage.
Three independent reports in 2003 demonstrated that MHC class I molecules and the cellular
machinery required for loading them were present in early phagosomes, likely as a result of the
endoplasmic reticulum (ER) fusing with the nascent phagosome (49-51). The cleaved peptides
are then transported back into the ER-phagosome compartment (or perhaps the ER itself as this
fusion event has been disputed (52)) and loaded onto MHC class I molecules with the help of
TAP and tapasin. Although this has yet to be proven for phagocytosed antigens, peptides
generated from antigens endocytosed by the mannose receptor were recently shown to be loaded
by endosomal TAP to form complexes that trafficked from the endosome to the cell membrane
(53). In the alternative vacuolar pathway, antigens remain in the phagosome as it matures by
fusion with late endosomes and lysosomes (54). Like in the MHC class II pathway,
endolysosomal proteases cleave antigen proteins into peptides. The peptides are thought to be
loaded onto recycling MHC class I molecules, perhaps by peptide exchange at low pH, and
trafficked to the surface (55).
1.4 NY-ESO-1 as a Cancer Immunotherapy Target
NY-ESO-1 is an attractive target for cancer immunotherapy because it is one of the most
immunogenic TAAs known, with an unusually large proportion of advanced patients developing
spontaneous humoral and cellular immune responses (56, 57). As a testament to its appeal, when
the Cancer Vaccine Collaborative decided to focus its efforts on a single antigen, NY-ESO-1 was
selected (58). A member of the cancer/testis family of TAAs, its expression is restricted to the
germ cells of the testes and perhaps the ovaries and placenta in normal tissues (59-61). On the
other hand, NY-ESO-1 mRNA has been detected in 20-30% of a broad range of tumors,
including melanomas, hepatocellular carcinoma, breast, prostate, bladder, ovarian, lung, and
thyroid cancers (60). NY-ESO-1 is an 18 kDa protein expressed in the cytosol or nucleus; it has
no known murine homologue and its function is unknown (61).
In a clinical trial of vaccination with HLA-A2-restricted NY-ESO-1 peptides and GM-
CSF as an adjuvant, four out of seven initially NY-ESO-1 seronegative patients mounted CD8+ T
cell responses (57). However, further research has shown that the peptide-induced CTLs are
inconsistent in their ability to recognize and kill tumor cells (62), and that their TCRs have
different structural features compared to spontaneously generated CTLs (63). Vaccination
strategies involving recombinant NY-ESO-1 protein appear to be more promising. In a clinical
trial, ten out of sixteen patients with resected, NY-ESO-1-positive melanomas immunized with
NY-ESO-1 protein complexed with ISCOMATRIX adjuvant developed CD8+ T cell responses,
compared to one out of sixteen who received protein alone (64). Even though the trial was not
designed to assess clinical efficacy, it was very encouraging that only two out of nineteen NY-
ESO-1/ISCOMATRIX-vaccinated melanoma patients relapsed during follow-up, compared to
nine out of sixteen who received NY-ESO-1 without adjuvant and five out of seven who
received a placebo. Other NY-ESO-1 vaccination strategies that are currently in phase I or II
clinical trials include formulation with cholesterol-bearing hydrophobized pullulan, live
recombinant Salmonella typhimurium and a vaccinia/fowlpox prime-boost strategy (58).
A recent preliminary study proposes that targeting NY-ESO-1-expressing tumor cells
may be akin to attacking "cancer's Achilles' heel" (65). Cebon et. al sorted a series of melanoma
cell lines for subpopulations that highly expressed CD133 (65). CD133 is expressed by a wide
variety of normal stem cells and may also be a cancer stem cell marker (66). These CD133hi
cells that were clonogenic in soft agar culture were also highly enriched for NY-ESO-1 and
could be selectively killed by NY-ESO-l-specific CTLs. This suggests that even though tumors
are heterogeneous in NY-ESO-1 expression, vaccinating against NY-ESO-1 could prevent tumor
growth and metastasis by eliminating the cancer stem cells.
1.5 Yeast as an Adjuvant and Vaccine
Saccharomyces cerevisiae embodies many of the qualities desired in vaccines: it is non-
pathogenic, Generally Recognized as Safe (GRAS) by the FDA, well-characterized and cheap to
produce. The adjuvant qualities of yeast have long been recognized; zymosan, a cell wall
preparation of S. cerevisiae composed largely of 1-glucans, has been used for over 50 years to
stimulate inflammatory cytokine production (67, 68). However, the wide variety of DC receptors
that are engaged by S. cerevisiae and other fungi are only recently being defined. Dectin-1, a
lectin receptor recognizing fungal f3-glucan, has been found to cooperate with Toll-like receptors
2 and 6 to stimulate secretion of the Thl cytokines IL-12 and TNF-a in response to zymosan (68).
Zymosan has also been found to co-engage Dectin-1 and another lectin receptor, DC-SIGN, to
stimulate biosynthesis of arachidonic acid (a precursor to prostaglandin E2 required for
migration) in human DCs (69). The mannan fraction of yeast cell walls has been shown to
stimulate proinflammatory cytokine production in monocytes (70) and dendritic cells (71).
Production of mannosylated recombinant antigens in S. cerevisiae (72) or Pichia pastoris (73)
yeast is a tactic used to enhance uptake by the mannose receptor, although this receptor is
dispensable for cell-associated antigen (74).
In 2001, Stubbs et al. pioneered the use of recombinant yeast to induce cellular immunity
(75). Immunization of mice with S. cerevisiae yeast expressing ovalbumin intracellularly was
demonstrated to protect against subsequent challenge by ovalbumin-expressing tumor cells. They
also showed that yeast was a powerful stimulator of murine DC maturation and IL-12 secretion.
More recently, yeast expressing mutated Ras oncoprotein was shown to induce shrinkage of
carcinogen-induced lung tumors in mice (76). There is clearly room for improvement because
only about one-quarter of the tumors were eradicated despite an intense dosing regiment of ten
weekly injections (76). The same group observed that prior immunization with control yeast did
not reduce the potency of subsequent immunization with antigen-expressing yeast, suggesting
that any immune responses mounted against yeast itself are non-neutralizing (77). In the past
year, two more TAAs were expressed intracellularly in yeast, the melanoma antigen MART-1
and carcinoembryonic antigen; both induced CD4+ and CD8+ T cells in vaccinated mice (78, 79).
This technology is currently being tested in a phase I clinical trial against chronic hepatitis C,
and no dose-limiting toxicity was observed after subcutaneous injection of heat-killed S.
cerevisiae (80).
1.6 Introduction to the Thesis
The goal of this thesis project is to use S. cerevisiae as a vaccine development platform to
evaluate factors that affect cross-presentation and to demonstrate proof-of-concept using the
cancer-testis antigen, NY-ESO-1. While several reports on yeast-based vaccines are described
above, improvements in the technology have essentially been limited to efforts to increase
intracellular antigen expression levels (e.g. gene copy number, promoter choice) (80). We
believe that cross-presentation can be made more efficient by designing antigen delivery vectors
that manipulate the kinetics of rate-limiting processes. In the proteasome-dependent route of
cross-presentation, the egress of antigen from the phagosome to the cytosol appears to be one
such process. Yeast surface display technology developed in the Wittrup laboratory enables us to
not only quantify and monitor antigen levels but also to manipulate the kinetics of antigen
release in the DC phagosome.
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Chapter 2
Establishing the Experimental System
2.1 Introduction
When this thesis project was first proposed, we decided to study antigen cross-
presentation and adjuvant effects using human cells, and if possible, with NY-ESO-1 instead of a
model antigen. If testing in an animal model became a compelling next step, our collaborators
were experienced in vaccinating HLA-A2-expressing transgenic mice (1, 2). In our own
laboratory, we planned to directly measure cross-presentation of NY-ESO-1 by human dendritic
cells (DCs) using an antibody fragment recognizing the NY-ESO-1 157-165/HLA-A2 complex (3).
This approach turned out to be unfeasible, and this chapter describes our preliminary work in
establishing a functional experimental system.
2.2 Human Monocyte-derived DCs
At the time, human DCs could be purchased from two companies: MatTek (Ashland,
MA) supplied DCs generated from umbilical cord blood progenitors and Lonza (Basel,
Switzerland) supplied DCs isolated from peripheral blood. However, these were prohibitively
expensive and DCs differentiated from human monocytes by culture with IL-4 and GM-CSF (4)
were much more prominent in the literature. Monocytes are typically enriched from peripheral
blood mononuclear cells (PBMCs) by either plastic adherence or magnetic-activated cell sorting
for CD14 +. To greatly increase the flexibility and convenience of performing DC experiments,
we instead purchased a large batch (-109 cells) of monocytes purified by counter-flow
centrifugal elutriation (Advanced Biotechnologies Inc, Columbia, MD) and cryopreserved these
in aliquots.
An initial experiment was performed to culture these monocytes in media containing
1000 U/ml each of IL-4 and GM-CSF for one week and to characterize the resulting cells by
flow cytometry. The floating and loosely adherent cells acquired an irregular morphology with
some visible dendrites (Fig. 2.1A) and had a surface antigen profile consistent with immature
monocyte-derived DCs: CD1a variable, CD11ahigh, CD14low, DC-SIGNhi, HLA-DRlow (Fig. 2.1B).
In contrast, the undifferentiated monocytes expressed CD14 at a much higher level but did not
express either DC-SIGN or CDla (not shown). The protocol for generating monocyte-derived
DCs was standardized and is provided in detail in Appendix B. 1.
2.3 DC Maturation by Yeast
Next, we wished to verify that human monocyte-derived DCs phagocytose yeast cells and
mature in response to this stimulus. At this point (2004), there were no published reports of the
effects of Saccharomyces cerevisiae cells on human DCs, although Stubbs et. al had reported
that this yeast activated murine bone marrow-derived DCs (5) and several groups had
investigated the interaction between Candida albicans and human DCs (6-8). Before we could
proceed, we needed a way to render the yeast non-viable, to prevent them from overwhelming
DCs in cell culture. Heat inactivation and antifungal agents were not optimal because of protein
denaturation and possible side effects, respectively; instead, we investigated inactivation by UV-
irradiation. Dose-response experiments exposing 107 yeast cells to 254 nm UV light in a
Stratalinker UV Crosslinker (Stratagene) showed that 1000-1200 J/m2 reduced the number of
colony forming units to the single digits. Higher doses could not consistently eliminate colony
growth, but simply performing the 1000 J/m 2 irradiation twice, swirling the dish in between,
solved the problem of yeast growth in DC culture.
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Figure 2.1, Phenotype of monocyte-derived DCs. Human monocytes were cultured in C10
medium (see Appendix B.1) with 1000 U/ml each of IL-4 and GM-CSF for 7 days.
A, Morphology of the resulting immature DCs as viewed by phase contrast microscopy.
B, The cells were labeled with PE-conjugated monoclonal antibodies against the indicated
surface markers and analyzed by flow cytometry. The clear histogram indicates staining with
goat a-mouse-PE, used here as a non-binding control.
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Yeast surface-displaying a truncated form of NY-ESO-1 were UV-irradiated and added
to immature monocyte-derived DCs at different ratios. After 48 h, the DCs were analyzed by
flow cytometry for the expression of five surface markers of DC maturation: CD40, CD80,
CD83, CD86, and HLA-DR. As shown in Fig. 2.2A, across a broad range of doses from 2 to 20
yeast per DC, DC upregulation of these maturation markers was comparable to that induced by a
strong Toll-like receptor agonist, lipopolysaccharide (LPS), with 5-10 yeast per DC being
optimal. We had previously found that the number of unphagocytosed yeast cells increased
sharply when the yeast-to-DC ratio increased above 20:1, which may reflect the maximum DC
phagocytic capacity. Consistent with the findings of Stubbs et al. using murine DCs (5), yeast
cells induced human DCs to secrete much more IL-12 than did LPS (Fig. 2.2B). In conclusion,
yeast cells exerted a strong, Thl adjuvant effect on human monocyte-derived DCs.
2.4 Yeast Surface Display of NY-ESO-1 Variants
Yeast surface display of NY-ESO-1 as a fusion to Aga2p was first performed by Renner
et al., who demonstrated the feasibility of using such yeast to screen patient sera for antibodies
against cancer antigens (9). However, in our own laboratory, we found NY-ESO-1 yeast surface
display levels to be barely detectable (Fig. 2.3C) and unsuitable for antigen production or for
studying cross-presentation (10). Therefore, post-doctoral fellow Andrea Piatesi undertook the
task of engineering better expressing NY-ESO-1 mutants (10). To summarize his results, he
hypothesized that the cysteine cluster (CCRC) at positions 75-78 was a bottleneck for expression
and rationally designed three mutants: NY-ESO-CS and NY-ESO-CA, where these Cys residues
were substituted with Ser or Ala residues, respectively, and NY-ESO-T, where the unstructured
N-terminal region up to the cysteine cluster was deleted (Figs. 2.3A, B).
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Figure 2.2, DC maturation in response to yeast. Human monocyte-derived DCs were seeded
in a 24-well plate (5 x 105 DCs in 1 ml per well), and LPS (1 gg/ml) or UV-irradiated pCT-ESO-
T yeast (at the indicated ratios) were added.
A, After 48 h, the cells from duplicate wells were pooled and divided into aliquots, each of
which was labeled with a-DC-SIGN-FITC and a PE-conjugated antibody against a DC
maturation marker. The cells were analyzed by flow cytometry and gated by DC-SIGN
expression to exclude unphagocytosed yeast; PE fluorescence was scaled by the results of the
LPS positive control.
B, IL-12p70 ELISA was performed on the cell culture supernatants. Error bars indicate the SD of
duplicate wells.
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Figure 2.3, Mutants of NY-ESO-1 with improved yeast surface display levels.
A, Sequence alignment of NY-ESO-1 with three rationally designed mutants. Dashes indicate no
change from NY-ESO-1.
B, Structure of NY-ESO-1 as predicted by the Rosetta algorithm, with the cysteine cluster
highlighted.
C, Flow cytometry histograms of yeast surface-displaying NY-ESO-1 and variants, labeled with
a-c-myc and a PE-conjugated secondary antibody.
Panels A and B are reproduced with permission from Fig. 1 of ref. (10) and panel C is adapted
from Figs. 2A and 4.
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To further improve upon the surface display levels, Piatesi performed directed evolution
on each of the three mutants, generating libraries by error-prone PCR and repeatedly sorting for
the highest expressing cells (10). The full-length NY-ESO-1 variants that were obtained had
mutations at either position 153 (Leu to His) or 156 (Leu to His/Arg) on an NY-ESO-CS or NY-
ESO-CA background. The position 156 mutation was less desirable because it had a higher
likelihood of affecting the processing and immunogenicity of the most widely studied MHC
class I epitope (157-165). The variant named NY-ESO-L5 (C75A/C 76A/C 78A/L153H), with a near
100-fold increase in surface display level over wild type (Fig. 2.3C), was selected for further
study.
2.5 Attempts to Detect NY-ESO-1 Peptide-MHC by Antibody Labeling
Now that we had both functional human DCs and yeast surface-displaying a high level of
an NY-ESO-1 variant, we could proceed with the proposed plan to detect cross-presentation by
directly labeling yeast-fed DCs with 3M4E5, a Fab fragment binding to the NY-ESO-1157.
165/HLA-A2 complex (3). Biotinylated 3M4E5 (b-3M4E5) was kindly provided to us by the
Renner lab. We were unable to detect an increase in 3M4E5 labeling between HLA-A2 DCs that
had phagocytosed yeast surface-displaying NY-ESO-L5 as compared to wild type yeast despite
extensive troubleshooting. For example, Fig. 2.4A shows the median fluorescence of DCs that
had been exposed to NY-ESO-L5-displaying or wild type yeast for various time periods and
subsequently labeled with b-3M4E5-streptavidin-PE complexes. Pre-incubating the b-3M4E5 at
a 4:1 stoichiometric ratio with streptavidin-PE was a strategy to increase the avidity (as opposed
to sequentially labeling with b-3M4E5 followed by streptavidin-PE). At none of the seven time
points was the signal caused by NY-ESO-L5-displaying yeast higher than the control.
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Figure 2.4, Low sensitivity of 3M4E5 labeling.
A, NY-ESO-L5-expressing or wild type EBY100 yeast were UV-irradiated and added to HLA-
A2 monocyte-derived DCs at a 10:1 ratio. After the indicated time, the DCs were labeled with a-
DC-SIGN-FITC and 100 nM of streptavidin-PE pre-loaded with a 4-fold molar ratio of b-3M4E5.
The cells were analyzed by flow cytometry and the median PE fluorescence of the FITC-gated
events was plotted. B and C, T2 cells were pulsed with 20 plg/ml of SLLMWITQA peptide for 2
h in serum-free medium.
B, The T2 cells were labeled with the indicated concentration of b-3M4E5, washed, and then
labeled with 10 gLg/ml of streptavidin-PE. C, The T2 cells were labeled with the indicated
concentration of streptavidin-PE that had been pre-loaded with b-3M4E5. Gray histograms
indicate unpulsed T2 cells labeled under the same conditions.
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Since the failure to detect a difference in 3M4E5 labeling may lie in insufficient cross-
presentation levels rather than the detection scheme, we also investigated labeling of peptide-
pulsed T2 cells, which express HLA-A2. Regardless of whether we sequentially labeled with b-
3M4E5 followed by streptavidin-PE or with pre-formed complexes, across a range of
concentrations, there was less than a log of difference in fluorescence between the peptide-pulsed
T2 cells and the unpulsed controls (Figs. 2.4B, C). Peptide pulsing results in an
unphysiologically large fraction of surface MHC class I molecules forming complexes with that
peptide, hence this low level of sensitivity did not bode well for detecting the much smaller
numbers of peptide-MHC complexes generated by cross-presentation. We finally abandoned this
strategy for detecting cross-presentation when Andreas Wadle from the Renner group brought
their materials (DCs, yeast-produced NY-ESO-1 and fresh b-3M4E5) to our laboratory but was
unable to demonstrate a significant difference in labeling (not shown).
2.6 Detection of Cross-presentation using a Model Antigen T Cell Clone
It was unclear whether problems with the reagent, such as inadequate affinity or batch-
specific issues like misfolding, degradation or incomplete biotinylation, contributed towards the
low levels of labeling with b-3M4E5. Nevertheless, we hypothesized that even an ideal antibody
against a peptide-MHC complex may not be sensitive enough to quantitatively measure cross-
presentation levels. Fewer than a hundred, and perhaps even just a single peptide-MHC complex
on a DC can trigger CD8+ T cell activation (11, 12), whereas flow cytometers typically require at
least hundreds of fluorophore molecules per cell for detection. We therefore explored the use of
T cell activation as an indirect measure of cross-presentation. Limited access to NY-ESO-1-
specific T cells prompted us to select a model antigen for which T cell clones or lines were
readily available. Monoclonal CD8 + T cells recognizing the immunodominant, HLA-A*0201-
restricted peptide NLVPMVATV (N9V), derived from cytomegalovirus (CMV) phosphoprotein
pp65, are available commercially (Proimmune, Oxford, UK). Two clones against Epstein-Barr
virus epitopes are also available, but the prevalence of CMV infection combined with the high
frequency of N9V-specific CTLs in infected individuals (13) allows for research continuity even
if the T cell clone were to become unavailable.
The extended peptide ARNLVPMVATVQGQN that was consistently immunogenic in
HLA-A*0201, CMV-positive individuals (14) was expressed in the yeast surface display system.
The surface display level was very high, exceeding that of NY-ESO-L5 (Fig. 2.5A). In the pilot
experiment, yeast surface-displaying N9V and wild type yeast were fed to HLA-A*0201
monocyte-derived DCs at three different doses. After either 3 h or 48 h, the DCs were co-
cultured with N9V-specific CD8+ T cells for 4 h in the presence of Brefeldin A. Intracellular
IFNy staining of fixed and permeabilized cells revealed that at 3 h post-feeding, a modest but
consistently higher than background level of T cell activation could be detected (Fig. 2.5B). At
the 48 h time point, the percentage of IFN-y-positive T cells was much greater and increased
with yeast dosage (Fig. 2.5C). This experiment proved that cross-presentation levels can be
measured by detecting IFNy secretion by activated cognate CD8÷ T cells, paving the way for the
work described in the subsequent chapters. The assay protocol was altered to use a cytokine
secretion-capture kit rather than intracellular cytokine staining and is detailed in Appendix B.2.
2.7 Production of Yeast-expressed NY-ESO-L5
Although NY-ESO-L5 was not ultimately used to study cross-presentation, Piatesi's
work in engineering NY-ESO-1 variants that are highly expressed in yeast (10) also served
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Figure 2.5, Detecting cross-presentation of the N9V epitope displayed on yeast using an
antigen-specific T cell clone.
A, The high yeast surface display level of N9V (gray fill) as detected by labeling with chicken a-
c-myc. Black line: yeast surface-displaying NY-ESO-L5; gray line: wild type yeast.
B and C, N9V-displaying yeast or control plasmidless yeast were added to HLA-A*0201
monocyte-derived DCs at the indicated ratios. The positive control DCs were pulsed with 1
p.g/ml synthetic N9V peptide and 30 p.g/ml poly I:C. N9V-specific T cells and Brefeldin A were
added either 3 h (B) or 48 h (C) later. After 4 h of co-culture, the cells were stained with a-CD8-
FITC, fixed and permeabilized, then stained with a-IFNy-PE and analyzed by flow cytometry.
The T cells were gated by FS/SS and CD8 labeling and the percentage of IFNy-positive T cells
was determined.
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another purpose. NY-ESO-1 protein used in human vaccination trials is expressed in bacteria and
purified from inclusion bodies (15). This material is of limited purity (perhaps due to the extreme
hydrophobicity of the C-terminus of NY-ESO-1), which raises concerns over the generation of
immune responses against bacterial contaminants (16). In particular, false positive reactions can
occur when the same material is then used to perform Delayed Type Hypersensitivity (DTH)
skin tests to monitor the anti-NY-ESO-1 immune response. Therefore, a source of NY-ESO-1
antigen produced in a non-bacterial host such as yeast is desirable. The rest of this chapter
describes our work in developing a strategy to produce yeast-expressed NY-ESO-L5, which was
previously published in ref. (10).
Initial attempts to secrete NY-ESO-L5 in yeast were unsuccessful: the yield was
extremely low and comparable to the CS-engineered variant (data not shown). An alternative
production strategy became necessary, as it appeared that the strong improvement in the display
level was insufficient to boost the production of NY-ESO-L5 to useful levels. Since the directed
evolution approach that we used is based on the display of the protein of interest as an Aga2p-
fusion, we tested secretion of the whole display fusion (Aga2p-Xa-HA-(G4S) 3-NY-ESO-1-c-myc)
by transforming the pCT-constructs of NY-ESO-1, NY-ESO-CS and NY-ESO-L5 in BJ5464a.
This yeast strain is Agalp-deficient, allowing the secretion of the fusion directly into the media.
Small scale secretion experiments were performed for the NY-ESO-1, NY-ESO-CS and NY-
ESO-L5 display fusions, and the resulting Western blots are shown in Fig. 2.6A. Interestingly,
only the NY-ESO-L5 fusion was efficiently secreted (Fig. 2.6A, lane 4). Both, the wt and the CS
fusions were nearly undetectable (Fig. 2.6A, lanes 2 and 3) suggesting that the L153H mutation is
largely responsible for the improved secretion of this antigen. The apparent MW of the fusion
observed on the Western blot was much higher than expected (ý 150 kDa instead of = 30kDa),
presumably due to the extensive glycosylation of Aga2p and of the Xa-HA-(G4S)3-linker. Aga2p
is a small glycoprotein (69 residues after cleavage of an 18-residue signal sequence) that is
known to be highly O-glycosylated (17). At least 10 of the 21 serine and threonine residues in
Aga2p are glycosylated showing an apparent mass of 33 kDa on SDS-PAGE (18). Initial
attempts to purify the NY-ESO-L5 display fusion by size-exclusion chromatography and/or by
metal-affinity chromatography of the same fusion with a C-terminal Hiss6-tag were of limited
success (data not shown). In order to simplify the purification process, the original display vector
was modified by introducing a more specific protease cleavage site (human rhino virus 3C; HRV
3C) right before the N-terminus of NY-ESO-L5. Moreover, the [Xa-HA-(G 4S)3] sequence was
shortened to a single G4S repeat and a Hiss6-tag was added just upstream of the HRV 3C site. The
C-terminal c-myc-tag was eliminated so that after HRV 3C cleavage, NY-ESO-L5 would be
released without any tag sequences. Finally, to improve retention on a metal-affinity column, an
additional Hiss6-tag was added at the N-terminus of Aga2p (following the signal peptide), leading
to the generation of the pHAH-L5 display construct [Hiss6-Aga2p-G4S-Hiss6-(HRV 3C)-(NY-
ESO-L5)]. While maintaining an essentially identical NY-ESO-L5 display and secretion level
compared to the original pCT-display construct (data not shown), this newly designed display
fusion is significantly smaller and allows a simple purification of NY-ESO-L5. We found that
instead of secreting the NY-ESO-L5 fusion from BJ5464a cells, higher purities can be achieved
by reductively cleaving the fusion protein from the surface of EBY100 cells (data not shown).
The reduction of the Aga2p-Agalp disulfide bonds with TCEP yielded the NY-ESO-L5 fusion
protein in a concentrated and partially purified form. The additional metal-affinity
chromatography step results in the specific enrichment of the NY-ESO-L5 display fusion and
allows the efficient isolation of NY-ESO-L5 by on-column
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Figure 2.6, Secretion and purification of NY-ESO-L5 from yeast.
A, Western blot analysis of the NY-ESO-1, NY-ESO-CS and NY-ESO-L5 original display
fusions ([Aga2p-Xa-HA-(G4S)3-(NY-ESO-1)-c-myc] fusions) secreted in BJ5464a. M: ECL-
marker; lane 1: SG-CAA media; lane 2: NY-ESO-1; lane 3: NY-ESO-CS; lane 4: NY-ESO-L5.
Arrow shows the strong signal generated by the NY-ESO-L5 fusion.
B, Western blot analysis of the re-designed NY-ESO-L5 fusion ([Hiss6-Aga2p-G4S-His6-(HRV3C)-(NY-ESO-L5)]) reduced from the surface of yeast with TCEP and purified by metal-affinity
chromatography (lane 1). Lane 2 shows the same sample after on column digestion with HRV3C protease instead of imidazole elution. Arrow indicates the band corresponding to NY-ESO-L5. All Western blots were performed using mAb E978 as the primary anti- NY-ESO-1detection reagent.
C, SDS-PAGE analysis (Coomassie blue stain) of the same samples shown in (B).
Reproduced with permission from ref. (10).
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digestion with HRV 3C protease. Western blot and SDS-PAGE analyses of the reduced fusion
purified by metal-affinity chromatography confirmed the presence of a diffuse band between 30
and 45 kDa (Fig. 2.6B, lane 1 and Fig. 2.6C, lane 1). When the metal-bound display fusion was
treated with HRV 3C protease, the released NY-ESO-L5 ran at around 20 kDa and was
recognized by a-NY-ESO-1 monoclonal antibody (Fig. 2.6B, lane 2 and Fig. 2.6C, lane 2).
Moreover, SDS-PAGE analysis shown in Figure 2.6C demonstrates that the obtained NY-ESO-
L5 is highly enriched (yield = 50 p.g/L of NY-ESO-L5) and the antigen purity is significantly
improved compared to the established cGMP purification of recombinant NY-ESO-1 from
inclusion bodies (15).
Recombinant E. coli-derived NY-ESO-1 protein has been shown to be efficiently cross-
presented when formulated in ISCOMATRIX (IMX) or as an immune complex (IC) (19). To be
considered a viable vaccine or DTH alternative it is critical to demonstrate that the NY-ESO-L5
mutant can also be processed for class I MHC-restricted presentation to NY-ESO-1-specific
CD8+ T cells. Therefore, NY-ESO-L5 protein and the Aga2p-NY-ESO-L5 fusion protein were
tested for efficiency of cross-presentation, to ensure that the Leul53His mutation and the AARA
cluster (75-78) did not alter antigen processing and loading. The results (Fig. 2.7) are from two
HLA-A2+ DC donors and are comparisons of the 157-165 NY-ESO-1 peptide vs. recombinant
NY-ESO-1/IMX vs. each of the mutant proteins added together with empty IMX. The peptide
response is taken as maximum response for each donor. Clearly, the mutations in the L5 version
of NY-ESO-1 do not ablate the presentation of the same peptide antigen recognized from wild-
type NY-ESO-1 protein.
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Figure 2.7, Cross-presentation of different NY-ESO-1 protein formulations. The 157-165
NY-ESO-1 peptide was used as a positive control. Recombinant NY-ESO-1, Aga2p-NY-ESO-
L5 and NY-ESO-L5 mixed with an equimolar amount of IMX (10 jig/mL) were used to pulse
monocyte-derived DCs from 2 HLA-A2+ donors. Antigen-pulsed DCs were co-cultured with
157-165 NY-ESO-1 peptide specific CD8 T cells and induction of IFN-y, production assessed by
intracellular cytokine staining. Reproduced with permission from ref. (10). This experiment was
performed by N. Robson and J. Cebon, Ludwig Institute for Cancer Research, Melbourne,
Australia.
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Chapter 3
Antigen Release Kinetics in the Phagosome are Critical to Cross-
presentation Efficiency'
3.1 Abstract
Cross-presentation of exogenous antigens in MHC class I molecules by dendritic cells is
the underlying basis for many developing immunotherapies and vaccines. In the phagosome-to-
cytosol pathway, antigens in phagocytosed particles must become freely soluble before being
exported to the cytosol, but the kinetics of this process has yet to be fully appreciated. We
demonstrate with a yeast vaccine model that the rate of antigen release in the phagosome directly
affects cross-presentation efficiency, with an apparent time limit of about 25 min post-
phagocytosis for antigen release to be productive. Antigen expressed on the yeast surface is
cross-presented much more efficiently than antigen trapped in the yeast cytosol by the cell wall.
The cross-presentation efficiency of yeast surface-displayed antigen can be increased by the
insertion of linkers susceptible to cleavage in the early phagosome. Antigens indirectly attached
to yeast through antibody fragments are less efficiently cross-presented when the antibody
dissociation rate is extremely slow.
1 Major portions of this chapter were previously published in:
Howland, S. W., and K. D. Wittrup. 2008. Antigen Release Kinetics in the Phagosome Are Critical to
Cross-Presentation Efficiency. J Immunol 180: 1576-1583.
3.2 Introduction
Vaccines that stimulate antibody production have enjoyed success for the past century,
but the development of vaccines that generate effective cellular immune responses, in particular,
CD8+ cytotoxic lymphocytes, remains a challenge. Such vaccines provide hope for the
prevention and treatment of cancer (1-3) as well as viral diseases like HIV (4), Hepatitis C (5)
and herpes simplex virus (6).
Part of this challenge arises from the fact that peptide-MHC class I complexes required to
prime CD8+ T cells are generally produced from the endogenous proteins of antigen-presenting
cells, principally dendritic cells (DCs)3. While alternative strategies such as adoptive transfer of
lymphocytes (7), DNA vaccines (8), and vaccination with exact peptide epitopes exist (9), cross-
presentation-the process by which peptides derived from exogenous antigens are displayed
with MHC class I molecules-remains central to most immunotherapy strategies. Early reports
of cross-presentation presented conflicting results as to whether this process required TAP and
was sensitive to proteasome inhibitors (10), or was TAP-independent and sensitive to protease
inhibitors (11, 12). At least two distinct mechanisms for cross-presentation emerged: the
phagosome-to-cytosol pathway and the vacuolar pathway (13). In the vacuolar pathway, peptides
are generated from internalized antigens by the action of endolysosomal proteases; the peptides
may then meet up with recycling MHC class I molecules. In the phagosome-to-cytosol route,
phagocytosed antigens escape to the cytosol to be processed by proteasomes and are loaded onto
nascent MHC class I molecules with the aid of TAP.
Quantitative mechanistic details about these pathways for cross-presentation are still
missing from the picture, which if discovered could lead. to the development of more effective
vaccines. We hypothesize that with particulate antigens that are cross-presented via the
phagosome-to-cytosol pathway, antigen release from the particles may be a rate-limiting step. To
our knowledge, antigen release rates within the phagosome have not been comprehensively
studied. In this work, we explore the effects of altering antigen release kinetics on cross-
presentation efficiency using a yeast vaccine model.
Recombinant yeasts show promise as vaccine candidates in mouse models (14, 15) and in
human blood cell assays (16-18). In particular, S. cerevisiae is attractive because it is non-
pathogenic, well-characterized, and is a strong adjuvant-Zymosan, a cell wall preparation of
this yeast, has been a valuable tool in immunology for over 50 years (19). S. cerevisiae potently
induced the maturation of murine bone marrow-derived DCs and secretion of interleukin-12 (14).
In our hands (unpublished) and others (16), human monocyte-derived DCs were similarly
activated. When the recombinant antigen is expressed intracellularly in yeast, the rate of antigen
release is primarily dictated by the rate of yeast cell wall degradation. With yeast surface display
technology (20), on the other hand, antigen is expressed on the cell wall exterior, permitting the
release kinetics to be manipulated.
3.3 Materials and Methods
3.3.1 Cells
Human HLA-A*0201 monocytes were obtained from two sources, purified either by
counter-flow centrifugal elutriation (Advanced Biotechnologies Inc, Columbia, MD) or negative
magnetic cell sorting (Biological Specialty Corporation, Colmar, PA). Similar results were
obtained with both sources. The monocytes were aliquoted into vials and cryopreserved in 90%
FBS, 10% DMSO. For each experiment, one or more vials were thawed and washed in C10
medium: RPMI 1640 with 10% FBS, 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium
pyruvate, lx non-essential amino acids, 50 itM 3-mercaptoethanol and Primocin (InvivoGen,
San Diego, CA). Unless otherwise indicated, media components were from Hyclone (Logan,
UT); low endotoxin products were chosen where available. 4-5x 106 monocytes were cultured per
well of a 6-well plate in 2.5 ml C10 medium supplemented with 1000 U/ml each of IL-4 and
GM-CSF (C10GF; cytokines from R & D Systems, Minneapolis, MN). After 2 and 4 days of
culture, each well was topped up with 0.5 ml C10GF; after 6 days of culture, floating and loosely
adherent immature monocyte-derived DCs were harvested by gentle resuspension.
Vials of a human CD8 + T cell line specifically recognizing the peptide NLVPMVATV in
the context of HLA-A*0201 were purchased from ProImmune (Oxford, UK). Each vial was
thawed and cultured overnight in RPMI 1640 with 10% FBS and 5 ng/ml IL-2 and used the next
day.
3.3.2 Yeast Surface Display
Plasmids for yeast surface display were based on pCT-CON (21) and were transformed
into EBY100 (20), a strain that expresses Agalp under galactose induction, using the Frozen EZ
Yeast Transformation II Kit (Zymo Research, Orange, CA). Yeast colonies were cultured to mid-
log phase at 30*C in selective SD-CAA medium (2% dextrose, 0.67% yeast nitrogen base, 0.5%
casamino acids, 0.1 M sodium phosphate, pH 6.0) and then induced in SG-CAA (SD-CAA with
galactose replacing dextrose) for 48 h at 200C. Single copies of some expression cassettes were
integrated into the EBY100 yeast chromosome using the integrating shuttle vector pRS304 (22).
The resulting yeast strains were grown up in rich YPD medium (1% yeast extract, 2% peptone,
2% dextrose) and induced in YPG (1% yeast extract, 2% peptone, 2% galactose) for 36 h at 200 C.
Yeast media nitrogen sources were obtained from BD (Franklin Lakes, NJ). Surface display
levels were measured by flow cytometry with chicken a-c-myc (Invitrogen, Carlsbad, CA) or
9e10 monoclonal antibody (Covance, Princeton, NJ). The number of copies per yeast cell was
estimated by comparison with Quantum Simply Cellular beads (Bangs Labs, Fishers IN).
3.3.3 Cross-presentation Assay
After 6 days of differentiation, immature monocyte-derived DCs were seeded in 96-well
round bottom plates at 1 or 2 x 10s cells in 200 jl C10OGF per well. Appropriate numbers of
yeast cells (measured by optical density at 600 nm with 1 OD = 107/ml) were rendered non-
viable by UV-irradiation (2 x 1000 J/m2 in a Stratalinker, Stratagene, La Jolla, CA), pelleted by
centrifugation and added to the DCs. For inhibition experiments, DCs were pre-incubated with
Z-FL-COCHO (10 pM; Calbiochem, San Diego, CA), lactacystin (5 jiM; Calbiochem) or
chloroquine (25 giM) for one hour before yeast samples were introduced. 24 h later, half the
medium was replaced with a T cell suspension, with 0.7-1 x 105 T cells per well. Following 4 h
of co-culture, the contents of each well were transferred to tubes for labeling with Miltenyi's
IFNy secretion assay kit (Bergisch Gladbach, Germany) according to the recommended protocol.
Briefly, cells were labeled with a bispecific antibody that captures secreted IFNy on the cell
surface during a 45 min incubation period in medium at 370C, and then labeled on ice for 30 min
with a-CD8-FITC (BD) and a-IFNy-PE (Miltenyi). In experiments involving FITC-conjugated
yeast, a-CD8-Alexa Fluor 647 (BD) was substituted. The percentage of CD8+ cells that were
IFNy+ was determined by flow cytometry (Coulter Epics XL, Fullerton, CA or BD
FACSCalibur). The cut-off PE fluorescence was set for each experiment such that about 0.5% of
T cells were IFN~+ in a negative control sample (no yeast or peptide). The positive control with 1
gM of the extended peptide ARNLVPMVATVQGQN (synthesized by GenScript, Piscataway,
NJ) resulted in 45-70% IFNy+ T cells.
3.3.4 Yeast Intracellular Expression
Intracellular expression of the same fusion protein as is expressed by surface display was
achieved by deleting the signal peptide of Aga2p, followed by transformation into BJ5464a
(Yeast Genetic Stock Center, Berkeley, CA). BJ5464a is isogenic to the parent strain of EBY100
and lacks the galactose-inducible Agalp gene. The resulting colonies were grown up in SD-CAA
and induced in SG-CAA for 12 h at 300C.
3.3.5 Slot Blot Comparison ofAntigen Levels
6 OD.ml of each yeast culture was washed with PBS, resuspended in 300 gl 25 mM
Tris(2-carboxyethyl)phosphine hydrochloride (TCEP, Soltec Ventures, Beverly, MA) in PBS,
and incubated for on ice for 30 min. The proteins released into solution by the reducing agent
were pooled with those from a second 30 min extraction with 25 mM TCEP. The yeast pellets
were then washed with spheroplast buffer (50 mM Tris-HCl, pH 7.5, 1.4 M sorbitol, 40 mM 03-
mercaptoethanol), incubated with 2.4 U Zymolyase (Zymo Research) in 120 gl spheroplast
buffer containing a protease inhibitor cocktail (Roche, Indianapolis, IN) for 15 min at 370C, and
boiled in 2% SDS for 5 min. The protein extracts were blotted onto nitrocellulose membrane
with a slot-blotting apparatus (Bio-rad, Hercules, CA). The membrane was blocked with 5%
milk powder, incubated with 9e10 ascites fluid (Covance) followed by goat a-mouse-horse
radish peroxidase (Pierce, Rockford, IL), developed with SuperSignal West Dura substrate
(Pierce), and imaged on a FluorS Imager (Bio-rad).
3.3.6 Surface Display Antigen Dose Normalization
In experiments where different linkers were used to surface-display antigen, several
cultures of each yeast sample were induced, and cultures with mean antigen levels within 10% of
each other were selected to minimize the effect of variable antigen dose on cross-presentation.
However, the variability in expression level across the panel of initial constructs (deleted linker,
unchanged, and C1-5) was too high for this approach to be satisfactory. Therefore, each yeast
sample was mixed with the appropriate amount of EBY100 yeast to normalize the antigen dose
while maintaining the 20:1 ratio of yeast to DCs.
3.3.7 Measuring Linker Susceptibility to Cathepsin S
0.2 OD.ml of each yeast sample was washed and incubated with the indicated amounts of
recombinant human Cathepsin S (CatS, Calbiochem) in 100 jl PBS at 370C. The yeast samples
were washed and labeled with 12CA5 monoclonal antibody (a-HA; Roche) and chicken a-c-myc,
followed by goat a-mouse-PE (Sigma-Aldrich, St. Louis, MO) and goat a-chicken-Alexa Fluor
488 (Invitrogen). The mean c-myc fluorescence of the HA' population was compared against
that of yeast samples that had not been treated with CatS.
3.3.8 Post-phagocytosis Analysis
DCs (2 x 105/well) were seeded in 96-well round bottom plates, with separate plates for
each time point. After adding the yeast samples (5 x 105/well), the plates were immediately
centrifuged briefly (200 x g, 1 min) to settle the yeast and were returned to the incubator. At each
time point, a plate was placed on ice and 90% of the medium in each well was replaced with cold
RIPA buffer (Sigma-Aldrich). The well contents were moved to tubes, vortexed to promote cell
lysis, and centrifuged to pellet the released yeast. The yeast was washed with RIPA buffer and
PBS with 0.1% bovine serum albumin (BSA) before being labeled for HA and c-myc epitopes as
described above.
3.3.9 Fluorescein-binding ScFvs
The fluorescein-binding scFvs used here were products of directed evolution for
decreased dissociation rate using yeast surface display (23). These scFvs were subcloned into
pRS316-based plasmids with an improved alpha mating factor pre-pro sequence (Rakestraw et
al., unpublished). Codons encoding the extended peptide ARNLVPMVATVQGQN were
inserted between the scFv C-terminus and the c-myc epitope. The resulting constructs were
transformed into the protein disulfide isomerase-overexpressing yeast strain YVH10 (24)
together with a dummy plasmid bearing the trp nutritional marker. Transformants were grown up
in SD-CAA and induced in YPG containing 0.1 M sodium phosphate, pH 6.0 for 3 days at 200C.
The culture supernatants containing approximately 10 mg/L of scFv-antigen were adjusted to pH
7.4 and dialyzed against PBS.
3.3.10 Fluorescein-conjugated Yeast
UV-irradiated BJ5654a yeast cells were washed three times in 0.4 M sodium carbonate,
pH 8.4 and resuspended in 10 tl/OD.ml of a freshly prepared 1.5 mg/tl solution of fluorescein-
PEG-NHS (MW 5000; Nektar, Huntsville, AL) in sodium carbonate buffer. The reaction was
allowed to proceed for 30 min at room temperature, after which the yeast was washed six times
with PBS containing 0.1% BSA. Fluorescein-conjugated yeast was loaded with antigen by
incubation with scFv-antigen culture supernatants (1 ml per 107 yeast) for 1 hour on ice. Flow
cytometry analysis (c-myc labeling) of the loaded yeast showed that the antigen levels mediated
by 4M2.3, 4M3.12 and 4M4.5 were within -5% of each other, but the level of 4M5.3-antigen
was about 15% higher. Labeling fluorescein-conjugated yeast with 4M5.3 fusion protein for 30
min followed by 30 min, 37C - incubation in pH 5.4 PBS containing 0.1% BSA and 1 gtM
fluorescein-biotin resulted in a final antigen level comparable to that mediated by the other scFvs.
This method of antigen level normalization was performed for the cross-presentation assay. In
addition, to reduce antigen loss before phagocytosis, the plate was centrifuged (200xg, 1 min)
immediately after addition of the yeast to the DCs.
3.3.11 Model Simulation
The mathematical model consisted of the following equations describing the amounts of yeast-
bound antigen (Ab), free antigen within the phagosome (Af) and cytoplasmic antigen (A0)
relative to the initial amount:
For 0 < t tpre , where tpre is the time prior to phagocytosis
dAt
= --ck ffAb
For tpre < t < tpre + tar , where tft is the time taken for a phagolysosome formation
dAb dA d4cd = -c 2kffAb d = c2k°Ab - kescAf = kescAfdt dt dt
For tpre + tna < t < 24 h
dA = -cko Ab - kdegAb f 3ko Ab - kescAf - kdegAf d = kescA,dt dt dt
These equations were solved in Matlab with the initial conditions Ab = 1, Af = A0 = 0. For a
given set of parameter values, the final value of A, (at 24 h) was determined for a wide range of
koff values. Ten logarithmically spaced values spanning three orders of magnitude were tested for
each of the following parameters: cl (0.1 - 10), c2 (10 - 1000), c3 (10 - 1000), kesc (0.01 - 1
min-'), and kdeg (0.01 - 1 min-1). An optimal ti/2 = ln(2)/koff was found to exist between 10 and
10s min for all 10s possible combinations of parameter values, which should span all reasonable
biological values. The time parameters, tpm and tmat, were fixed at 30 min and 20 min respectively.
The former value is an estimate but is not a critical value since it is always multiplied by cl,
which was varied widely. The latter value was deemed reasonable based on the post-
phagocytosis time course analysis we performed.
3.4 Results
3.4.1 Yeast Surface-displayed Antigen is Cross-presented to CD8+ T cells
We selected the well-characterized HLA-A*0201 -restricted peptide NLVPMVATV
(N9V), derived from CMV phosphoprotein pp65 as our model antigen, for which cognate CD8+
T cells are available commercially. To ensure proper antigen processing, we included its native
flanking sequences in the yeast surface display construct, in the form of the 15-mer
ARNLVPMVATVQGQN that was consistently immunogenic in HLA-A*0201, CMV-positive
individuals (25). The yeast surface display construct consisted of a fusion of this extended
peptide to the yeast mating adhesion receptor subunit Aga2p via a (G4S)3 linker, with HA and c-
myc epitope tags for detection purposes (Fig. 3.1A). We created the yeast strain EBYN9V with
co-inducible chromosomal copies of this construct and Agalp, with expression resulting in
-120,000 copies/cell of the Aga2p-N9V fusion anchored to the yeast cell wall by disulfide bonds.
To test for cross-presentation, EBYN9V yeast were added to HLA-A*0201 monocyte-
derived DCs at various ratios. The DCs avidly phagocytosed the yeast with an average maximum
"capacity" of about 20 yeast per DC (numbers of unphagocytosed yeast rose sharply at higher
ratios). Twenty four hours later, the DCs were co-cultured for four hours with a CD8+ T cell line
specifically recognizing the N9V/HLA-A*0201 complex. An IFNy secretion cell capture FACS
assay was performed on the T cells to quantify the percentage of cells that had been activated as
a result of cross-presentation by the DCs. As shown in Fig. 3.1B, EBYN9V yeast resulted in
dose-dependent cross-presentation at levels much higher than the background caused by
EBY100 yeast lacking the N9V surface display construct. We decided to use the 20:1 yeast:DC
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Figure 3.1, Antigen displayed on the surface of yeast is cross-presented more efficientlythan antigen expressed intracellularly in yeast.
A, Diagram of the yeast surface display system of strain EBYN9V. The N9V epitope is in bold.B, Dose response of EBYN9V on cross-presentation. EBYN9V and wild type EBY100 yeast
were added to DCs at the indicated ratios. After 24 h, the DCs were assayed for the ability to
stimulate IFNy secretion in co-cultured N9V-specific T cells. Error bars represent the standarddeviations of duplicate wells.
C, EBYN9V yeast and yeast expressing the same Aga2p-N9V fusion protein intracellularly were
added to DCs at a 20:1 ratio and tested for the ability to stimulate IFNy secretion in co-culturedN9V-specific T cells. Lactacystin (5 tM) or chloroquine (25 tM) were added to some wells anhour before the yeast were introduced. Error bars represent the standard deviations of duplicate
wells.
D, Samples of the two yeast cultures and wt yeast were subjected to extensive reduction to
release proteins disulfide-bonded to the cell wall. Subsequently, the yeast were treated withZymolyase and lysed. The proteins reduced off the cell wall and the lysed cell extracts were slot-blotted onto the same nitrocellulose membrane and labeled for c-myc.
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ratio for future cross-presentation experiments to minimize the signal-to-noise ratio; note that the
concentration of peptide equivalents at this dose is only 4 nM.
3.4.2 Surface-displayed Antigen is Cross-presented Much More Efficiently than Intracellular
Antigen
We next compared cross-presentation of yeast surface-displayed antigen to antigen
expressed inside the cytosol of yeast. By deleting the signal peptide, the same Aga2p-N9V fusion
protein was expressed intracellularly in yeast. At the same 20:1 yeast:DC ratio, cross-
presentation resulting from intracellular antigen was only half that from surface-displayed
antigen (Fig. 3.1C). This result was obtained even though the expression level of intracellular
antigen was 20-30x the surface display level. In the slot blot in Fig. 3.1D, the amount of antigen
in an intracellular extract of 1 x 106 cytosolically expressing yeast is equivalent to the amount of
antigen reduced off the cell walls of 2-4 x 107 surface-displaying yeast. The blot also
demonstrates that with both yeast cultures, antigen expression was restricted to the intended
location.
To try to understand the marked difference in cross-presentation efficiency between
surface-displayed and intracellular antigens, we studied the effects of inhibitors of either the
phagosome-to-cytosol route or the vacuolar route. Cross-presentation of surface-displayed
antigen was strongly inhibited by lactacystin, a proteasome inhibitor, whereas chloroquine,
which raises the endolysosomal pH, had no inhibitory effect and was actually slightly beneficial
(Fig. 3.1C). We deduced that the phagosome-to-cytosol pathway is the major mechanism of
cross-presentation with yeast surface-displayed antigen. Chloroquine has been observed to
increase the cross-presentation efficiency of soluble antigens, possibly because it increases
membrane permeability and hence antigen escape into the cytosol (26), and may be having a
similar subtle effect here. Cross-presentation of intracellular antigen was inhibited by both
lactacystin and chloroquine (Fig. 3.1C). It is unclear whether cross-presentation of intracellular
antigen proceeds by a combination of the phagosome-to-cytosol and vacuolar routes, or whether
only the phagosome-to-cytosol route is involved, with chloroquine reducing the rate at which the
yeast cell wall was breached, thus slowing antigen export into the DC cytosol. In any case, it is
clear to us that having antigen exposed on the yeast surface provides a significant advantage for
cross-presentation due to greater accessibility to the DC cytosol compared to having antigen
trapped by the thick yeast cell wall.
3.4.3 Manipulating the Kinetics ofAntigen Release with Different Linkers
We hypothesized that the rate at which antigen is released from a phagocytosed particle
influences the efficiency of cross-presentation, since antigen release is a necessary step before
export into the cytosol can occur. The yeast surface display model provided an excellent means
to test this hypothesis. We conjectured that with EBYN9V yeast, the N9V antigenic peptide
could be released from the yeast cell wall by proteolysis in the phagosome or by reduction of the
disulfide bonds tethering Aga2p to Agalp. The rate of the former mechanism could potentially
be manipulated by including protease recognition sites N-terminal to the antigenic peptide. We
targeted Cathepsin S (CatS) because unlike most other cathepsins that are active only in acidic
conditions found later in phagosomal maturation, its operating range extends from pH 5.0 to 7.5
(27). Furthermore, phagosomes in macrophages and DCs fuse preferentially with endocytic
compartments enriched in CatS, with CatS activity detected in ten-minute-old phagosomes (28).
Five potential CatS recognition sites culled from the literature are listed in Table 3.1. In
some cases, four amino acid residues on either side of a known CatS cleavage point were used.
These sequences, termed Cl to C5, were each inserted individually between the (G4S) 3 linker
and the extended antigenic peptide. An additional construct was created where the (G4S) 3 linker,
a suspected CatS cleavage site, was deleted. To test whether these sequences were recognized in
their new context, yeast expressing the modified plasmid constructs were incubated with
recombinant CatS and analyzed for loss of the c-myc epitope. CatS had negligible effect on HA
epitope levels, indicating that the polypeptide chains linking together HA, Aga2p, Agalp and the
cell wall remained intact. While the addition of Cl, C2, and C5 increased CatS cleavage, C3 and
C4 had the opposite effect and were apparently not recognized and/or disrupted a pre-existing
recognition site (Fig. 3.2A). Deleting the (G4S) 3 linker altogether conferred the greatest
resistance to CatS cleavage. When yeast with these different linker sequences were phagocytosed
by DCs, the resulting pattern of cross-presentation was strikingly similar to the pattern of CatS
cleavage (Fig. 3.2B). Performing Spearman's rank correlation on the rankings listed in Table 3.1,
CatS susceptibility and cross-presentation efficiency were found to be positively correlated at the
significance level of P < 0.05, supporting our hypothesis that faster antigen release within the
phagosome results in more efficient cross-presentation. Note that one would not expect the rank
order correspondence to be perfect because it is likely that other cathepsins, which may share
some degree of substrate specificity with CatS, also play a role in antigen release towards cross-
presentation.
Table 3.1. Linker modifications and resulting effects on cross-presentation
Name Modification Reference CatS cleavage Cross-presentation
rank order rank order
Deleted (G4S) 3 deleted - 7 7
Unchanged - - 4 4
C1 EKARVLAEAA inserted (42) 2 1
C2 SSAESLK inserted (43) 3 2
C3 NWVCAAKF inserted (34) 6 5
C4 GILQINSR inserted (34) 5 6
C5 QWLGAPVP inserted (44) 1 3
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Figure 3.2, Correlation between linker susceptibility to CatS cleavage and cross-presentation efficiency.
A and C, Yeast surface-displaying N9V with different linkers (described in Table 3.1) wereincubated with 50 ng (A) or 20 ng (C) of recombinant CatS for 15 min at 370C. The percentagedecrease in c-myc levels in comparison to yeast before CatS treatment was determined by flowcytometry.
B and D, The yeast samples with different linkers were added to DCs and assayed for the abilityto stimulate IFNy secretion in co-cultured T cells 24 h later. The results were normalized by thepercentage of IFNy• T cells stimulated by yeast with the unmodified linker (B) or a single insertof the Cl sequence (D). In (B), there were significant differences in surface display levelsbetween constructs (as detected by flow cytometry, the mean expression levels in arbitrary unitswere 1677, 1258, 1526, 1323, 1430, 1853 & 1279 from left to right). Each yeast culture samplewas mixed with wt yeast to normalize the delivered antigen dose to that of the lowest-expressingconstruct. This was unnecessary in (D) as the surface display levels were within 10% of eachother. Error bars represent standard deviations between duplicate (B) or triplicate (D) wells.
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In an attempt to further increase antigen release rates by CatS, we created constructs with
tandem repeats of C1 and C2 sequences. Tandem repeats of C2 did not further enhance CatS
susceptibility (not shown), but the rate of CatS cleavage increased with the number of tandem
copies of C1 (Fig. 3.2C). Consistent with our hypothesis, there was a corresponding increase in
cross-presentation efficiency (Fig. 3.2D).
3.4.4 Antigen released by CatS is Processed by Proteasomes
Yeast strains were created with chromosomally integrated expression cassettes for the
constructs with the deleted (G4S)3 linker, with a single C1 insertion, and with four tandem Cl
repeats, selected for being representative of the entire range of CatS susceptibilities. These yeast
strains displayed the expected rank order of cross-presentation efficiency across a range of yeast
to DC ratios: (C1)4 > C1 > deleted (Fig. 3.3A). The differences in cross-presentation efficiency
were largely diminished when the DCs were pretreated with a specific CatS inhibitor (10 gM Z-
FL-COCHO) (Fig. 3.3A), showing that CatS cleavage was indeed primarily responsible for these
differences. Since the disparities in cross-presentation efficiency were not completely eliminated,
it is possible that other proteases may have played minor roles in antigen release; alternatively,
CatS was not completely inhibited. The gains in cross-presentation efficiency with increased
CatS susceptibility were not due to the vacuolar route becoming dominant; instead, cross-
presentation of all three strains remained inhibited by lactacystin and unaffected or slightly
improved by chloroquine (Fig. 3.3B), suggesting that the antigen released by CatS moved from
the phagosome to the cytosol.
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3.4.5 Evidence of a Time Window for Productive Antigen Release
With these integrated expression yeast strains, at least 98% of the yeast cells expressed
the surface-displayed antigen (compared to -75% for transformed yeast subject to plasmid loss),
so antigen loss that occurred after phagocytosis could be clearly distinguished. We developed an
assay for monitoring in vivo antigen processing involving lysing the DCs at various time points
after phagocytosis was initiated, followed by labeling the released yeast with a-HA and a-c-myc
antibodies. Antigen release by proteolytic cleavage of the linker C-terminal to the HA epitope (or
less likely, cleavage of the antigenic peptide or the c-myc epitope) results in HA+, c-myc" yeast.
We observed that between 5 and 25 min post-phagocytosis, this population was largest with the
(Cl) 4 linker and smallest with the deleted linker (Fig. 3.3C). This is consistent with CatS
attacking the linkers at different rates during this early stage of phagosomal maturation, and
supports the notion that early proteolytic release was responsible for the variation in cross-
presentation efficiency. During the first 20 min or so, very little antigen was released in a way
that would cause the loss of both epitopes (Fig. 3.3D), such as disulfide bond reduction or
enzymatic attack of the yeast cell wall, Agalp or Aga2p. Between 25-30 min post-phagocytosis,
the double-negative population started rising rapidly, suggesting that the phagosomes had fused
with late endosomes or lysosomes that provided a more acidic environment and a larger
complement of active proteases. The differences in antigen loss levels between the three strains
diminished at these later time points, and presumably, all the yeast cells would eventually lose
their attached antigen. This suggests that antigen release rates early in phagosomal maturation
are key to cross-presentation efficiency; antigen released after the 25 min time point may be
mostly degraded by lysosomal proteases rather than cross-presented.
3.4.6 Manipulating the Kinetics ofAntigen Release Using Fluorescein-binding ScFvs
One of the earliest applications of yeast surface display was to perform directed evolution
of a fluorescein-binding single chain variable fragment (scFv) of an antibody to select for
mutants with increased affinity (23). The existence of a pool of mutants spanning over four
orders of magnitude in dissociation rate provided the opportunity to manipulate antigen release
kinetics in a manner distinct from proteolytic release. We first loaded yeast expressing these
scFv mutants with fluorescein-tagged extended peptides, but the surface display levels of these
scFvs were low and variable. We selected one scFv (4M3.12) to perform directed evolution,
finding a combination of five mutations that increased the surface display level by 4-5 fold
(HEAF3.12, see Appendix A.11). However, when these same mutations were made in other
highly homologous scFvs, the surface display levels only increased 1-2 fold (not shown). Finally,
we inverted the topology and loaded fluorescein-conjugated yeast with scFv-
ARNLVPMVATVQGQN-c-myc fusion proteins, with the attendant advantage that the delivered
antigen dose would be independent of the protein expression level. Four scFvs, with attributes
listed in Table 3.2, were selected from the mutant pool to be produced as scFv-antigen fusions.
Table 3.2. Properties of fluorescein-binding scFvs
Name Dissociation half-time at
pH 7.4, 25°C* pH 5.4, 370 C
4M2.3 22 min < 1 min
4M3.12 4.0 h 4.8 min
4M4.5 26 h 9.8 min
4M5.3 5.7 days 1.9 h
*From (23)
We developed a mathematical model based on the schematic in Fig. 3.4A to predict the
cross-presentation outcome. In this model, the scFv-antigen fusion dissociates from yeast cells in
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Figure 3.4, Mathematical modeling and experimental results for cross-presentation 
of
antigen attached to yeast cells by scFv binding.
A, Schematic of a simple model describing antigen release, export and degradation before 
and
after phagocytosis. The unbroken arrows represent first-order processes with associated 
rate
constants that make up an ordinary differential equation-based model.
B, A representative plot of cytoplasmic antigen versus koff when the equations were solved 
with
reasonable parameter values (pre-phagocytosis time of 30 min, cl = 4, c2 = 50, c3 = 100, ks =
0.02 min-1, kdeg = 0.1 min- ).
C, Fluorescein-conjugated yeast were incubated with culture supernatants containing secreted
scFv-antigen fusion proteins, washed, and added to DCs to perform cross-presentation assays.
The results of three separate experiments (represented by the three line/marker combinations)
were scaled such that unloaded fluorescein-conjugated yeast gave a result of 1 whereas a 1 [iM
extended peptide positive control gave a result of 100.
D, Fluorescein-conjugated yeast loaded with scFv-antigen were incubated with DCs for 15 min,
after which the DCs were placed on ice and lysed with RIPA buffer. The released yeast cells
were analyzed for the presence of the c-myc epitope tag by flow cytometry.
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three stages, the first encompassing the handling steps and time lag before phagocytosis by DCs,
the second being the estimated 20 min window in phagosome maturation before the transition
into a phagosolysosome, the third stage. We made the simplifying approximation that for all
scFvs, the dissociation rates during these three stages could each be expressed as a
proportionality constant multiplied by the measured dissociation rate at neutral pH and 25"C
(koff). ScFv-antigen released prior to phagocytosis is assumed to be lost, whereas scFv-antigen
released in the phagosome escapes to the cytosol at a rate kesc. When the phagosome matures into
a phagolysosome, proteases degrade both yeast-bound and free antigen with the rate constant kdeg.
Protease activity that could cause antigen release rather than destruction of the epitope was
neglected. We assumed that the final level of cross-presentation is proportional to the amount of
antigen that escapes to the DC cytosol. The solution to the ordinary differential equations
comprising this model describes a bell-shaped curve for cytosolic antigen versus koff (Fig. 3.4B).
The existence of a koff value optimal for cross-presentation was a property of the model that was
robust to simultaneous parameter variations spanning three orders of magnitude. At very high koff
values, most of the antigen is lost prior to phagocytosis, whereas at very low koff values, little
antigen is freed in the phagosome and the majority is degraded in the phagolysosome.
If antigen release rates in the phagosome did not affect cross-presentation, we would
expect to see cross-presentation efficiencies rising monotonically with decreasing koff due to the
increased dose taken up by the DCs. Instead, the results of three independent cross-presentation
experiments confirmed the existence of the model-predicted optimum, with the femtomolar
fluorescein binder 4M5.3 resulting in less cross-presentation than the lower affinity 4M4.5 (Fig.
3.4C). When the yeast were extracted from lysed DCs 15 min post-phagocytosis, antigen loss
was shown to decrease with increasing affinity (Fig. 3.4D). Although the dissociation half-time
of 4M5.3 is almost two hours in vitro even at pH 5.4, 370 C, proteolysis by CatS or other early
phagosomal proteases contributed to a baseline level of antigen release not accounted for in the
model; hence, the 4M5.3-antigen fusion gave rise to higher than expected levels of cross-
presentation.
3.5 Discussion
We have shown by three distinct types of experiments that antigen release kinetics from
phagoctosed yeast cells influences the efficiency of cross-presentation occurring via the
phagosome-to-cytosol route. First, protease-accessible antigen exposed on the yeast external
surface is cross-presented much more efficiently than antigen trapped inside the tough cell wall.
Second, increasing the susceptibility to CatS cleavage of the linker between the antigen and its
cell wall anchor resulted in increased cross-presentation efficiency. Third, there exists an optimal
affinity for antibody fragments used to attach antigen to the yeast surface, with extremely low
dissociation rates being detrimental for cross-presentation efficiency.
Although this evidence was obtained with yeast, we believe that the hypothesis applies to
other particulate vaccines, since antigen release in the phagosome logically precedes phagosome-
to-cytosol translocation. Indeed, in one of the earliest demonstrations of cross-presentation, it
was observed that ovalbumin passively adsorbed to latex beads was more efficiently cross-
presented than ovalbumin conjugated to the same beads, although no explanation was put forth at
that time (29). Particulate vaccines have advantages over soluble vaccines in that they are not
diluted by diffusion, and are targeted to phagocytic professional antigen-presenting cells. It
behooves particulate vaccine developers to take antigen release kinetics into consideration and to
perform research into methods of optimizing these kinetics for their vaccine systems. An
alternative strategy is to bypass the requirement for freeing antigen in the phagosome, as
illustrated by microparticles that released antigen directly in the cytosol (30).
Our analysis of antigen loss occurring post-phagocytosis suggests that there exists a
limited time window for productive antigen release. In the case of yeast surface display, it
appears that antigen freed after the 25 min time point did not contribute significantly to cross-
presentation. The 25 min time point coincided with a sudden rise in antigen loss by means other
than cleavage of the linker, possibly indicating phagosome fusion with late endosomes or
lysosomes. With macrophages that had phagocytosed yeast, the phagosomal pH took 20-25
minutes to decrease to a minimum of about 5.0 (31). A time course analysis of protease activity
in murine DC phagosomes showed that Cathepsins B, L and Z jumped in activity between 20
and 30 min after phagocytosis (28). On the other hand, Savina et al. recently showed that
phagosomes in murine DCs do not acidify significantly for 3 h (32). The connection between
phagosome acidification and acquisition of proteolytic activity remains unclear, as well as how
these may be affected by DC status and the nature of the particle.
The three constructs with different linkers that we compared displayed the greatest
variation in antigen loss during the 10-20 min window, so it is likely that the major source of
N9V peptide ultimately cross-presented was antigen freed during this time frame. With
endocytosed antigen, it has been suggested that antigen destined for cross-presentation exited
early from the endosomal pathway; the bulk of the antigen was colocalized with late
endosomal/lysosomal markers after 25 min but did not contribute to cross-presentation (33). In
the same study by Palliser et al., aggregated protein antigen was observed to be cross-presented
almost ten times less efficiently than the monomeric form. A possible explanation for this result
is that aggregates that were not dispersed soon after uptake could not egress to the cytosol and
were not cross-presented.
The narrow time window available for antigen release suggests that CatS, unusual among
cathepsins for being active at up to neutral pHs, may play a special role in phagosome-to-cytosol
cross-presentation. Roles for CatS in the vacuolar route of cross-presentation (30) and class II
presentation (34) have previously been identified.
In our mathematical model, after 20 min of phagosome maturation, proteolytic
degradation of antigen competed with antigen export into the cytosol. Thus, only a small fraction
of antigen released after 25 min or so contributed to cross-presentation. However, we further
speculate that phagolysosome formation may in some way close off the means for antigen egress
to the cytosol, thus imposing another limit on the time window for productive antigen release.
Teleologically, it would make sense for the class II epitopes generated in phagolysosomes to be
retained rather than exported to the cytosol. The nature of this phagosomal "pore" remains a
mystery, although it appears to have a size limit, with 40 K but not 500 K dextran being
translocated (35). Several years ago, at least three studies provided evidence that membranes of
the endoplasmic reticulum (ER) contribute to the nascent phagosome (36-38), leading to
speculation that ER-resident proteins like the Sec61 translocon or Derlp (39) may be responsible.
ER-phagosome fusion has since been disputed (40), but Cresswell et. al recently demonstrated
the involvement of ER retrotranslocation mechanisms in cross-presentation (41). Solving this
mystery would represent a significant advance in the state-of-the-art and may permit the
development of techniques to either increase the rate of antigen export to the cytosol or extend
the time window for which this mechanism is active. Increasing the transport of antigen to the
cytosol in this manner, combined with more complete antigen release during the critical time
window, could lead to the development of more effective vaccines designed to raise cellular
immunity against virus-infected cells and cancer cells.
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Chapter 4
Inducing Efficient Cross-Priming using Antigen-Coated Yeast
Particles2
4.1 Abstract
Saccharomyces cerevisiae stimulates dendritic cells and represents a promising candidate
for cancer vaccine development. Effective cross-presentation of antigen delivered to dendritic
cells is necessary for successful induction of cellular immunity. Here, we present a yeast-based
vaccine approach that is independent of yeast's ability to express the chosen antigen, which is
instead produced separately and conjugated to the yeast cell wall. The conjugation method is
site-specific (based on the SNAP-tag) and designed to facilitate antigen release in the dendritic
cell phagosome and subsequent translocation for cross-presentation. We demonstrate that non-
site-specific chemical conjugation of the same protein hinders cross-presentation. Phagosomal
antigen release was further expedited through the insertion of the invariant chain ectodomain as a
linker, which is rapidly cleaved by Cathepsin S. The dose of delivered antigen was increased in
several ways: by using yeast strains with higher surface amine densities, by using yeast hulls
(cell wall fragments) instead of whole cells, and by conjugating multiple layers of antigen. The
novel multi-layer conjugation scheme takes advantage of Sfp phosphopantetheinyl transferase
and remains site-specific; it enables the antigen dose to grow linearly with the number of layers.
We show that whole yeast cells coated with one layer of the cancer-testis antigen NY-ESO-1 and
yeast hulls bearing three layers were able to cross-prime naive CD8÷ T cells in vitro, with the
latter resulting in higher frequencies of antigen-specific cells after ten days. This cross-
2 Major portions of this chapter will shortly be published in:
Howland, S. W., Tsuji, T., Gnjatic, S., Ritter, G., Old, L. J. and K. D. Wittrup, 2008. Inducing Efficient
Cross-Priming using Antigen-Coated Yeast Particles. J Immunother 31.
presentation-efficient antigen conjugation scheme is not limited to yeast and can readily be
applied towards the development of other particulate vaccines.
4.2 Introduction
The goal of cancer vaccination is to elicit a tumor-protective immune response against
cancer-associated antigens, in order to defeat cancer in much the same way as we have defeated
many infectious diseases. However, despite the leaps made in understanding of cellular immune
function and tumor immunology, objective response rates in cancer vaccine clinical trials have
been disappointingly low (1). Many early generation cancer vaccines were simply peptide or
protein injections, sometimes paired with a cytokine adjuvant. With respect to infectious diseases,
it has been pointed out that modem peptide or protein vaccines are problematic in that they are
often considerably less immunogenic than primitive vaccines made from live or dead organisms
(2). New, more immunogenic vaccine approaches, including ones that more closely mimic
pathogens, are required in the field of cancer immunotherapy.
One such promising new approach is the use of recombinant S. cerevisiae yeast
expressing antigen in the cytosol (3-10) or on the cell wall (11, 12). With its fungal cell wall,
yeast cells are avidly phagocytosed and induce maturation of dendritic cells (DCs) and the
secretion of Thl-type cytokines (3, 5-10) S. cerevisiae is not pathogenic and despite its potent
effect on the innate immune system, subcutaneous administration of heat-killed yeast did not
exhibit dose-limiting toxicity in phase I clinical trials (10). The adjuvant properties of yeast are
only half the story, as successful vaccine development also requires that a sufficient dose of
antigen be delivered to the DCs in a way that facilitates processing and MHC class I presentation
(i.e. cross-presentation).
We have previously shown that timely antigen release from the yeast cell upon
phagocytosis by DCs is critical for efficient cross-presentation (12). In that study, the extended
peptide antigen was recombinantly expressed on the cell wall as a fusion to the mating adhesion
receptor subunit Aga2p, in a technique termed yeast surface display (13). Yeast surface-
displayed antigen was cross-presented much more efficiently than antigen expressed in the yeast
cytosol, and cross-presentation could be further enhanced by inserting linkers susceptible to
Cathepsin S (CatS) cleavage between the antigen and Aga2p (12). While this model system was
useful for studying the impact of phagosomal antigen release kinetics upon cross-presentation, its
utility as an immunotherapy vaccine candidate is limited by the reliance on yeast expression
levels for antigen delivery. For many reasons, it is often desirable to immunize with a full-length
protein as opposed to a known peptide epitope, and yeast surface display levels of the former
may not be adequate or optimal. We therefore set out to develop a system for attaching soluble
protein antigens to the yeast cell wall, so as to decouple antigen dose from yeast expression
levels while retaining a desirable antigen release profile upon DC phagocytosis.
We focused our attentions on the highly immunogenic cancer-testis antigen, NY-ESO-1,
which has been widely tested in cancer vaccine clinical trials (reviewed in (14) and (15)). NY-
ESO-1 is surface-displayed very poorly by yeast, and although a combination of rational design
and directed evolution approaches identified a mutant that has a 100-fold improved display level
(16), the number of copies per yeast cell still did not reach peptide display levels. In contrast,
NY-ESO-1 can be expressed solubly and at high yield in E. coli when fused to maltose-binding
protein (MBP, unpublished observation by A. Piatesi).
Our challenge was to conjugate bacterially expressed NY-ESO-1 to the yeast cell wall, in
a manner facilitating release of the antigenic domain in the DC phagosome. Insertion of a CatS-
susceptible linker, which worked admirably with yeast surface display, would likely be foiled by
conventional chemical conjugation methods where the reaction can occur at multiple amino acid
positions along the fusion protein. For example, a reaction scheme based on primary amines
might bind a lysine residue of NY-ESO-1 directly to the cell wall, thus preventing release when
the CatS-susceptible linker is cleaved. Consequently, we turned to site-specific conjugation
methods where the reaction is mediated by a protein and is restricted to a known amino acid
residue.
4.3 Materials and Methods
4.3.1 Reagents
Recombinant human cytokines were obtained from R & D Systems (Minneapolis, MN).
Monoclonal a-NY-ESO-1 antibody, clone E978, was obtained from Sigma-Aldrich (St. Louis,
MO). Dye-conjugated monoclonal antibodies against CD8 and DC markers were from BD
Biosciences (San Jose, CA) except for a-CD40 (Calbiochem, Gibbstown, NJ), a-CD86
(Chemicon, Billerica, MA) and a-HLA-DR (Leinco, St. Louis, MO).
4.3.2 Cells
Human HLA-A*0201 monocytes purified by negative magnetic cell sorting from
leukapheresis packs were purchased from Biological Specialty Corporation (Colmar, PA). The
monocytes were cryopreserved in 90% fetal bovine serum (FBS), 10% DMSO and aliquots were
thawed as needed. The monocytes were cultured in C10 medium-RPMI-1640 with 10% FBS, 2
mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 1 x non-essential amino acids, 50 pM
f3-mercaptoethanol and Primocin (InvivoGen, San Diego, CA)-supplemented with 1000 U/ml
each of IL-4 and GM-CSF in 6-well plates (4-5 x 106 monocytes in 2.5 ml medium per well).
Each well was fed with 0.5 ml cytokine-supplemented C10 on days 2 and 4; on day 5 or 6, the
floating and loosely adherent immature monocyte-derived DCs were harvested by gentle
resuspension.
A human CD8+ T cell line specifically recognizing the cytomegalovirus-derived peptide
NLVPMVATV (N9V) in the context of HLA-A*0201 was obtained from ProImmune (Oxford,
UK). The vials of frozen cells were thawed and cultured overnight in RPMI-1640 with 10% FBS,
5 ng/ml IL-2 and Primocin before use.
PBMCs were isolated by Ficoll-Paque density gradient centrifugation from HLA-A2
buffy coats (Research Blood Components, Brighton, MA). A portion of the PBMCs from each
donor were cryopreserved in 90% FBS, 10% DMSO while the rest were subjected to magnetic
cell separation by an autoMACS Separator (Miltenyi Biotec, Auburn, CA). CD8 and CD45RO
microbeads (Miltenyi) were used sequentially in positive and negative selection modes according
to the manufacturer's protocol to isolate CD8+ CD45RO- cells.
4.3.3 Yeast
S. cerevisiae strain BJ5464a (ATCC, Manassas, VA) was grown in YPD medium (1%
yeast extract, 2% peptone and 2% dextrose) in a 300 C shaker. Plasmids for yeast surface display
were constructed based on pCTCON2 (17), and the shuttle vector pRS304 (18) was used to
integrate expression cassettes into EBY100 (13), a yeast strain that expresses Agalp under
galactose induction. In particular, the strain SWH100 was created from EBY100 by integrating
an Aga2p-HA expression cassette, constructed by substituting two stop codons between the PstI
and BamHI sites in pCTCON2. SWHl00 was grown to mid-log phase in SD-CAA medium (2%
dextrose, 0.67% yeast nitrogen base, 0.5% casamino acids, 0.1 M sodium phosphate, pH 6.0) at
300 C and induced for 12 h at 300C in YPG (1% yeast extract, 2% peptone and 2% galactose).
Yeast cell densities were estimated by measuring the absorbance at 600 nm, with an OD of 1
taken to be 1 x 107 cells/ml.
4.3.4 MBP fusion proteins
Plasmids for E. coli expression of MBP fusion proteins were constructed using pMAL-
c2x (New England Biolabs, Ipswich, MA) as the vector backbone. The plasmid for expressing
MSCE was constructed by inserting sequences encoding the SNAP tag (AvaI/EcoRI; from
pSS26b, Covalys, Witterswil, Switzerland), the CatS-susceptible linker (C1)4 and the CMV-
derived peptide ARNLVPMVATVQGQN (EcoRIIBamHI; from pCT-(C1) 4-N9V (12)), and the
CS variant of NY-ESO-1, with C to S mutations at positions 75, 76 and 78 (BamHI/HindIII;
from pCT-NY-ESO-CS (16)). To express MS74NEY2, further modifications included replacing
the (C1)4 coding sequence with that of aa 73-207 of human CD74 (EcoRIINheI; from cDNA
clone LIFESEQ1001730, Open Biosystems, Huntsville, AL) and C-terminal insertion of a
sequence encoding TVQL-(G 4S)3-DSLEFIASKLA-H6 (ybbR tag (19) is underlined).
Plasmid-bearing BL21(DE3)-RIPL bacteria (Stratagene, La Jolla, CA) in 1 L LB broth
were induced at an OD600 of 0.7 with 0.3 mM isopropyl-o-D-thiogalactoside for 4-6 h at 200C.
The cell pellet was frozen, thawed, resuspended in 25 ml of the appropriate column buffer
containing Complete Protease Inhibitor Cocktail (Roche Applied Science, Indianapolis, IN) and
lysed by sonication. For fusion proteins lacking a His6 tag, the cell lysate was clarified by
centrifugation (20000 x g, 30 min, 4°C) and loaded onto an amylose resin (New England
Biolabs) column equilibrated with amylose resin buffer (AR buffer; 20 mM Tris-HCl pH 7.4,
200 mM NaCl, 1 mM DTT, 1 mM EDTA). The column was washed with 50 column volumes
(CV) of AR buffer containing 0.1% Triton X-114 (Sigma-Aldrich; to reduce endotoxin content
(20)), followed by 5 CV of AR buffer and eluted with 5 CV of AR buffer containing 10 mM
maltose. The eluate was further subjected to size exclusion chromatography (Superdex 200
10/300 GL, GE Healthcare, Piscataway, NJ) to purify full-length protein. For fusion proteins
containing a C-terminal His6 tag, the clarified cell lysate was loaded onto a TALON resin
(Clontech, Mountain View, CA) column equilibrated with Talon buffer (20 mM Tris-HCl pH 7.4,
20 mM NaC1, 5 mM P-mercaptoethanol). The column was washed with 10 CV Talon buffer and
eluted with 5 CV Talon buffer with 150 mM imidazole. The eluate was then subjected to
amylose resin affinity chromatography as described above. For more thorough endotoxin
removal, the purified protein used in the in vitro immunization and DC maturation experiments
(see below) was treated with Polymyxin B-agarose (Sigma-Aldrich).
4.3.5 SNAP-tag conjugation to yeast
Yeast cells were UV-irradiated (2 x 1000 J/m2 in a Stratagene Stratalinker), washed 5x
with PBS + 0.01% CHAPS (the detergent reduces yeast adherence to tube walls) and once with
dimethylformamide (DMF). A pellet of 1 OD.ml or 10' yeast (or the equivalent amount of yeast
hulls) was resuspended in 10 gl DMF containing 0.2 mg BG-GLA-NHS (Covalys), shaken at
300 C for 2 h and washed 3x with PBS + 0.1% bovine serum albumin (BSA). The BG-modified
yeast was then resuspended in 0.4 ml PBS and 0.1 ml of 60 plM SNAP-tagged fusion protein
(dissolved in AR buffer with 10 mM maltose) and rotated at 300C for 5 h. The yeast was washed
at least twice with PBS + 0.1% BSA before use. Conjugation levels were monitored by flow
cytometry (e.g. labeling with a-NY-ESO-1 followed by Alexa Fluor 488-conjugated goat a-
mouse antibody).
4.3.6 Conjugation to yeast by reductive amination
2.5 OD.ml of UV-irradiated BJ5464a yeast was washed thrice and resuspended in 450 pl
0.1 M sodium acetate pH 5.5 buffer. After the addition of 50 pl 100 mM NaIO4 dissolved in the
same buffer, the yeast was incubated on ice for 20 min and then washed twice with 1 ml sodium
acetate buffer. The yeast was resuspended in 200 pl1 50 p.M MSCE protein that had been buffer-
exchanged into PBS + 1 mM DTT. NaCNBH3 (2 pll of a 1 M solution in 10 mM NaOH) was
added and the tube was rotated at 40C for three days.
4.3.7 N9V cross-presentation assay
Immature monocyte-derived DCs were seeded in 96-well round bottom plates with 2 x
105 DCs in 200 Cl cytokine-supplemented C10 medium per well. Yeast cells or yeast hulls were
added to the DCs at the indicated ratios; after 24 h, half the medium was replaced by 100 pl of
0.7 - 1 x 106 cells/ml suspension of N9V/HLA-A*0201-specific T cells. Four hours later, the
cells in each well were transferred to tubes to perform an IFN'y secretion assay (Miltenyi)
according to the manufacturer's protocol. Briefly, the cells were labeled for 5 min with a
bispecific antibody that captures secreted IFNy, incubated in medium for 45 min at 370 C, and
labeled with a-CD8-FITC and a-IFNy-PE. The fraction of CD8+ cells that were also IFNy+ was
determined by flow cytometry, with the gate for IFNy fluorescence set such that the negative
control test (no stimulus added to the DCs) gave a result of 0.5% or lower.
4.3.8 ELISpot assay
Monocytes were isolated by CD14 magnetic cell sorting (Miltenyi) from the PBMCs of a
healthy HLA-Cw3 donor and differentiated into DCs by culturing for 6 days in the presence of
GM-CSF and IL-4. DCs were pulsed overnight with NY-ESO-1 92-100 peptide or antigen-coated
yeast (20 yeast per DC). The DCs were washed and seeded at 5 x 104 cells/well in a mixed
cellulose ester membrane filter plate (Millipore, Billerica, MA) pre-coated with a-IFNy (1-D 1K,
Mabtech, Mariemont, OH) together with the indicated number of C5 cells. C5 is an HLA-Cw3-
restricted CD8 + T cell clone recognizing NY-ESO-1 92-100 (21). After 24 h of co-culture, the plate
was developed with biotinylated a-IFNy (7-B6-1, Mabtech), streptavidin-alkaline phosphatase
conjugate (Roche) and BCIP/NBT substrate (Sigma) for evaluation with a CTL ImmunoSpot
Analyzer.
4.3.9 CatS cleavage time course
For each time point, 0.2 OD.ml of antigen-conjugated yeast was resuspended in 100 pl
AR buffer. Recombinant CatS solution (Calbiochem; 20 ng in 100 p1l AR buffer) was added and
each tube was incubated at 370 C for the indicated time before the yeast was washed with cold
PBS + 0.1% BSA. The yeast was labeled with a-NY-ESO-1 followed by Alexa Fluor 488-
conjugated goat a-mouse IgG prior to analysis by flow cytometry.
4.3.10 Multi-layer conjugation
Sfp phosphopantetheinyl transferase was produced as described by Yin et. al (19) except
that BL21(DE3)-RIPL was used as the expression strain and the bacteria were lysed by
sonication. BG-CoA was synthesized by reacting 1 mg (2.0 gpmoles) of BG-maleimide (Covalys)
dissolved in 0.5 ml DMF with an equal volume of PBS containing 1.5 gpmoles of Coenzyme A
trilithium salt (Sigma-Aldrich). After incubating at 300 C for 24 h, the presence of the product
was confirmed by mass spectrometry. 1 mM DTT was added to quench the excess BG-
maleimide and the BG-CoA solution was used without purification. The initial layer of fusion
protein containing both the SNAP and ybbR tags was conjugated to BG-modified yeast (or yeast
hulls) as described above. 1 OD.ml of coated yeast was resuspended in 200 .1 PBS + 0.1% BSA
containing 10 mM MgC12, 75 pM BG-CoA and 12.5 p.M Sfp. The yeast was incubated at 370 C
for 1.5 h with occasional vortexing and washed twice with PBS + 0.1% BSA. The next layer was
conjugated by mixing the yeast with 0.4 ml PBS and 0.1 ml 60 gM fusion protein for 2 h at 300 C.
The Sfp/BG-CoA reaction and the SNAP-tag conjugation reaction were alternated to add more
layers.
4.3.11 Yeast hulls
A 1 L culture of induced SWH100 yeast was pelleted, washed, and resuspended in 200
ml PBS to give an OD value of 25. The yeast suspension was passed twice through an M-
110EH-30 Microfluidizer processor (Microfluidics, Newton, MA) at 30,000 psi using the G10Z
(87 gm) interaction chamber. 40 ml of lysed yeast suspension was pelleted by centrifugation at
2000 x g for 5 min and then washed once with 100 ml PBS + 0.1% CHAPS, once with 100 ml
20% ethanol, and four times with 100 ml PBS + 0.01% CHAPS. The yeast fragments were
resuspended in 100 ml PBS + 0.01% CHAPS and were stored in aliquots at -70 0 C. We assumed
that there was no change in the cell wall material concentration during processing and washing,
and treated the final yeast hull suspension as being equivalent to 10 OD of yeast.
4.3.12 In vitro immunization experiment
Nine wells of a 24-well plate were each seeded with 5 x 105 immature human monocyte-
derived DCs in 1 ml C10 medium containing IL-4 and GM-CSF. Either unmodified yeast hulls,
SWH00 whole yeast conjugated with one layer of MS74NEY2, or yeast hulls coated three
times were added to the wells in triplicate, at a dose equivalent to 10 yeast per DC. The next day,
CD8+ CD45RO T cells were isolated from the PBMCs of three HLA-A2 donors as described
and resuspended in CTL medium (RPMI-1640 with 10% FCS, 50 gM f3-mercaptoethanol, 12.5
mM HEPES, pH 7.3 and Primocin). The in vitro immunization assay conditions were adapted
from a protocol for generating CD8+ T cell clones (22). For each donor, 5 x 106 naYve T cells in 1
ml CTL medium were added directly to three DC wells with the three test conditions. In addition,
2 x 106 na'ive T cells from each donor were labeled with 20 gl a-CD8-FITC and 10 gl
SLLMWITQV/HLA-A*0201 peptide-MHC pentamer (ProImmune) in a total volume of 100 gl
for 30 min on ice prior to analysis by flow cytometry (day 0 results). On day 3, 75% of the
medium was replaced by fresh CTL medium containing IL-2 and IL-7 to give final
concentrations of 2.5 ng/ml and 5 ng/ml, respectively. The medium was refreshed in this manner
every 2-3 days, and on day 7, the cells were transferred to a 12-well plate with the well volume
doubling to 4 ml. On day 10, 2 x 106 cells from each well were labeled for CD8 and peptide-
MHC pentamer binding as described above. To restimulate the T cells, 3 x 107 PBMCs from
each donor were thawed, gamma-irradiated (35 Gy), and resuspended in 3 ml CTL medium
containing 40 gpM SLLMWITQV peptide (synthesized by AnaSpec, San Jose, CA). The PBMCs
were seeded at 1 ml per well of a 12-well plate, and 3 h later, 5 x 106 day 10 T cells from each
test condition were added in 3 ml CTL medium to donor-matched PBMC wells. On day 12 and
every 2-3 days later, the cells were fed with fresh medium containing IL-2 and IL-7 and split
when overcrowded. Flow cytometry analysis was again performed on day 20.
4.3.13 DC maturation experiment
Wells of a 24-well plate were each seeded with 4 x 105 immature monocyte-derived DCs
in 0.8 ml C10 medium containing IL-4 and GM-CSF. The stimuli (either 1 p.g/ml E. coli 055
lipopolysaccharide, LPS, from GE Healthcare, 0.5 tpM MS74NEY2 or 10 yeast per DC doses of
naked or antigen-coated whole yeast or yeast hulls) were added in duplicate to the wells. After
48 h, the culture supernatant from each well was set aside to be tested for IL-12p70 content using
the OptEIA ELISA kit (BD Biosciences). The manufacturer's protocol was followed and both 2x
and 20x dilutions of each sample in PBS were tested to cover a wide range of IL-12
concentrations. The DCs from duplicate wells were pooled and then divided into 5 portions; each
aliquot was labeled with a-DC-SIGN-FITC and a phycoerythrin-conjugated antibody against one
of 5 markers of DC maturation (CD40, CD80, CD83, CD86 and HLA-DR). The flow cytometry
data were gated by DC-SIGN expression to exclude non-DC events.
4.4 Results
4.4.1 Antigen Conjugated to Yeast via the SNAP-tag is Cross-presented
The SNAP-tag is a 20 kDa protein domain derived from human O(6)-alkylguanine-DNA
alkyltransferase, which reacts with benzyl guanine (BG) moieties resulting in the formation of a
covalent thioether bond (23). We anticipated that SNAP-tagged NY-ESO-1 fusion protein could
be site-specifically conjugated to yeast cell surfaces modified with BG. Due to the limited
availability of NY-ESO-1-specific T cell clones, we decided to use a peptide derived from
cytomegalovirus (CMV) pp65 as a surrogate antigen: ARNLVPMVATVQGQN (HLA-A*0201
epitope N9V is underlined). Cross-presentation of this epitope by DCs stimulated with yeast
surface-displaying the peptide can be detected using commercially available cognate CD8+ T
cells (12).
We designed two fusion proteins, MSCcmyc and MSCE, both containing (in order from
N terminus to C): MBP for yield, solubility and ease of purification, SNAP-tag for site-specific
conjugation, four tandem repeats of the CatS-susceptible linker EKARVLAEAAS (12), and the
CMV peptide. MSCE further included NY-ESO-1 as the C-terminal component, whereas
MSCcmyc had only a final c-myc tag for detection purposes. Both fusion proteins were
expressed in E. coli and purified by amylose affinity chromatography (including extensive
washes with 0.1% Triton X-114 to greatly reduce endotoxin content (20)) and size exclusion
chromatography. Wild type BJ5464a yeast cells (BJ5a for short) were reacted with an amine-
reactive BG derivative (BG-GLA-NHS) and subsequently incubated with either MSCcmyc or
MSCE protein. The SNAP-tag mediated conjugation was successful as determined by flow
cytometry for c-myc and NY-ESO-1, respectively (not shown).
To test for cross-presentation, the antigen-conjugated yeast as well as the control BG-
only yeast were added to immature HLA-A*0201 monocyte-derived DCs. Twenty four hours
later, the DCs were co-cultured for four hours with an N9V-specific CD8÷ T cell clone. Cross-
presentation of the N9V epitope could be assessed by quantifying the percentage of CD8÷ cells
that had responded by secreting interferon gamma (IFNy). As shown in Fig. 4.1A, yeast coated
with either fusion protein induced cross-presentation at levels significantly above the background
caused by BG-BJ5a yeast alone. The presence of NY-ESO-1 in the fusion protein did not
interfere with cross-presentation of the surrogate CMV epitope, so we continued using MSCE for
subsequent experiments.
4.4.2 Site-specificity of Conjugation is Crucial for Cross-presentation
We had investigated SNAP-tag-mediated conjugation on the premise that conventional
chemical conjugation methods create covalent bonds at random sites in the protein and can
interfere with antigen release in the DC phagosome and subsequent transport to the cytosol. To
test this premise, we conjugated the same fusion protein, MSCE, to the yeast cell wall using
either the SNAP-tag to BG reaction or by reductive amination. In the latter chemical conjugation
scheme, the sugars on the yeast cell wall were partially oxidized with sodium meta-periodate to
generate aldehyde groups, which form covalent bonds with lysine side chains in MSCE in the
presence of sodium cyanoborohydride as a reducing agent. To enable a fair comparison, the
concentration of MSCE used during SNAP-tag-mediated conjugation was reduced so as to match
the conjugation level achieved by reductive amination (resulting in a mere 2% difference as
determined by flow cytometry). Fig. 4.1B shows that antigen conjugated by reductive amination
was not cross-presented at significant levels, unlike antigen attached via the SNAP-tag.
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Figure 4.1, Antigen site-specifically conjugated to yeast via the SNAP-tag is cross-presented,
with yeast expressing Agalp and Aga2p giving rise to higher conjugation and cross-
presentation levels.
A-C, Yeast with or without conjugated antigen were added to DCs at a 20:1 ratio. After 24 h, the
DCs were assayed for the ability to stimulate N9V-specific CD8 + T cells to secrete IFNy. Error
bars indicate SDs of duplicate wells. A, BJ5a yeast cells modified with BG were coated via the
SNAP-tag reaction with either no protein, MSCcmyc or MSCE. B, MSCE was conjugated to
BJ5a yeast either chemically by reductive amination or site-specifically via the SNAP-tag/BG
reaction. The conjugation level of the latter method was matched to the former (within 5%) by
reducing the MSCE concentration. C, MSCE was conjugated to either BJ5a yeast or yeast
surface-displaying 4-10 tandem repeats of the sequence GGGGKGS (with X in LysX indicating
the repeat number). The negative control was BG-BJ5a lacking MSCE.
D, BG and MSCE were conjugated to either BJ5a (grey fill), LysX yeast (where X = 4, 6, 8, or
10; grey lines), or yeast surface-displaying a short peptide lacking lysines (black dashed line).
The yeast cells were labeled for flow cytometry with a-NY-ESO-1 followed by an Alexa Fluor
488-conjugated secondary antibody. The four histograms corresponding to the LysX yeast strains
were not distinguished by color as they essentially overlaid each other.
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4.4.3 Increasing Amine Density and Conjugation Levels on Yeast
Since BG-GLA-NHS reacts with primary amines on the yeast cell wall, we hypothesized
that the antigen dose per yeast cell could be increased by surface-displaying lysine-rich
polypeptides. To this end, we constructed yeast strains expressing 4-10 tandem repeats of the
sequence GGGGKGS fused to Aga2p on the cell wall. These yeast strains, termed LysX where
X indicates the number of added lysines, were reacted with BG-GLA-NHS followed by MSCE
and tested for cross-presentation. The results revealed that all the modified yeast strains induced
about twice as many CD8+ T cells to secrete IFNy as compared to wild type BJ5a, but the
number of extra lysine residues appeared to be inconsequential (Fig. 4.1C). By analyzing the
NY-ESO-1 conjugation levels by antibody labeling and flow cytometry, we discovered that a
yeast strain surface-displaying a lysine-less peptide resulted in the same NY-ESO-1 density as
the LysX strains, which was about 6-fold that on BJ5a (Fig. 4.1D). Similar results were obtained
when fluorescently tagged MSCE was conjugated, eliminating antibody access limits as a
confounding factor (not shown). It appears that the expression of Agalp and Aga2p in the yeast
surface display system fully accounts for the increase in numbers of amines available for
conjugation. Steric hindrance may impose an upper limit on the number of bulky MSCE
molecules that can be attached surrounding a single Agalp-Aga2p complex. The yeast strain
SWH100 with inducible expression of Agalp and HA-tagged Aga2p was created and used
henceforth instead of BJ5a.
4.4.4 An NY-ESO-1 Epitope is Cross-presented
Before investigating further improvements in the antigen conjugation strategy, we wanted
to ensure that cross-presentation was not limited to the surrogate epitope. Using an HLA-Cw3-
restricted CD8+ T cell clone specifically recognizing the NY-ESO-1 epitope LAMPFATPM (21),
we performed an ELISpot assay to detect IFNy secretion in response to DCs that had
phagocytosed antigen-conjugated yeast. When MSCE fusion protein was conjugated, a
significant number of spots were formed, in contrast to when MSCcmyc (with c-myc replacing
the NY-ESO-1 domain) was conjugated (Fig. 4.2).
4.4.5 CD74 as a CatS-mediated Antigen Release Mechanism
The decision to include (C1)4, a CatS-susceptible linker consisting of 4 repeats of the
sequence EKARVLAEAAS, in MSCE was driven by its effectiveness in boosting cross-
presentation efficiency with yeast surface-displaying the CMV peptide (12). However, when we
deleted (C1)4 from MSCE and conjugated it to SWH100 yeast via the SNAP-tag, the cross-
presentation efficiency did not decrease significantly. To shed light on this observation, we
digested both proteins in solution with CatS and studied the fragmentation patterns. N-terminal
sequencing of one of the earliest fragments revealed that the CMV epitope itself,
NLVPMVAITV, can be cleaved by CatS at the indicated position. As competition between
antigen release and epitope destruction may be a confounding factor, we sought to eliminate the
CatS cleavage site. According to Rtickrich et. al, only V, L, M, C, and F are found in the P2
position of effective CatS cleavage sites (24). Mutating the epitope to NLVPMIATV prevented
CatS cleavage while maintaining recognition by the CD8÷ T cell clone used in our cross-
presentation assays. This mutated CMV epitope was used henceforth, but there remained no
clear benefit in cross-presentation when (C1)4 was included versus deleted.
We hypothesized that (C1)4 in the context of MSCE may be inaccessible to phagosomal
CatS, perhaps because it assumes a compact instead of extended conformation when sandwiched
between two sizeable protein domains (SNAP-tag and NY-ESO-1). In contrast, in the yeast
surface display model, the linker was more exposed and had only a short peptide C-terminal to it.
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Figure 4.2, Cross-presentation on an NY-ESO-1 epitope as detected by ELISpot. HLA-Cw3
DCs were pulsed overnight with antigen and then cultured at 5 x 104 cells/well with the indicated
ratio of a HLA-Cw3-restricted CD8 + T cell clone recognizing NY-ESO-1 92. 100. Lys6 yeast
conjugated with MSCE (containing NY-ESO-1) or MSCcmyc (lacking NY-ESO-1) were each
added to the DCs at a 20:1 ratio. This experiment was performed by T. Tsuji, Ludwig Institute
for Cancer Research, New York Branch.
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Figure 4.3, The extracellular domain of CD74 is highly susceptible to CatS cleavage andimproves cross-presentation efficiency when used as a linker. Fusion protein variants
containing either no linker, (C1) 4 or CD74 (aa 73-207) between the SNAP-tag and the CMV andNY-ESO-1 antigens were conjugated to SWH100 yeast in parallel.
A, The conjugated yeast were added at a 15:1 ratio to DCs, which a day later were tested for
their ability to activate antigen-specific CD8 + T cells. Error bars indicate SDs of triplicate wells.
B, The conjugated yeast (2 x 10 per test) were incubated with 20 ng CatS and incubated at 370Cfor different time periods. The loss of the NY-ESO-1 domain was monitored by antibody
labeling and flow cytometry.
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Seeking an alternative polypeptide sequence that would not be obscured by the flanking
domains and would be rapidly cleaved by CatS, the human invariant chain was considered. CatS-
mediated degradation of the invariant chain, also called CD74, is known to be a prerequisite
before MHC class II molecules can acquire peptides (25). More than a dozen CatS cleavage sites
have been identified in the CD74 sequence (24). We therefore produced a new fusion protein
replacing (C1) 4 with the ectodomain of CD74 (aa 73-207). SWH100 yeast coated with fusion
protein containing CD74 as a linker induced more efficient cross-presentation than when either
no linker or (C1)4 was used (Fig. 4.3A). As expected, when yeast cells coated with each of the
three fusion proteins were incubated with a limiting concentration of CatS, the loss of the NY-
ESO-1 domain was dramatically faster when CD74 was used as the linker (Fig. 4.3B).
4.4.6 A Reaction Scheme for Producing Multiple Coats ofAntigen
Although SNAP-tag-mediated conjugation to SWH100 resulted in an average of 5-7.5 x
105 molecules of antigen per yeast cell, or about 4-6x the typical yeast surface display level for a
short peptide, we believed that vaccine potency could be enhanced by further increasing the
conjugation level. The experiments with the LysX yeast strains (Fig. 4.1C & D) suggested that
the addition of more primary amine groups to the yeast cell wall would be futile, so we instead
pursued the strategy of building up multiple layers of conjugated antigen. To retain rapid
phagosomal antigen release by CatS cleavage of the CD74 ectodomain, any new reactions would
also need to be site-specific.
Yin et al. have developed a system for site-specific protein labeling using the enzyme Sfp
phosphopantetheinyl transferase (Sfp for short), which covalently transfers small molecule tags
linked to Coenzyme A (CoA) to the serine residue of a peptide tag called ybbR (sequence:
DSLEFIASKLA) (19). We conjugated BG-maleimide to the free sulfhydryl group of CoA
(forming BG-CoA) with the intention of using Sfp to add a fresh layer of BG to yeast coated
with ybbR-tagged fusion protein, thus allowing a second coat to be conjugated via the SNAP-tag
reaction. Our initial experiments inserting the ybbR tag either between MBP and the SNAP-tag
or as a C-terminal fusion to NY-ESO-1 failed to generate a significant second layer. Steric
hindrance appeared to be an obstacle, which was solved by the addition of a glycine/serine linker
between NY-ESO-1 and the ybbR tag. The final version of the fusion protein, named
MS74NEY2, comprised (in order from N terminus to C): MBP, SNAP-tag, CD74 ectodomain,
the mutated CMV peptide ASARNLVPMIATV, NY-ESO-1, TVQL (a CatS-sensitive peptide
(24)), (GGGGS) 3 linker, ybbR tag, and His6 tag (for easy purification of the full-length protein).
Under the appropriate reaction conditions, SNAP-tag conjugation and Sfp-mediated BG
labeling could be alternated to build up multiple coats of fusion protein. Four coats of
MS74NEY2 protein sparsely labeled with FITC (F/P ratio of 0.5) were layered onto SWH100
yeast, and samples from each reaction cycle were analyzed by flow cytometry (Fig. 4.4A). The
increase in fluorescence was essentially linear, suggesting that there was no significant loss in
conjugation efficiency as the number of cycles increased. Yeast coated with 0-4 layers of
unlabeled MS74NEY2 were added to DCs at the low dose of only 2:1. At this dose, yeast coated
with a single coat of antigen elicited cross-presentation at nearly background levels, whereas
each subsequent antigen layer resulted in an increase in cross-presentation level (Fig. 4.4B).
4.4.7 Antigen can be Coated onto Yeast Hulls for Cross-presentation
With this vaccine model, both the functions of antigen delivery and adjuvancy are
fulfilled by the cell wall of yeast; presumably, the yeast cytoplasm is dispensable. We anticipated
that using yeast cell wall fragments instead of whole yeast cells may hold potential advantages.
The antigen density would be increased on a per-volume basis, possibly permitting a higher dose
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Figure 4.4, Antigen dose and cross-presentation efficiency can be increased by conjugating
multiple coats of antigen and by using yeast hulls.
A, MS74NEY2 was lightly labeled with FITC and conjugated to SWH100 yeast in multiplelayers by alternately performing SNAP-tag/BG and Sfp/BG-CoA reactions. The yeast cells withdifferent numbers of antigen coats were directly analyzed by flow cytometry.
B, SWH100 whole yeast cells with 0-4 coats of MS74NEY2 (unlabeled) were added to DCs at a2:1 ratio. After 24 h, the DCs were co-cultured with N9V-specific T cells and assess for their
ability to stimulate IFNy secretion. Error bars indicate SDs of duplicate wells.C, SWH100 yeast hulls were conjugated with a single layer of MS74NEY2 and added to DCs at
varying doses. The same cross-presentation assay was performed.
D-F, Confocal microscopy images of yeast hulls coated with one (D), two (E), or three (F) layers
of MS74NEY2 lightly tagged with FITC.
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to be delivered to each DC, whereas the variety and quantity of native yeast proteins that are also
cross-presented would be reduced. Induced SWH100 yeast cells were disrupted at very high
shear rates with a Microfluidizerl processor. After two passes, the resulting fragments had mean
and median diameters of 1.7 pm and 0.9 pm respectively, as determined by static light scattering.
After several washes, the fragments, henceforth termed yeast hulls, were subjected to
conjugation with BG-GLA-NHS followed by MS74NEY2, using the same reaction conditions as
were developed for whole yeast cells. We quantified the yeast hulls in terms of the numbers of
originating whole yeast (estimated by measuring OD600), assuming negligible loss during
processing and washing.
A dose-response cross-presentation assay was performed by adding antigen-coated yeast
hulls to DCs. The coated yeast hulls were surprisingly potent: the lowest dose tested, nominally
equivalent to 2 yeast per DC, resulted in a near-maximal response. In contrast, singly coated
whole yeast elicited barely detectable levels of cross-presentation at the equivalent dose (Fig.
4.4B). Increasing the dose of yeast hulls from 5 to 30 yeast equivalents per DC did not result in
higher percentages of IFNy~ T cells (Fig. 4.4C). The total number of recovered CD8+ T cells
dropped with increasing dose (not shown), suggesting a role for TCR-triggered activation-
induced cell death (AICD) in limiting the assay response. We could not accurately quantify the
level of antigen conjugation to yeast hulls by flow cytometry (the low forward and side scatter
profile of the hulls overlapped with artifactual events), but the levels appeared to be qualitatively
higher than achieved with whole yeast despite their smaller size distribution. We speculate that
cell wall disruption may have revealed additional primary amine groups for conjugation, perhaps
located on the inner face of the cell wall or at fissure sites. The alternating reaction scheme for
conjugating multiple layers of antigen was also effective on yeast hulls. Figures 4.4D-F are
confocal microscopy images of yeast hulls coated with 1-3 layers of MS74NEY2 lightly labeled
with FITC (F/P ratio of 0.1). In addition to the increased fluorescence, the yeast hulls displayed a
greater tendency to aggregate with three coats of antigen.
4.4.8 NY-ESO-l-specific In Vitro Immunization of Naive CD8 + T Cells
The multiple refinements that we have made to improve our antigen-coated yeast-based
vaccine strategy have thus far been tested primarily by detecting cross-presentation of the
surrogate CMV epitope using a T cell clone. We now wished to investigate if the vaccine
candidates are capable of priming naIve CD8+ T cells to elicit NY-ESO-l-specific immunity.
CD8 ÷ CD45RO" T cells were isolated from the PBMCs of three HLA-A*0201 donors by
magnetic cell sorting. The naIve CD8+ T cells were added at a 10:1 ratio to DCs (from a fourth
donor) that had been stimulated the previous day with either unconjugated yeast hulls, whole
yeast cells carrying one coat of MS74NEY2, or yeast hulls with three coats of antigen. Before
and after 10 days of co-culture, the cells were labeled with a SLLMWITQV/HLA-A*0201
peptide-MHC pentamer, with the peptide being the well-characterized NY-ESO- 157-16s epitope
with the final Cys residue mutated to Val to avoid oxidation-related issues (26).
As shown in Fig. 5, the naive precursor frequencies were around 0.02% with all three
donors, and the frequency of higher avidity T cells (arbitrarily defined as those falling within the
rectangular gate) were in the 0.003-0.005% range. Ten days after stimulation by the DCs, the
frequencies of pentamer-positive CD8÷ T cells increased under all nine test conditions. The
proliferation of pentamer-positive T cells after "immunization" with yeast hulls lacking NY-
ESO-1 may be a result of extensive TCR degeneracy observed in many experiments (27-33),
with theoretical analysis suggesting a TCR ligand repertoire size of 106-107 peptide epitopes (34).
With all three donors, the yeast hulls coated with three layers of antigen elicited the highest
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proportion of pentamer-stained cells, with almost double the frequency of high avidity T cells as
compared to the yeast-hull-only controls. The singly coated whole yeast cells, which delivered a
smaller dose of antigen as compared to the 3-coat yeast hulls, gave rise to intermediate pentamer-
positive T cell frequencies with two out of the three donors. Although the double-positive events
are rare and not clearly distinct from the pentamer-negative cells, we believe that they represent
genuine NY-ESO-l-specific T cells because restimulation with peptide-pulsed autologous
PBMCs on day 10 expanded the double-positive populations to 5-20% by day 20 (Fig. 4.6). We
conclude that DCs fed either whole yeast cells coated with one layer of MS74NEY2 or yeast
hulls coated three times were able to prime naive, NY-ESO-1-recognizing CD8+ T cells, with the
latter formulation being initially more potent.
4.4.9 DC Maturation by Yeast Particles
The ability of S. cerevisiae yeast to stimulate inflammatory cytokine secretion by murine
splenocytes (7, 8) and DCs (3, 9) and to induce maturation of human (6) and murine (3, 9) DCs
is well-established. In our preliminary experiments, yeast cells upregulated various markers of
maturation in human monocyte-derived DCs to an extent comparable with 1 pg/ml LPS and
induced even more IL-12 secretion than LPS. We now investigated whether the processes of
antigen conjugation and cell disruption would alter the immunostimulatory properties of yeast.
SWH100 yeast and yeast hulls, each with and without a single layer of conjugated antigen, were
added to immature DCs at the nominal dose of 10 yeast per DC. After 48 h, the DCs were
analyzed for the expression levels of CD40, CD80, CD83, CD86 and HLA-DR (all markers of
DC maturation), whereas the cell culture supernatants were subjected to an IL-12p70 ELISA
assay. As we had observed previously, whole unconjugated yeast upregulated the maturation
markers to levels similar to those caused by LPS (Fig. 4.7A) and massively induced IL-12
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Figure 4.6, Peptide/MHC pentamer-positive T cells primed by yeast particles continue 
to
multiply after re-stimulation with peptide-pulsed autologous PBMCs. On day 
10 of the
experiment described in Fig. 4, PBMCs from each donor were thawed, gamma-irradiated, 
and
pulsed with 40 pM SLLMWITQV peptide for 3 h. Day 10 T cells from each test condition (5 x
106 per well) were co-cultured with 107 donor-matched PBMCs in 4 ml CTL medium (with 10
pM peptide) in a 12-well plate. The cells were fed and split as necessary. Flow cytometry
analysis after labeling with a-CD8-FITC and PE-conjugated SLLMWITQV/HLA-A*0201
pentamer was performed on day 20.
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Figure 4.7, DC maturation in response to yeast is influenced by cell integrity and antigen
conjugation. Immature DCs were stimulated with either LPS (1 jig/ml) or soluble fusion protein
(0.5 gM) or whole SWH100 yeast or yeast hulls either unmodified or conjugated with one layer
of antigen (each at a dose equivalent to 10 yeast per DC).
A, Two days later, the DCs were labeled with a-DC-SIGN-FITC and a PE-conjugated antibody
against one of the five selected markers of DC maturation. The flow cytometry results were
gated by DC-SIGN positivity and the median PE fluorescence in each test was compared against
the result with unstimulated DCs.
B, The cell culture supernatants after two days were tested for IL-12p70 by ELISA. Readings
calculated to be lower than 5 pg/ml were considered undetectable (ud). Error bars indicate SDs
of duplicate wells.
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secretion (Fig. 4.7B). To our surprise, uncoated yeast hulls behaved very differently compared to
whole yeast, causing strikingly less marker upregulation and no detectable IL-12 secretion.
Antigen conjugation had opposite effects on whole yeast and yeast hulls, slightly reducing DC
maturation and IL-12 secretion by whole yeast while increasing these metrics with yeast hulls.
Although some IL-12 was secreted by DCs exposed to antigen-coated yeast hulls, the quantity
was two orders of magnitude lower than that caused by coated or uncoated whole yeast (Fig.
4.7B). The effects of antigen conjugation were not simply caused by endotoxin contamination or
some intrinsic property of the protein, since soluble fusion protein alone (at 0.5 jIM, roughly
100x the level of yeast-conjugated antigen present in a well) had little effect on the DCs (Fig.
4.7).
4.5 Discussion
We present here a flexible vaccine-oriented scheme for conjugating antigen to yeast
particles that has undergone multiple refinements with the aim of maximizing cross-presentation.
The fusion protein MS74NEY2 represents the latest embodiment, consisting of the following
functional elements: MBP, SNAP-tag, CD74 ectodomain, 15-mer CMV-derived surrogate
antigen, NY-ESO-1 cancer-testis antigen, glycine/serine linker, ybbR tag and His6 tag. We have
demonstrated cross-presentation of both the surrogate antigen and an NY-ESO-1 HLA-A2
epitope; these antigens can readily be exchanged to suit different immunotherapy applications.
The highly hydrophobic NY-ESO-1 protein used in clinical trials is purified from E. coli
inclusion bodies (35), but insertion of MBP as the N-terminal domain enabled our fusion
proteins to be expressed solubly and also facilitated purification. For other antigens, MBP may
be omitted or replaced if desired. A key feature of our conjugation scheme is its site-specific
nature, which ensures that antigen can be released in the DC phagosome to translocate to the
cytosol for entry into the MHC class I processing pathway. The initial layer of fusion protein is
conjugated to BG-derivatized particles through the formation of a stable thioether bond with the
SNAP-tag domain. We showed that cross-presentation is highly inefficient when a non-site-
specific chemical conjugation method was used to attach the same protein to yeast. The lack of
efficacy is especially noteworthy considering that there were no reactive lysine residues within
the CMV peptide and only one in the C-terminal direction. This suggests that merely "tethering"
an epitope on both ends with no intervening phagosomal protease sites can impede cross-
presentation. To expedite phagosomal antigen release in our scheme, we inserted the extremely
CatS-susceptible CD74 ectodomain between the SNAP-tag tether and the antigens, resulting in
improved cross-presentation efficiency.
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In addition to developing the conjugation scheme with antigen release kinetics in mind,
we have also made several improvements to increase antigen dose delivery. The first refinement
was to use a yeast strain expressing Agalp and Aga2p, which provided more free amines on the
cell wall for BG and fusion protein conjugation compared to the wild type. Fusing lysine-
containing polypeptides to Aga2p did not further increase the antigen density in this first layer,
so we devised a novel multi-layer conjugation strategy that is retains site-specificity. Sfp enzyme
is used to attach BG-linked CoA to the ybbR tags of one antigen layer, thus permitting the next
layer to be added via the SNAP-tag/BG reaction. We experienced no loss in conjugation
efficiency in building up to four antigen layers (suggesting that further coats can be added almost
indefinitely) and demonstrated that cross-presentation levels rose with the number of layers.
Finally, breaking up the cell wall into fragments prior to conjugation further increased the
amount of antigen delivered per yeast cell equivalent, probably because the surfaces that were
revealed provided additional free amines for BG attachment.
While the use of yeast hulls instead of whole yeast improves antigen delivery and reduces
native yeast protein content, it is at present unclear whether yeast hulls will ultimately be more
effective in the setting of immunotherapy. A major reason behind the attractiveness of yeast-
based vaccines is their ability to mature DCs and stimulate the secretion of pro-inflammatory
cytokines, obviating the need for additional adjuvants (5). To our surprise, yeast hulls were
significantly inferior to whole yeast cells in inducing DC maturation, and more importantly, they
elicited little or no IL-12 secretion. In retrospect, this observation is not without precedent as
several groups have reported that Zymosan, a preparation of S. cerevisiae cell wall particles, is a
poor inducer of DC IL-12 secretion despite its long-standing reputation as a pro-inflammatory
agent (36-38). IL-12 secretion is likely to be important to vaccine efficacy because it plays a role
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in enhancing the clonal expansion of primed CD8+ T cells (39, 40), perhaps by increasing
resistance to AICD (41).
The disparity in DC reactions to whole yeast cells and yeast cell wall fragments is
puzzling and warrants further investigation. One possibility is that an immunostimulatory
component is lacking in yeast hulls, which was either removed with the yeast cytoplasm or
washed away from the cell wall fragments. Re-evaluation of the wash steps may be helpful in the
latter case. In the former case, a possible candidate is double-stranded RNA from viruses that
ubiquitously infect yeast cells (42). It has been observed that a combination of Zymosan and poly
I:C (a synthetic double-stranded RNA analog) stimulates far greater levels of IL-12 secretion
than either agent alone (38), raising the intriguing possibility that whole yeast cells induce
massive IL-12 secretion through a similar synergism. If this is the case, conjugating poly I:C to
yeast hulls may present a simple solution. An alternative explanation stems from the complex
structure of the yeast cell wall, with fragmentation resulting in the exposure of different
molecular patterns leading to altered signaling cascades in DCs. To elaborate, the outer layer of
the S. cerevisiae cell wall is composed primarily of mannan (hypermannosylated proteins),
which in undamaged yeast cells largely masks the inner layer of pl,3-glucan, 01,6-glucan and
chitin (43). Our observation that antigen conjugation (and thus partial disruption of the molecular
patterns) had opposite effects on whole yeast cells and yeast hulls could be an indication that DC
recognition of the inner cell wall layer partially counteracts the maturation signals derived from
ligands in the outer layer.
Vaccination experiments in vivo will be required to discover the effects of yeast particle
choice on T cell memory and protective immunity and to develop an optimal formulation
(possibly a mixture of uncoated whole yeast and coated yeast hulls). At the same time, the
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conjugation scheme presented here is not restricted to yeast and can easily be applied to any
particle that is or can be amine-functionalized, including heat-killed bacteria and bacterial ghosts,
polymer and inorganic microspheres, ribosomes and liposomes. Although the ability of antigen-
coated particles to induce protective tumor immunity was demonstrated almost 15 years ago (44),
particulate antigen delivery vehicles (with the exception of virus-like particles) have received
little attention in the field of cancer immunotherapy. Co-delivery of adjuvant and antigen in
particles holds several advantages over injection of soluble agents, including a high local
concentration that does not quickly dissipate, assurance that both adjuvant and a minimum bolus
of antigen are delivered to the same cell, and inherent targeting for uptake by phagocytic cells
(besides DCs, macrophages (45) and neutrophils (46) are also capable of cross-priming). Poor
phagosomal escape of antigen represents one barrier to the development of particulate vaccines,
and the conjugation strategy described here presents a novel way to break this barrier.
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Appendix A - Sequences of Key Plasmids
A.1 pHAH-L5
Backbone: pCT2
Description: Used for NY-ESO-L5 production by reduction off the cell wall of surface-
displaying yeast. Cleavage with human rhinovirus 3C protease releases untagged NY-ESO-L5,
whereas aga2p, which is flanked by two His6 sites, remains bound to the metal affinity resin.
1--> Aga2p with His6 inserted after signal peptide
1 ATGCAGTTAC TTCGCTGTTT TTCAATATTT TCTGTTATTG CTTCAGTTTT
I--> His6 <--I
51 AGCACATCAC CATCATCATC ACCAGGAACT GACAACTATA TGCGAGCAAA
101 TCCCCTCACC AACTTTAGAA TCGACGCCGT ACTCTTTGTC AACGACTACT
151 ATTTTGGCCA ACGGGAAGGC AATGCAAGGA GTTTTTGAAT ATTACAAATC
201 AGTAACGTTT GTCAGTAATT GCGGTTCTCA CCCCTCAACA ACTAGCAAAG
<--H1--> GGGGS <--11-->
251 GCAGCCCCAT AAACACACAG TATGTTTTTG GTGGAGGAGG CTCTCATCAC
His6 <--INhel 1--> HRV 3C site <--II-->
301 CATCATCACC ATGCTAGCTT
NY-ESO-1 (L5 mutant)
351 CGAAGGCCGG GGCACAGGGG
401 GCCCTGGCAT TCCTGATGGC
451 GCGGGTGCCA CGGGCGGCAG
501 CTCGGGGCCG GGAGGAGGCG
551 CAGGGCTGAA TGGAGCCGCC
601 CTGCTTGAGT TCTACCTCGC
651 GCTGGCCCGC AGGAGCCTGG
701 GGGTGCTTCT GAAGGAGTTC
751 CTGACTGCTG CAGACCACCG
801 CCAGCAGCTT TCCCTGTTGA
851 TTTTGGCTCA GCCTCCCTCA
GGAAGTTTTG TTTCAAGGTC CAATGCAGGC
GTTCGACGGG CGATGCTGAT GGCCCAGGAG
CCAGGGGGCA ATGCTGGCGG CCCAGGAGAG
AGGTCCCCGG GGCGCAGGGG CAGCAAGGGC
CCCCGCGGGG TCCGCATGGC GGCGCGGCTT
AGAGCCGGGG CCAGGGGGCC GGAGAGCCGC
CATGCCTTTC GCGACACCCA TGGAAGCAGA
CCCAGGATGC CCCACCGCTT CCTGTGCCAG
ACTGTGTCCG GCAACATACT GACTATCCGA
CCAACTGCAG CTCTCCATCA GCTCCTGTCA
TGTGGATCAC GCAGTGCTTT CTGCCCGTGT
<-- * XhoI
GGGCAGAGGC GCTAACTCGA G
A.2 pCT-N9V
Backbone: pCT2
Description: Basic N9V surface-display construct, with the epitope in the context of the extended
15-mer CMV-derived peptide.
1
51
101
151
201
S--> Aga2p
ATGCAGTTAC TTCGCTGTTT TTCAATATTT TCTGTTATTG CTTCAGTTTT
AGCACAGGAA CTGACAACTA TATGCGAGCA AATCCCCTCA CCAACTTTAG
AATCGACGCC GTACTCTTTG TCAACGACTA CTATTTTGGC CAACGGGAAG
GCAATGCAAG GAGTTTTTGA ATATTACAAA TCAGTAACGT TTGTCAGTAA
TTGCGGTTCT CACCCCTCAA CAACTAGCAA AGGCAGCCCC ATAAACACAC
251 AGTATGTTTT TAAGGACAAT AGCTCGACGA TTGAAGGTAG ATACCCATAC
HA tag <--IPstI I--> (G4S)3 linker
301 GACGTTCCAG ACTACGCTCT GCAGGCTAGT GGTGGAGGAG GCTCTGGTGG
<- - INheI - -> ARNLVPMVATVQGQN
351 AGGCGGTAGC GGAGGCGGAG GGTCGGCTAG CGCTAGAAAT TTGGTTCCAA
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<-- BamHI --> c-myc tag
401 TGGTTGCTAC TGTTCAAGGT CAAAACGGAT CCGAACAAAA GCTTATTTCT
<-- I* * XhoI
451 GAAGAGGACT TGTAATAGCT CGAG
A.3 pCTc-N9V
Backbone: pCT-N9V
Description: Modified from the pCT-N9V plasmid by replacing the signal peptide of aga2p with
just an initial methionine. When transformed into a yeast strain lacking agalp, the aga2p fusion
protein is expressed intracellularly upon induction instead of being surface-displayed.
Metl--> Aga2p without signal peptide
1 ATGCAGGAAC
51 ATCGACGCCG
101 CAATGCAAGG
151 TGCGGTTCTC
<--I
201 GTATGTTTTT
tag
251 ACGTTCCAGA
301 GGCGGTAGCG
351 GGTTGCTACT
TGACAACTAT ATGCGAGCAA ATCCCCTCAC CAACTTTAGA
TACTCTTTGT CAACGACTAC TATTTTGGCC AACGGGAAGG
AGTTTTTGAA TATTACAAAT CAGTAACGTT TGTCAGTAAT
ACCCCTCAAC AACTAGCAAA GGCAGCCCCA TAAACACACA
I--> HA
AAGGACAATA GCTCGACGAT TGAAGGTAGA TACCCATACG
<--IPstI I--> (G4S)3 linker
CTACGCTCTG CAGGCTAGTG GTGGAGGAGG CTCTGGTGGA
<- - INheI - -> ARNLVPMVATVQGQN
GAGGCGGAGG GTCGGCTAGC GCTAGAAATT TGGTTCCAAT
<--IBamHI I--> c-myc tag
GTTCAAGGTC AAAACGGATC CGAACAAAAG CTTATTTCTG
<--I* * XhoI
401 AAGAGGACTT GTAATAGCTC GAG
A.4 pCT-C1-N9V
Backbone: pCT-N9V
Description: The Cl linker, EKARVLAEAA, was inserted between the (G4S)3 linker and the
A15N peptide in pCT-N9V. The final Ala is encoded by the NheI site. Only the sequence
between the PstI and NheI sites are shown; the rest is identical to pCT-N9V.
PstI -- > (G4S) 3 linker
1 CTGCAGGCTA GTGGTGGAGG AGGCTCTGGT GGAGGCGGTA GCGGAGGCGG
<-I I - > EKARVLAEAA <-- INheI
51 AGGGTCGGCT AGTGAAAAAG CTAGAGTTTT GGCTGAAGCT GCTAGC
A.5 pCT-C2-N9V
Backbone: pCT-N9V
Description: The C2 linker, SSAESLK, was inserted between the (G4S)3 linker and the A15N
peptide in pCT-N9V. Only the sequence between the PstI and NheI sites are shown; the rest is
identical to pCT-N9V.
PstI -- > (G4S) 3 linker
1 CTGCAGGCTA GTGGTGGAGG AGGCTCTGGT GGAGGCGGTA GCGGAGGCGG
<--I I--> SSAESLK <-- INhel
51 AGGGTCGGCT AGTTCTTCTG CTGAATCTTT GAAAGCTAGC
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A.6 pCT-C3-N9V
Backbone: pCT-N9V
Description: The C3 linker, NWVCAAKF, was inserted between the (G4S)3 linker and the Al5N
peptide in pCT-N9V. Only the sequence between the PstI and NheI sites are shown; the rest is
identical to pCT-N9V.
PstI -- > (G4 S) 3 linker
1 CTGCAGGCTA GTGGTGGAGG AGGCTCTGGT GGAGGCGGTA GCGGAGGCGG
<--I - - > NWVCAAKF <- - INheI
51 AGGGTCGGCT AGTAATTGGG TTTGTGCTGC TAAATTTGCT AGC
A.7 pCT-C4-N9V
Backbone: pCT-N9V
Description: The C4 linker, GILQINSR, was inserted between the (G4S)3 linker and the A15N
peptide in pCT-N9V. Only the sequence between the PstI and NheI sites are shown; the rest is
identical to pCT-N9V.
PstI -- > (G4S) 3 linker
1 CTGCAGGCTA GTGGTGGAGG AGGCTCTGGT GGAGGCGGTA GCGGAGGCGG
<-- 1--> GILQINSR <-- NheI
51 AGGGTCGGCT AGTGGTATTT TGCAGATTAA TTCTAGAGCT AGC
A.8 pCT-C5-N9V
Backbone: pCT-N9V
Description: The C5 linker, QWLGAPVP, was inserted between the (G4S)3 linker and the A15N
peptide in pCT-N9V. Only the sequence between the PstI and NheI sites are shown; the rest is
identical to pCT-N9V.
PstI --> (G4S) 3 linker
1 CTGCAGGCTA GTGGTGGAGG AGGCTCTGGT GGAGGCGGTA GCGGAGGCGG
<--I I--> QWLGAPVP <-- Nhel
51 AGGGTCGGCT AGTCAATGGT TGGGTGCTCC AGTTCCAGCT AGC
A.9 pNL-N9V
Backbone: pCT-N9V
Description: The (G4S)3 linker of pCT-N9V was deleted by digesting with PstI and NheI and
ligating the blunt ends generated by using Klenow fragment to remove the PstI 3' overhang and
fill in the NheI 5' overhang.
1--> Aga2p
1 ATGCAGTTAC TTCGCTGTTT TTCAATATTT TCTGTTATTG CTTCAGTTTT
51 AGCACAGGAA CTGACAACTA TATGCGAGCA AATCCCCTCA CCAACTTTAG
101 AATCGACGCC GTACTCTTTG TCAACGACTA CTATTTTGGC CAACGGGAAG
151 GCAATGCAAG GAGTTTTTGA ATATTACAAA TCAGTAACGT TTGTCAGTAA
201 TTGCGGTTCT CACCCCTCAA CAACTAGCAA AGGCAGCCCC ATAAACACAC
<--I I-->
251 AGTATGTTTT TAAGGACAAT AGCTCGACGA TTGAAGGTAG ATACCCATAC
110
HA tag <- - I -- > ARNLVPMVATVQGQN
301 GACGTTCCAG ACTACGCTCC TAGCGCTAGA AATTTGGTTC CAATGGTTGC
<-- IBamHI -- > c-myc tag
351 TACTGTTCAA GGTCAAAACG GATCCGAACA AAAGCTTATT TCTGAAGAGG
<-- I* * XhoI
401 ACTTGTAATA GCTCGAG
A.10 pCT-(C1)4-N9V
Backbone: pCT-N9V
Description: Four copies of the C1 linker were inserted between the (G4S)3 linker and the NheI
site of pCT-N9V. Only the sequence between the PstI and NheI sites are shown; the rest is
identical to pCT-N9V.
PstI -- > (G4S) 3 linker
1 CTGCAGGCTA GTGGTGGAGG AGGCTCTGGT GGAGGCGGTA GCGGAGGCGG
<--I I--> EKARVLAAA <--I 1-->
51 AGGGTCGGCT AGTGAAAACG CTAGAGTTTT GGCTGAAGCT GCTAGTGAAA
EKARVLAEAA <--I - -> EKARVLAEAA
101 AAGCTAGAGT TTTGGCTGAA GCTGCTAGTG AAAAAGCTAG AGTTTTGGCT
<--I I--> EKARVLAEAA <-- INheI
151 GAAGCTGCTA GTGAAAAAGC TAGAGTTTTG GCTGAAGCTG CTAGC
A.11 HEAF 3.12
Backbone: pCT
Description: "HEAF" is short for high-expressing anti-fluorescein and it is a mutant of Eric
Boder's 4M3.12 fluorescein-binding scFv. Introduction of five mutations, K182N, F186S, S187P,
F315S and N351D (numbered from the start of the aga2p fusion protein) increased the
expression level by 4-5 fold. However, the mutations also weakened the affinity and gave rise to
a bi-exponential koff curve. Only the sequence between the NheI and XhoI sites are shown, with
the mutations highlighted.
NheI I-->
GCTAGCGACG
AGGTGATCAA
GTAATGGAAA
CCAAAGGTCC
CAGGTTCAGT
GAGTGGAGGC
GTTCCGTGGA
TGATGATGCT
ATGCTAAGAA
GTGCAACCTG
TTTTAGTGAC
TGGAGTGGAT
TATTCAGATT
AAGTAGTGTC
TCTATTACTG
scFv
TCGTTATGAC TCAAACACCA
GCCTCCATCT CTTGCAGATC
CACCTATTTA CGTTGGTACC
TGATCTACAA iGTTTCCAAC
GGCAGTGGAT CAGGGACAGA
TGAGGATCTG GGAGTTTATT
CGTTCGGTGG AGGCACCAAG
AAGAAGGATG CTGCTAAGAA
AGATGGTGAC GTCAAACTGG
GGAGGCCCAT GAAACTCTCC
TACTGGATGA ACTGGGTCCG
AGCACAATIT AkGAAACAAC
CTGTGAAAGG CAGATTCACC
TATCTGCAAA T•AACCACTT
TACGGGTTCT TACTATGGTA
CTATCACTTC
TAGTCAGAGC
TGCAGAAGCC
CGAT.CTG
TTTCACGCTC
TCTGCTCTCA
CTTGAAATTA
GGATGATGCT
ATGAGACTGG
TGTGTTACCT
CCAGTCTCCA
CTTATAATTA
ATCTCAAGAG
AAGAGTTGAA
TGGACTACTT
<--II--> c-myc tag
751 ACTTCAGTCA CCGTCTCCTC AGAACAAAAG CTTATTTCTG
<- -I* * XhoI
801 GTAATAGCTC GAG
CTGTTAGTCT
CTTGTACACA
AGGCCAGTCT
GAGTCCCAGA
AAGATCAGCA
AAGTACACAT
AGTCCTCTGC
AAGAAAGATG
AGGAGGCTTG
CTGGATTCAC
GAGAAAGGAC
TGAAACATAT
ATGATTCCAA
GACACGGGTA
GGGTCAAGGA
AAGAAGACTT
1
51
101
151
201
251
301
351
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651
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A.12 pMSCE
Backbone: pMal-c2x (New England Biolabs)
Description: The first construct used for bacterial expression of a fusion protein containing NY-
ESO-1 (CS mutant) that can be site-specifically conjugated to yeast via the SNAP-tag.
NdeII--> Cytoplasmic maltose-binding protein
1 CATATGAAAA
51 AGGCTATAAC
101 GAATTAAAGT
TCGAAGAAGG TAAACTGGTA ATCTGGATTA
GGTCTCGCTG AAGTCGGTAA GAAATTCGAG
CACCGTTGAG CATCCGGATA AACTGGAAGA
ACGGCGATAA
AAAGATACCG
GAAATTCCCA
CAGGTTGCGG
CCGCTTTGGT
ACAAAGCGTT
TACAACGGCA
GATTTATAAC
TCCCGGCGCT
TTCAACCTGC
GGGTTATGCG
GCGTGGATAA
ATTAAAAACA
TGCCTTTAAT
GGTCCAACAT
ACCTTCAAGG
TATTAACGCC
ACTATCTGCT
CTGGGTGCCG
ACGTATTGCC
ACATCCCGCA
AACGCCGCCA
CAACTGGCGA TGGCCCTGAC
GGCTACGCTC AATCTGGCCT
CCAGGACAAG CTGTATCCGT
AGCTGATTGC TTACCCGATC
AAAGATCTGC TGCCGAACCC
GGATAAAGAA CTGAAAGCGA
AAGAACCGTA CTTCACCTGG
TTCAAGTATG AAAACGGCAA
CGCTGGCGCG AAAGCGGGTC
AACACATGAA TGCAGACACC
AAAGGCGAAA CAGCGATGAC
CGACACCAGC AAAGTGAATT
GTCAACCATC CAAACCGTTC
GCCAGTCCGA ACAAAGAGCT
GACTGATGAA GGTCTGGAAG
TAGCGCTGAA GTCTTACGAG
GCCACTATGG AAAACGCCCA
GATGTCCGCT TTCTGGTATG
GCGGTCGTCA GACTGTCGAT
<--I SacI I--> No0 linker
1101 GACTAATTCG AGCTCGAACA ACAACAACAA
I--> SNAP-tag
GGATGGACAA
GGCAAACTGG
GCTGGGTAAA
CCGCCGTGCT
AACGCGTATT
GCTGCATCAT
GGAAACTGCT
CTGGCGGCCC
GCTGAGCGGT
GCTCTAGCGG
AGATTGCGAA ATGAAACGTA
AACTGAGCGG CTGCGAACAG
GGCACCAGCG CGGCCGATGC
GGGTGGTCCG GAACCGCTGA
TTCATCAGCC GGAAGCGATT
CCGGTGTTTC AGCAGGAGAG
GAAAGTGGTT AAATTTGGCG
TGGCGGGTAA TCCGGCGGCC
AACCCGGTGC CGATTCTGAT
TGCGGTTGGC GGTTATGAAG
ATTATCTTCT
GTTGGCTGAA
TTACCTGGGA
GCTGTTGAAG
GCCAAAAACC
AAGGTAAGAG
CCGCTGATTG
GTACGACATT
TGACCTTCCT
GATTACTCCA
CATCAACGGC
ATGGTGTAAC
GTTGGCGTGC
GGCAAAAGAG
CGGTTAATAA
GAAGAGTTGG
GAAAGGTGAA
CCGTGCGTAC
GAAGCCCTGA
TAACAATAAC
CCACCCTGGA
GGCCTGCATG
GGTTGAAGTT
TGCAGGCGAC
GAAGAATTTC
CTTTACCCGT
AAGTGATTAG
ACCGCCGCCG
TCCGTGCCAT
GTGGTCTGGC
1651 TGGCTGCTGG CCCATGAAGG TCATCGTCTG GGTAAACCGG
GGGCACACGA
ATCACCCCGG
TGCCGTACGT
CGTTATCGCT
TGGGAAGAGA
CGCGCTGATG
CTGCTGACGG
AAAGACGTGG
GGTTGACCTG
TCGCAGAAGC
CCGTGGGCAT
GGTACTGCCG
TGAGCGCAGG
TTCCTCGAAA
AGACAAACCG
CGAAAGATCC
ATCATGCCGA
TGCGGTGATC
AAGACGCGCA
<--IAvaI:used to clone
AACAACCTCG SNAP-tag but not
unique after NY-
TAGCCCGCTG ESO-CS was added
AAATTAAACT
CCGGCCCCGG
CGCGTGGCTG
CGGTTCCGGC
CAGGTGCTGT
CTATCAGCAG
TTAAAACCGC
CGTGTGGTTA
GGTGAAAGAG
<--IEcoRI
GTCTGGGAGA
I--> GGGGS <--I I--> (Cl)4
1701 ATTCGGAGGC GGAGGGTCGG CTAGTGAAAA AGCTAGAGTT TTGGCTGAAG
1751 CTGCTAGTGA AAAAGCTAGA GTTTTGGCTG AAGCTGCTAG TGAAAAAGCT
1801 AGAGTTTTGG CTGAAGCTGC TAGTGAAAAA GCTAGAGTTT TGGCTGAAGC
<--INheIJ--> ASARNLVPMVATVQGQN (surrogate CMV antigen)
1851 TGCTAGCGCT AGAAATTTGG TTCCAATGGT TGCTACTGTT CAAGGTCAAA
<--IBamHI 1--> NY-ESO-CS
1901 ACGGATCCAT GCAGGCCGAA GGCCGGGGCA CAGGGGGTTC GACGGGCGAT
1951 GCTGATGGCC CAGGAGGCCC TGGCATTCCT GATGGCCCAG GGGGCAATGC
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851
901
951
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1451
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1551
1601
2001
2051
2101
2151
2201
2251
2301
2351
TGGCGGCCCA GGAGAGGCGG
CAGGGGCAGC AAGGGCCTCG
CATGCGCGGCG CGGCTTCAGG
GGGGCCGGAG AGCCGCCTGC
CACCCATGGA AGCAGAGCTG
CCGCTTCCCG TGCCAGGGGT
CATACTGACT ATCCGACTGA
CCATCAGCTC CTGTCTCCAG
2401 TGCTTTCTGC CCGTGTTTTT
HindIII
2451 AAAGCTT
GTGCCACGGG CGGCAGAGGT CCCCGGGGCG
GGGCCGGGAG GAGGCGCCCC GCGGGGTCCG
GCTGAATGGA AGCAGCAGAA GCGGGGCCAG
TTGAGTTCTA CCTCGCCATG CCTTTCGCGA
GCCCGCAGGA GCCTGGCCCA GGATGCCCCA
GCTTCTGAAG GAGTTCACTG TGTCCGGCAA
CTGCTGCAGA CCACCGCCAA CTGCAGCTCT
CAGCTTTCCC TGTTGATGTG GATCACGCAG
GGCTCAGCCT CCCTCAGGGC AGAGGCGCTG
A.13 pMSCcmyc
Backbone: pMal-c2x
Description: Used to produce a control protein lacking NY-ESO-1. Its sequence is identical to
that of pMSCE except that there is only a c-myc tag between the BamHI and HindIII sites (only
this is shown below).
BamHI I--> c-myc tag *HindIII
1 GGATCCGAAC AAAAACTTAT TTCTGAAGAG GACTTGTAAG CTT
A.14 pCT-LyslO
Backbone: pCT2
Description: Used to surface display a polypeptide containing 10 lysine residues in the form of
repeats of the sequence GGGGKGS. The sequences of the other pCT-LysX plasmids can be
inferred by analogy.
1
51
101
151
201
|--> Aga2p
ATGCAGTTAC
AGCACAGGAA
AATCGACGCC
GCAATGCAAG
TTGCGGTTCT
<--
251 AGTATGTTTT
HA tag
301 GACGTTCCAG
351 ATCTGGTGGA
401 GAGGCGGTAA
451 AAAGGATCTG
TTCGCTGTTT TTCAATATTT TCTGTTATTG
CTGACAACTA TATGCGAGCA AATCCCCTCA
GTACTCTTTG TCAACGACTA CTATTTTGGC
GAGTTTTTGA ATATTACAAA TCAGTAACGT
CACCCCTCAA CAACTAGCAA AGGCAGCCCC
I
CTTCAGTTTT
CCAACTTTAG
CAACGGGAAG
TTGTCAGTAA
ATAAACACAC
-- >
TAAGGACAAT AGCTCGACGA TTGAAGGTAG ATACCCATAC
<-- PstI 1--> KGS(GGGGKGS)9
ACTACGCTCT GCAGAAAGGA TCTGGTGGAG GCGGTAAAGG
GGCGGTAAAG GATCTGGTGG AGGCGGTAAA GGATCTGGTG
AGGATCTGGT GGAGGCGGTA AAGGATCTGG TGGAGGCGGT
GTGGAGGCGG TAAAGGATCT GGTGGAGGCG GTAAAGGATC
BamHI
<--I --> c-myc tag
501 TGGTGGAGGC GGTAAAGGAT CCGAACAAAA GCTTATTTCT GAAGAGGACT
<--I* * XhoI
551 TGTAATAGCT CGAG
A.15 pRS304-aga2p-HA
Backbone: pRS304
113
Description: Integrating shuttle vector used to derive SWH100 yeast from EBY100 yeast. Upon
galactose induction, HA-tagged aga2p protein (with no additional fusions) is expressed.
I -- > aga2p
ATGCAGTTAC
AGCACAGGAA
AATCGACGCC
GCAATGCAAG
TTGCGGTTCT
TTCGCTGTTT
CTGACAACTA
GTACTCTTTG
GAGTTTTTGA
CACCCCTCAA
TTCA
TATG
TCAA
ATAT
CAAC
<--
251 AGTATGTTTT TAAGGACAAT AGCT
tag <--I
301 GACGTTCCAG ACTACGCTCC TAGC
ATATTT TCTGTTATTG CTTCAGTTTT
ICGAGCA AATCCCCTCA CCAACTTTAG
LCGACTA CTATTTTGGC CAACGGGAAG
TACAAA TCAGTAACGT TTGTCAGTAA
TAGCAA AGGCAGCCCC ATAAACACAC
I--> HA
'CGACGA TTGAAGGTAG ATACCCATAC
* * BamHI
TAATAG GGTGGCGGAT CC
A.16 pMSICE
Backbone: pMSCE
Description: The (C 1)4 sequence in pMSCE was replaced with a pH-sensitive self-cleaving intein,
Al-CM (DW Wood et al., 1999, Nature Biotech. 17: 889-892). In this particular plasmid, the first
codon downstream of the intein encodes Met; other versions were made where this codon was
changed to alter the cleavage kinetics. Only the sequence between the EcoRI and NheI sites is
shown, with the rest being identical to pMSCE.
EcoRI i-->
1 GAATTCGCCC
51 AACGCATCGC
101 TGGCTGCTGC
151 TTCGACCAGG
201 CATCCTGTGG
251 GTGCCGCCGG
301 TTCGATGGAT
351 CGCGGATGCC
401 TCCGCTATTC
451 TTCGGCCTCG
<--I
501 TGTACACAAC
intein
TCGCAGAGGG
ATCGAGGATG
CAAGGACGGA
GAACGCGGGA
GCGACACCCG
GGAACTCCGC
TCGGTGACAG
CTGGATGACA
CGTGATCCGA
AGGTCGAGGA
Met NheI
ATGGCTAGC
CACTCGGATC
TTGTCGGTGG
ACGCTGCGTG
TGTGATCGGG
ATCACAAGGT
AAGGGAGACA
TGCGCCGATT
AATTCCTGCA
GAAGTGCTGC
ACTGCACACC
TTCGATCCGG
GCGCAAGCCT
CGCGGCCCGT
TTGCGGATCG
GCTGACAGAG
GGGTGGCGCA
CCGGCGCGCG
CGACATGCTG
CAACGCGGCG
CTCGTCGCCG
TCACCGGTAC
ATTCATGTCG
GGTGTCCTGG
CCGGTGGCGC
TACGGCTGGC
ACCGCGACGC
TGCAGGCGCT
GCGGAAGAAC
GGCACGGACG
AAGGGGTTGT
A.17 pMS74NEY2
Backbone: pMal-c2x
Description: This construct produces the latest generation fusion protein that permits multi-layer
conjugation to yeast particles; phagosomal antigen release is mediated by the ectodomain of the
invariant chain, CD74. The N9V epitope was mutated to NLVPMIATV to inhibit CatS cleavage.
Purification of the full-length protein is facilitated by the C-terminal His6tag.
NdeIl--> Cytoplasmic maltose-binding protein
1 CATATGAAAA TCGAAGAAGG TAAACTGGTA ATCTGGATTA
51 AGGCTATAAC GGTCTCGCTG AAGTCGGTAA GAAATTCGAG
101 GAATTAAAGT CACCGTTGAG CATCCGGATA AACTGGAAGA
151 CAGGTTGCGG CAACTGGCGA TGGCCCTGAC ATTATCTTCT
201 CCGCTTTGGT GGCTACGCTC AATCTGGCCT GTTGGCTGAA
251 ACAAAGCGTT CCAGGACAAG CTGTATCCGT TTACCTGGGA
ACGGCGATAA
AAAGATACCG
GAAATTCCCA
GGGCACACGA
ATCACCCCGG
TGCCGTACGT
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TACAACGGCA
GATTTATAAC
TCCCGGCGCT
TTCAACCTGC
GGGTTATGCG
GCGTGGATAA
ATTAAAAACA
TGCCTTTAAT
GGTCCAACAT
ACCTTCAAGG
TATTAACGCC
ACTATCTGCT
CTGGGTGCCG
ACGTATTGCC
ACATCCCGCA
AACGCCGCCA
<-- I SacI I- ->
1101 GACTAATTCG AGCTCGAACA
I--> SNAP-tag
GGATGGACAA
GGCAAACTGG
GCTGGGTAAA
CCGCCGTGCT
AACGCGTATT
GCTGCATCAT
GGAAACTGCT
CTGGCGGCCC
GCTGAGCGGT
GCTCTAGCGG
AGATTGCGAA
AACTGAGCGG
GGCACCAGCG
GGGTGGTCCG
TTCATCAGCC
CCGGTGTTTC
GAAAGTGGTT
TGGCGGGTAA
AACCCGGTGC
TGCGGTTGGC
AGCTGATTGC
AAAGATCTGC
GGATAAAGAA
AAGAACCGTA
TTCAAGTATG
CGCTGGCGCG
AACACATGAA
AAAGGCGAAA
CGACACCAGC
GTCAACCATC
GCCAGTCCGA
GACTGATGAA
TAGCGCTGAA
GCCACTATGG
GATGTCCGCT
GCGGTCGTCA
1651 TGGCTGCTGG CCCATGAAGG TCATCGTCTG GGTAAACCGG
I--> CD74 ectodomain (aa 73-207)
1701 ATTCCAGCAG CAGGGCCGGC
TGCAGCTGGA
AGCAAGATGC
AGCCCTGCCC
CAGAGGACCA
TACCCGCCAC
CACCATGGAG
GGCTCCTGTT
GAACCTGCGC
GCATGGCCAC
CAGGGGCCCA
TGTGATGCAC
TGAAGGGGAG
ACCATAGACT
TGAAATGAGC
TTACCCGATC GCTGTTGAAG
TGCCGAACCC GCCAAAAACC
CTGAAAGCGA AAGGTAAGAG
CTTCACCTGG CCGCTGATTG
AAAACGGCAA GTACGACATT
AAAGCGGGTC TGACCTTCCT
TGCAGACACC GATTACTCCA
CAGCGATGAC CATCAACGGC
AAAGTGAATT ATGGTGTAAC
CAAACCGTTC GTTGGCGTGC
ACAAAGAGCT GGCAAAAGAG
GGTCTGGAAG CGGTTAATAA
GTCTTACGAG GAAGAGTTGG
AAAACGCCCA GAAAGGTGAA
TTCTGGTATG CCGTGCGTAC
GACTGTCGAT GAAGCCCTGA
N10 linker
ACAACAACAA TAACAATAAC
ATGAAACGTA CCACCCTGGA
CTGCGAACAG GGCCTGCATG
CGGCCGATGC GGTTGAAGTT
GAACCGCTGA TGCAGGCGAC
GGAAGCGATT GAAGAATTTC
AGCAGGAGAG CTTTACCCGT
AAATTTGGCG AAGTGATTAG
TCCGGCGGCC ACCGCCGCCG
CGATTCTGAT TCCGTGCCAT
GGTTATGAAG GTGGTCTGGC
TGGACAAACT GACAGTCACC TCCCAGAACC
HindIII (makes final site not unique)
ATGAAGCTTC CCAAGCCTCC CAAGCCTGTG
CCCGCTGCTG ATGCAGGCGC TGCCCATGGG
TGCAGAATGC CACCAAGTAT GGCAACATGA
CTGCTCCAGA ATGCTGACCC CCTGAAGGTG
CTTCCCGGAG AACCTGAGAC ACCTTAAGAA
GGAAGGTCTT TGAGAGCTGG ATGCACCATT
AGGCACTCCT TGGAGCAAAA GCCCACTGAC
<--INheI I--> ARNLVPMIATVQGQN
2101 GCTCCACCGG CTAGCGCTAG AAATTTGGTT
<--I BamHI I--> NY-ESO-CS
2151 AGGTCAAAAC GGATCCATGC AGGCCGAAGG
2201 CGGGCGATGC TGATGGCCCA GGAGGCCCTG
2251 GGCAATGCTG GCGGCCCAGG AGAGGCGGGT
2301 CCGGGGCGCA GGGGCAGCAA GGGCCTCGGG
2351 GGGGTCCGCA TGGCGGCGCG GCTTCAGGGC
2401 GGGGCCAGGG GGCCGGAGAG CCGCCTGCTT
2451 TTTCGCGACA CCCATGGAAG CAGAGCTGGC
2501 ATGCCCCACC GCTTCCCGTG CCAGGGGTGC
2551 TCCGGCAACA TACTGACTAT CCGACTGACT
2601 GCAGCTCTCC ATCAGCTCCT GTCTCCAGCA
2651 TCACGCAGTG CTTTCTGCCC GTGTTTTTGG
CCAATGATTG CTACTGTTCA
CCGGGGCACA
GCATTCCTGA
GCCACGGGCG
GCCGGGAGGA
TGAATGGAAG
GAGTTCTACC
CCGCAGGAGC
TTCTGAAGGA
GCTGCAGACC
GCTTTCCCTG
CTCAGCCTCC
GGGGGTTCGA
TGGCCCAGGG
GCAGAGGTCC
GGCGCCCCGC
CAGCAGAAGC
TCGCCATGCC
CTGGCCCAGG
GTTCACTGTG
ACCGCCAACT
TTGATGTGGA
CTCAGGGCAG
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CGTTATCGCT
TGGGAAGAGA
CGCGCTGATG
CTGCTGACGG
AAAGACGTGG
GGTTGACCTG
TCGCAGAAGC
CCGTGGGCAT
GGTACTGCCG
TGAGCGCAGG
TTCCTCGAAA
AGACAAACCG
CGAAAGATCC
ATCATGCCGA
TGCGGTGATC
AAGACGCGCA
<--IAvaI:used to clone
AACAACCTCG SNAP-tag but not
unique after NY-
TAGCCCGCTG ESO-CS was added
AAATTAAACT
CCGGCCCCGG
CGCGTGGCTG
CGGTTCCGGC
CAGGTGCTGT
CTATCAGCAG
TTAAAACCGC
CGTGTGGTTA
GGTGAAAGAG
<--IEcoRI
GTCTGGGAGA
1151
1201
1251
1301
1351
1401
1451
1501
1551
1601
1751
1801
1851
1901
1951
2001
2051
BsrGI
<-- -- > TVQL<-- I -- > (G4 S) 3 linker
2701 AGGCGCACTG TACAGCTGGG TGGCGGCGGT AGCGGTGGCG GTGGCTCTGG
<--II--> ybbR tag (DSLEFIASKLA) <-- I-->
2751 CGGTGGTGGC TCCGATTCTC TTGAATTTAT TGCTAGTAAA CTTGCGCACC
His6 tag <--I* HindIII
2801 ATCACCACCA CCATTGAAAG CTT
A.18 IIIa5.3.7
Backbone: pCT
Description: This is one of the two fibronectin domains evolved to bind to human FcyRIIIA that
was selected for further investigation. Only the sequence between the PstI and BamHI sites is
shown (i.e. the (G4S)3 linker and the fibronectin domain).
PstI
1 CTGCAGGCTA
51 TGGTTCTGCT
101 CGACCCCCAC
151 TACAGGATCA
201 CACTGTGCCT
251 GAGTTGATTA
301 TCTTATCCAA
BamHI
351 GGGATCC
GTGGTGGTGG
AGCGTTTCCG
CAGCCTACTG
CTTACGGAGA
GGTACCGAGT
TACCATCACT
TTTCCATTAA
TGGTTCTGGT
ATGTTCCGAG
ATCAACTGGG
AACAGGAGGA
CTATCGCTAC
GTGTATGCTG
TTACCGAACA
GGCGGTGGTT
GGACCTGGAA
ATTTGCCCTT
AATAGCCCTG
CATCAGCGGC
TCGCTTCTAG
GAAATTGACA
CTGGTGGTGG
GTTGTTGTTG
TTCGGACTCT
TCCAGGGGTT
CTTAAACCTG
TGGGTCTAAC
AACCATCCCA
A.19 IIIa6.2.6
Backbone: pCT
Description: This is one of the two fibronectin domains evolved to bind to human FcyRIIIA that
was selected for further investigation. Only the sequence between the PstI and BamHI sites is
shown (i.e. the (G4S)3 linker and the fibronectin domain).
PstI
1 CTGCAGGCTA
51 CTCTGCTAGC
101 CCCCCACCAG
151 AGGATCGCTT
201 TGTGCCTGGT
251 TTGATTATAC
301 TATCCAATTT
BamHI
351 ATCC
GTGGTGGTGG
GTTTCTGATG
CCTACTGATC
ACGGAGAAAC
ACCGACTCTC
CATCACTGTG
CCATTAATTA
TGGTTCTGAT
TTCCGAGGGA
AACTGGGATA
AGGAGGAAAT
TCGCTACCAT
TATGCTGTCA
CCGGACAGAA
GGTGGTTCTG
CCTGGAAGTT
TGCCCTTTTC
AGCCCTGTCC
CAGCGGCCTT
CTTCTAGTGG
ATTGACAAAC
GTGGTGGTGG
GTTGTTGCGA
GGACTCTTAC
AGGAGTTCAC
AAACCTGGAG
GTCTAACTCT
CATCCCAGGG
A.20 HIa7.2.6
Backbone: pCT
Description: This is one of the two fibronectin domains evolved to bind selectively to human
FcyRIIA but not FcyRIIB that was selected for further investigation. Only the sequence between
the PstI and BamHI sites is shown (i.e. the (G4S) 3 linker and the fibronectin domain).
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PstI
1 CTGCAGGCTA GTGGTGGTGG
51 TGGTTCTGCT AGCGTTTCTG
101 CGACCCCCAC CAGCCTACTG
151 TATTACAGGA TCTTTTACGG
201 GTTCACTGTG CCTGCCCTCT
251 CTGGAGTTGA TTATACCATC
301 GATTGGCCAA TTTCCATTAA
BamHI
351 GGGATCC
TGGTTCTGGT
ATGTTCCGGG
ATTAGCTGGT
AGAAACAGGA
GTCCCGGGGC
ACTGCGTATG
TTACCGAACA
GGTGGTGGTT CTGGTGGTAG
GGACCTGGAA GTTGTTGCTG
GTACCCATCT ACATTGGGAT
GGAAATAGCC CTGTCCAGGA
TACCATTAGC GGCCTTAAAC
CTGTCACTGT GGGGGGGGAT
GAAATTGACG AACCATCCCA
A.21 IIa8.2.7
Backbone: pCT
Description: This is one of the two fibronectin domains evolved to bind selectively to human
FcyRIIA but not FcyRIIB that was selected for further investigation. Only the sequence between
the PstI and BamHI sites is shown (i.e. the (G4S)3 linker and the fibronectin domain).
PstI
1 CTGCAGGCTA GTGGTGGTGG
51 TGGTTCTGCT AGCGTTTCTG
101 CGACCCCCAC CAGCCTACTG
151 TATTACAGGA TCTTTTACGG
201 GTTCACTGTG CCTGCCCTCT
251 CTGGAGTTGA TTATACCATC
301 GATTGGCCAA GTTCCATTAA
BamHI
351 GGGATCC
TGGTTCTGGT GGTGGTGGTT CTGGTGGTAG
ATGTTCCGGG GGACCTGGAA GTTGTTGCTG
ATTAGCTGGT GTACCCATCT ACATTGGGAT
AGAAACAGGA GGAAATAGCC CTGTCCAGGA
GTCCCGGGGC TACCATTAGC GGCCTTAAAC
ACTGCGTATG CTGTCACTGT GGGGGGGGAT
TTACCGAACA GAAATTGACG AACCATCCCA
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Appendix B - Details of Selected Protocols
B.1 Generation of monocyte-derived DCs
Monocyte sources
Elutriated monocytes from Advanced Biotechnologies Inc (07-210-000)
or
Monocytes purified by negative magnetic cell sorting from leukapheresis packs from Biological
Specialty Corporation (custom product)
The expected yield from either company is roughly 109 cells. At the time I made my inquiry,
ABI only had one known HLA-A*0201 donor. The first batch from this donor worked well but
subsequent batches gave rise to abnormal cross-presentation results.
CIO medium
500 ml RPMI-1640 with glutamine (HyClone SH30027.01)
50 ml low endotoxin fetal calf serum (FCS, HyClone SH30073.03, no need to heat inactivate)
5 ml 100x non-essential amino acids (HyClone SH30238.01)
5 ml 100 mM sodium pyruvate (Hyclone SH30239.01)
5 ml 1 M Hepes solution, pH 7.2-7.4 (HyClone discontinued, switched to Amresco J848)
1 ml Primocin (InvivoGen ant-pm-1)
1.75 dl P3-mercaptoethanol (final concentration of 50 ýtM)
Filter sterilize after mixing.
Cytokines
Recombinant human IL-4 (R&D Systems 204-IL, treat as 2.9x 104 U/ pg)
Recombinant human GM-CSF (R&D Systems 215-GM, treat as 1.5 x104 U/ g)
Dissolve each in PBS + 1% BSA to 1 x 10 U/ml and freeze in 0.5 ml aliquots. Keep one aliquot
at 40 C.
Monocyte cryopreservation
* Before the monocytes arrive, thaw 2 aliquots of 50 ml FCS. Add 12.5 ml sterile DMSO to 50
ml FCS. Chill both the FCS and the FCS + 20% DMSO on ice. Also chill about 50 cryogenic
vials. Ensure that at least 3 "Mr Frosty" containers are available and at room temperature.
* Centrifuge the monocytes at 200xg for 10 min and discard the supernatant.
* The monocyte preparation from BSC also contains platelets. To remove the platelets, wash
twice with PBS (fill each 50 ml tube), centrifuging as above. These wash steps can be
omitted with ABI's elutriated monocytes.
* Resuspend in 25 ml cold FCS (less if listed cell yield is fewer than 109 cells).
* Count the cells with trypan blue and the hematocytometer. The viability should be >90% and
the cell concentration should be 4-6 x 107 cells/ml. Add FCS if necessary.
* Add an equal volume of cold FCS + 20% DMSO drop-wise while gentle swirling. Keep cold.
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* Fill cryogenic vials on ice with 1 ml of cell suspension. It is a good idea to also make a few
0.5 ml aliquots for smaller experiments.
* Place vials in a "Mr Frosty" container and immediately move to the -700 C freezer. Transfer
vials to the liquid nitrogen tank after 4-24 h.
Generation of immature moDCs
The instructions given below are for a typical experiment. My final batch of monocytes was
cryopreserved at 2.6 x 107 monocytes per vial. One vial cultured in one 6-well plate typically
resulted in 4-7 x 106 DCs.
Day 0
* Pre-warm the C10 medium. Thaw a vial of monocytes in the 370 C water bath, swirling
gently until only a small chunk of ice (-~10% by volume) remains.
* Move the vial's contents to a 15 ml conical tube. Add 9 ml C10 medium gradually while
swirling the tube gently (add drop-wise at first, then slowly speed up).
* Centrifuge at 200xg for 8 min. Meanwhile, combine 25 ml of C 10 with 0.25 ml each of IL-4
and GM-CSF (1000 U/ml each) to make up C10GF medium.
* Resuspend the monocytes in 15 ml C10OGF and seed 2.5 ml in each well of a 6-well tissue
culture plate. Place in humidified 370 C, 5% CO2 incubator. Store the remaining C10OGF at
40C.
Day 2
* Add 0.5 ml of warm C10OGF to each well. The cells should now be irregular in shape.
Day 4
* Add 0.5 ml of warm C10OGF to each well. The cells should now be larger and irregularly
shaped with some visible dendrites.
Day 6 (or day 5 if pressed for time)
* Harvest the floating or loosely adherent DCs by gentle resuspension. Centrifuge at 200xg for
6 min in a 50 ml tube.
* Add an equal volume of supernatant to the remaining C10OGF and discard the rest of the
supernatant. Resuspend the DCs in this partially recycled C10GF, count, and adjust to the
desired cell density.
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B.2 Cross-presentation assay with N9V-specific T cells
Materials needed
Day 6 immature HLA-A2 DCs as described in the previous protocol
A15N positive control peptide (ARNLVPMVATVQGQN, synthesized by GenScript)
A vial of frozen CD8+ T cells specific against N9V/HLA-A2 (ProImmune C008-0B)
RPMI/FCS medium (RPMI-1640 with glutamine, 10% FCS, Primocin; see B. 1 for suppliers)
Recombinant human IL-2 (R&D Systems 202-IL)
Labeling buffer (PBS + 0.5% BSA + 2 mM EDTA)
Human IFNy secretion assay detection kit (Miltenyi 130-054-202) consisting of Catch Reagent
and a-IFNy-PE
a-CD8-FITC antibody (BD Biosciences 555634)
Day 6 morning
* For each desired test condition, seed 1-2 x 105 DCs in 200 yl C 10OGF in a well of a 96-well
round bottom plate (e.g. BD Falcon 353077). The optimal number of DCs per well may vary
between batches of monocytes.
* Allow the DCs to settle in the incubator for 30-90 min while the antigens are being prepared.
* Add the antigens to the respective wells. One well should be left unstimulated as a negative
control, whereas 10 gM A15N peptide should be added to a positive control well. To add
yeast cells, the yeast should be pelleted and resuspended in some medium taken from the
target DC well.
* Return the plate to the incubator and note the time.
Day 6 evening
* Pre-warm the RPMI/FCS medium. Thaw a vial of N9V-specific T cells in the 370 C water
bath, swirling gently until only a small chunk of ice remains.
* Move the vial's contents to a 15 ml conical tube. Slowly add 2 ml RPMI/FCS drop-wise
using a 1 ml pipette tip while gently swirling the tube. Continue adding another 7 ml
RPMI/FCS drop-wise using a 10 ml pipette. I have found the T cells to be quite sensitive to
osmotic shock.
* Centrifuge at 200xg for 10 min and completely aspirate the supernatant.
* Resuspend the cells in 4 ml RPMI/FCS and add 5 ng/ml IL-2. Seed 1 ml each in 4 wells of a
24-well tissue culture plate and incubate overnight.
Day 7
* About 40 minutes before 24 h have elapsed since antigen addition, carefully set aside 0.5 ml
of medium from each T cell well without disturbing the cells.
* Combine, resuspend, and count the T cells in the presence of trypan blue. Adjust the live T
cell concentration to 0.7-1 x 106 cells/ml. The viability can sometimes be as low as 50%.
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* Remove 100 gl of medium from each DC well without disturbing the cells. Add 100 l1 of T
cells and gently resuspend.
* Centrifuge the plate at 200xg for about 1 min to settle the cells, then return the plate to the
incubator (this should be approximately 24 h since antigen addition).
* Four hours later, place the plate on ice and move the contents of each well to a
microcentrifuge tube containing 1 ml cold labeling buffer.
* Centrifuge the tubes at 300xg, 41C for 10 min. To reduce cell loss, centrifuge for 7 minutes,
then rotate the tubes 1800 (e.g. from having the lid hinge facing the center of the rotor to
facing outside) to centrifuge for a further 3 min. The subsequent centrifugation steps should
be performed in the same manner.
* Aspirate the supernatant and resuspend each cell pellet in 100 ll of a solution consisting of
10% Catch Reagent, 90% labeling buffer.
* Incubate for 5 min on ice, then add 1 ml warm RPMI/FCS.
* Incubate at 370C for 45 min with gentle rotation. If a MACSmix tube rotator is not available,
place the tubes in a water bath and invert them every 5-7 min.
* Place the tubes on ice and add 0.5 ml cold labeling buffer. Centrifuge and aspirate.
* Optional wash step: Add 0.5 ml cold labeling buffer, centrifuge and aspirate.
* Resuspend each cell pellet in 100 pCl of a solution consisting of 20% a-CD8-FITC, 10% a-
IFNy-PE, 70% labeling buffer. Incubate for 30 min on ice.
* Add 0.5 ml cold labeling buffer to each tube. Centrifuge and aspirate.
* Analyze the cells on a flow cytometry machine. The events should be gated by forward and
side scatter and by the FITC channel to identify the CD8+ T cells. The assay readout is the
percentage of such cells that are PE-positive. Since the PE-positive and PE-negative
populations are not clearly distinct, draw the region such that -0.5% (or fewer) of the CD8+
T cells in the negative control are PE-positive.
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B.3 Expression and purification of MS74NEY2
Solutions to prepare
LB + glucose:
10 g tryptone, 5 g yeast extract, 5 g NaCi, 2 g glucose. Dissolve in 1 L water and autoclave.
0.5 M IPTG:
Dissolve 1.19 g isopropyl-3-D-thiogalactopyranoside in 10 ml ddH20. Filter sterilize and store at
4°C protected from light.
Column buffer base:
20 mM Tris-HC1, pH 7.4, 200 mM NaCl
3 M imidazole stock:
Dissolve 10.2 g imidazole in 40 ml ddH20. Adjust pH to 7.5 with HCI and add ddH20 to bring
volume to 50 ml.
1 M maltose stock:
Dissolve 18.0 g maltose in ddH20 to give a final volume of 50 ml.
Talon buffer:
Prepare just before use and keep cold. To 200 ml column base buffer, add 5 mM P-
mercaptoethanol (70.1 gl).
Amylose resin buffer:
Prepare just before use and keep cold. To 150 ml column base buffer, add 1 mM EDTA (0.3 ml
of a 0.5 M EDTA stock) and 23.1 mg dithiothreitol (DTT).
Amylose wash buffer:
Move 100 ml of the above amylose resin buffer to a new bottle, add 0.1 ml Triton X-114 (Sigma)
and stir. The wash buffer will be cloudy at room temperature but will become clear when chilled.
Transformation, growth and induction
* Transform pMS74NEY2 plasmid into BL21(DE3)-RIPL competent cells (Stratagene)
according to the manufacturer's protocol, which can be scaled down to use only 25 gl of
competent cells. Plate 50 tl of the transformation mix onto an LB + ampicillin plate and
incubate at 370 C overnight.
* In the evening of the next day, inoculate 2 culture tubes each with 5 ml LB + glucose + 100
glg/ml ampicillin + 34 jtg/ml chloramphenicol. I split one colony between the two tubes.
Shake at 300 C overnight (-16 h) or at 370 C for -12 h.
* Add the 10 ml of culture to 1 L LB + glucose (without antibiotics) in a large Tunair flask.
Shake at 370C until the OD600 reading reaches -0.7 (about 2.5 h).
* Add 0.3 mM IPTG (0.6 ml of 0.5 M stock) and move the flask to the 20 0 C shaker.
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* After 6 h of induction, harvest the bacteria by centrifugation at 12,000xg for 5 min,
preferably into one centrifuge bottle.
* Discard the supernatant. Freeze the pellet overnight at -200C.
Lysis
* Thaw the bacterial pellet in cold water. Dissolve one EDTA-free Complete Protease Inhibitor
Cocktail Tablet (Roche 04 693 132 001) in 50 ml cold Talon buffer. Resuspend the bacteria
in 25 ml of Talon buffer + protease inhibitors and transfer to a 50 ml conical tube on ice.
* Sonicate the suspension to lyse the bacteria. With the Cooney lab's sonicator, I set the
amplitude to 30% and the pulse rate to 2 s on, 2 s off. I sonicated four times for 1 min each,
letting the sample rest on ice for 1 min between each go.
* Add 10 ml Talon buffer + protease inhibitors and centrifuge at 20,000xg, 40 C for 40 min.
Make sure to use tubes that can withstand this g-force.
* Filter the supematant using a Nalgene Supor machV filter (others will likely clog). Check the
pH and adjust it to 7.4 with NaOH if needed.
Talon metal affinity chromatography
* Pack 5 ml (bed volume) Talon metal affinity resin (Clontech) in a 2.5 cm diameter column in
the cold room. Equilibrate with 25 ml Talon buffer.
* Load the clarified lysate and adjust the stopcock to reduce the flow rate to < 1 ml/min.
* Wash with 50 ml Talon buffer (with full flow rate).
* Elute with 25 ml Talon buffer + 150 mM imidazole, collecting 5 ml fractions. Check the
A280 absorbance of the fractions.
Amylose resin affinity chromatography
* Pack 2 ml (bed volume) amylose resin (New England Biolabs) in a 1 cm diameter column in
the cold room. Equilibrate with 10 ml amylose resin buffer.
* Load the protein-containing fractions eluted from the Talon resin. Instead of mixing the
fractions, I load them consecutively in order of protein content (least to most).
* Wash with 100 ml amylose wash buffer.
* Wash with 10 ml amylose resin buffer.
* Elute with 10 ml amylose resin buffer + 10 mM maltose.
Concentration
* Check A280 of eluted protein. For MS74NEY2, MW = 100381, E = 112830 cm-1 M-1. Expect
a yield of 5-10 mg.
* Concentrate the protein to 60 [tM using an Amicon Ultra MWCO 30K centrifugal filter
(Millipore). The protein should be stable for several months stored at 40C.
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B.4 Conjugating one or more layers of MS74NEY2 onto SWH100 yeast
Reagents needed for first layer
SWH100 yeast
BG-GLA-NHS (2 mg vial, Covalys BB 186)
Dimethylformamide (DMF)
MS74NEY2 protein (60 pM in amylose resin elution buffer, see B.3)
PBS
CHAPS stock solution, 1% (w/v) in PBS
PBS/BSA (PBS + 0.1% BSA)
Reagents needed for subsequent layers
Sfp phosphopantetheinyl transferase, 0.25 mM solution prepared as described by Yin J, Lin AJ,
Golan DE, et al. "Site-specific protein labeling by Sfp phosphopantetheinyl transferase"
Nat Protoc 2006;1(1):280-5.
BG-CoA, synthesized as described below
1 M MgCl2 stock solution
BG-CoA synthesis
* Dissolve 1 mg of BG-maleimide (BB056, Covalys; MW 489.5) in 0.5 ml DMF.
* Weigh out >1.2 mg of Coenzyme A trilithium salt (C3019, Sigma; MW 785.3) and dissolve
in PBS to make a 3 mM solution.
* Add 0.5 ml Coenzyme A solution (1.5 gmoles) drop-wise to the BG-maleimide (2.04
pmoles) while stirring.
* Flush the tube with nitrogen gas, close the cap and place in the 30"C incubator for 24 h.
* Verify by mass spectrometry. Example spectra are shown in Fig. B. 1
* Add 1 p1 of a 1 M solution of DTT and incubate at 300C for 2 h to quench the excess BG-
maleimide. Store at -200C.
SWHI 00 culture and induction
* Inoculate 5 ml of SD-CAA with a colony of SWH100 yeast from a freshly streaked SD-CAA
agar plate. Culture in a 300 C shaker until mid-log phase (-18 h). For larger culture volumes,
pick more colonies rather than increasing the growth time (e.g. 5 colonies for 50 ml).
* Pellet by centrifugation 5 OD.ml of yeast and resuspend in 5 ml of YPG.
* Shake at 300C for 12 h, then store at 40 C.
* Optional: check expression levels of aga2p-HA by labeling with a-HA and analyzing by flow
cytometry.
BG-SWH1 00 preparation
* Pellet by centrifugation >10 OD.ml of induced SWH100 yeast split between two
microcentrifuge tubes
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Figure B.1, MALDI mass spectra of BG-CoA in negative and positive modes. The peaks of
interest have been annotated.
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* Wash each tube 4x with 1 ml PBS + 0.01% CHAPS.
* Resuspend each pellet in 1 ml PBS + 0.01% CHAPS and transfer to a 35 mm Petri dish. UV-
irradiate with 1000 J/m2 in a Stratalinker 1800 (Stratagene). Swirl each Petri dish and UV-
irradiate again with 1000 J/m2.
* Pool the yeast, measure the OD600 and pellet 5 OD.ml of yeast in each of two
microcentrifuge tubes.
* Wash each pellet in 0.2 ml DMF, being careful to aspirate completely.
* Dissolve 2 mg of BG-GLA-NHS in 100 ll DMF. Resuspend each yeast pellet in 50 [ll of this
solution. BG-GLA-NHS is unstable and should be used immediately after dissolving.
* Place the tubes in a 300 C shaker for 2 h.
* Wash each pellet 3 x with PBS/BSA. Resuspend in 0.5 ml PBS/BSA and store at 40C.
Conjugation of the initial layer of antigen
These instructions are written for conjugating antigen to 1 OD.ml of yeast. Scale accordingly.
* Pellet 1 OD.ml of BG-SWH100 in a 0.5 ml tube.
* Resuspend in 400 gll of PBS and add 100 tl of 60 gM MS74NEY2.
* Gently rotate at 300C for 5 h, using a MACSmix tube rotator (Miltenyi).
* Pellet by centrifugation and aspirate. Since the antigen-conjugated yeast can be quite sticky,
centrifuge at maximum speed for 30 s, then rotate the tube 1800 (e.g. from having the lid
hinge facing the center of the rotor to facing outside) and centrifuge for 30 s. All future
centrifugations should be performed in this manner.
* Wash once (if proceeding with subsequent layers) or twice with 0.5 ml PBS/BSA.
Conjugation of subsequent layers of antigen
These instructions are written for conjugating antigen to 1 OD.ml of yeast. Scale accordingly.
* Resuspend 1 OD.ml of yeast coated with one layer of MS74NEY2 in 200 .1 of PBS/BSA
containing 1 mM MgCl2, 12.5 pLM Sfp and 75 ipM BG-CoA:
- 178 pl PBS/BSA
- 2 pl 1 MMgC12
- 10 pl 0.25 mM Sfp
- 10 pl 1.5 mM BG-CoA
* Incubate at 370C for 90 min, vortexing every 30 min.
* Pellet by centrifugation, aspirate, and wash twice with 0.5 ml PBS/BSA.
* Resuspend yeast in 400 .l of PBS and add 100 pl of 60 pLM MS74NEY2. Gently rotate at
30'C for 2 h.
* Pellet by centrifugation, aspirate, and wash with 0.5 ml PBS/BSA.
* Repeat the steps in this section as desired.
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Appendix C -Self-cleaving pH-sensitive Inteins for Antigen Release
C.1 Introduction
In Chapter 2, we demonstrated the importance to cross-presentation of having yeast-
attached antigen be released rapidly upon phagocytosis by dendritic cells (DCs). In Chapter 3,
the initial antigen release mechanism that we included in the vaccine design, the (C1)4 sequence,
had no beneficial effect on cross-presentation. We eventually replaced this with the invariant
chain ectodomain that is rapidly cleaved by phagosomal Cathepsin S, but before that, we also
investigated an alternative antigen release strategy based upon the acidification of phagosomes as
they mature. One potential advantage of pH-triggered antigen release over protease-mediated
mechanisms is that the release kinetics will not be limited by protease activity or concentration
even at high antigen concentrations.
Inteins are polypeptide sequences within a larger protein that are able to excise
themselves and splice together the flanking sequences. Wood et. al engineered a pH-sensitive
mini-intein that cleaves at its C-terminus but not the N-terminus and does not perform splicing (1,
2). The cleavage rate of this intein is optimal at pH 6 and is considerably slower at neutral and
alkaline pH and at low temperatures. The cleavage rate is also affected by the first amino acid
residue (+1 aa) after the C-terminus of the intein, with Cys leading to faster cleavage than Met
(2). We hypothesized that replacing the (C1)4 sequence in MSCE with the intein would result in
more efficient cross-presentation from the antigen-conjugated yeast, and furthermore, that the
release kinetics could be optimized by choosing the appropriate +1 aa.
C.2 Materials and Methods
A plasmid containing the intein sequence (pET/ELP-I-CAT) was generously provided by
David Wood. This sequence was PCR-amplified using primers to add flanking EcoRI and NheI
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sites and Met or an alternative +1 aa and subcloned into pMSCE. The protein was produced in E.
coli and purified as described in Chapter 4.3.4, except the chromatography buffers were adjusted
to pH 8.5 instead of 7.4. Also, for the faster cleaving inteins (Cys or Ser as the +1 aa), the culture
flask was plunged into ice-cold water to cool the contents down to 200 C just before induction,
and the induction time was reduced to 2 h at 200C.
To determine the cleavage kinetics of each intein-containing protein, eight aliquots of 1
pl 60 jgM protein added to 19 •l 80 mM sodium phosphate, pH 6.0, 150 mM NaCl were
incubated at 370 C for various times, then boiled with SDS-PAGE sample buffer for 5 min. After
SDS-PAGE and staining with SimplyBlue Safestain (Invitrogen), the bands were imaged on a
Biorad Fluor-S imager and quantified using the automatic band detection function in the
Quantity One software. After cleavage, the C-terminal protein fragment (mostly NY-ESO-1) was
disproportionately poorly stained. The ratio of the density of the upper band (full length) to the
sum of the densities of the upper and middle (N-terminal fragment after cleavage) bands could
be fitted to an exponential decay over time (with a constant background term) to determine the
cleavage half-life.
Each intein-containing fusion protein was conjugated to BG-SWH100 yeast as described
in Appendix B.4, except that the PBS used was adjusted to pH 8.5 and the reaction time was
reduced to 2 h to reduce self-cleavage. The cross-presentation assays were performed as
described in Chapter 4.3.7.
C.3 Results
For the pilot experiment, we produced the protein MSICE with the self-cleaving intein
and Met as the +1 aa between the SNAP-tag and N9V. Conjugating this to yeast, we observed an
improvement in cross-presentation over yeast conjugated with protein lacking such a linker or
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with (C1)4 as the linker (not shown). This encouraging result prompted us to produce and
characterize four other intein-containing fusion proteins, with Cys, Ser, Thr, or Gly as the +1 aa,
which varied considerably in their self-cleavage kinetics (Table C.1). However, there was no
obvious relationship between the kinetics and the cross-presentation efficiency of the proteins
when conjugated to yeast (Fig. C.1). All the intein-containing constructs were slightly improved
over the linkerless construct. To investigate the reason for the improvement, we mutated the final
residue of the intein from Asn to Ala, preventing the Asn rearrangement necessary for self-
cleavage. Yeast-conjugated fusion protein containing this inactive intein was still cross-presented
as well as the version containing the functional intein and slightly better than when no linker or
(C1)4 was present (Fig. C.2). A lower yeast-to-DC ratio of 7.5:1 was used in this experiment to
ensure that the assay output was not saturated.
C.4 Conclusion
Although the insertion of the intein provided a slight but reproducible benefit to cross-
presentation, pH-triggered self-cleavage was ruled out as the mechanism. Instead, it is likely that
the intein simply contains some sequences that are susceptible to proteases in the early
phagosome. When MSICE (functional or inactivated) is digested with Cathepsin S in vitro, many
more fragments are generated than when MSCE is digested (not shown), supporting this
hypothesis. Since the fastest self-cleaving intein has a half-life of only 9 min at pH 6.0, 370C, it
seems quite likely that proteolysis precedes acidification during phagosome maturation.
Table C.1 - Intein self-cleavage half-life at pH 6.0, 370C
+1 aa C S T M G
t2/ (min) 9 16 33 45 166
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Figure C.1, Improved cross-presentation from intein-containing constructs does not arise
from self-cleavage. InteinX indicates X as the +1 aa. Error bars indicate S.D. of duplicate wells.
A, Yeast conjugated to fusion proteins containing the indicated inteins were added to DCs at a
20:1 ratio. The cross-presentation assay was performed after 24 h.
B, Yeast conjugated to fusion proteins with the indicated linkers (between the SNAP-tag and
N9V) were added to DCs at a 7.5:1 ratio. The cross-presentation assay was performed after 24 h.
The inactive intein has an Ala instead of Asn as its C-terminal residue.
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Appendix D - Fibronectin Domains for Increasing IgG Binding to
Activating over Inhibitory Fc Receptors
D.1 Introduction
The therapeutic effects of many antibodies used to treat cancer have been found to arise
from the recruitment of immune effector cells by engaging Fc receptors (FcRs) (1). The Fcy
family of receptors recognizes immunoglobulins (IgGs). In humans, cross-linking of the
activating receptors FcyRIA, FcyRIIA (RIIA) and FcyRIIIA (RIIIA) triggers endocytosis and
phagocytosis, release of cytokines, chemokines and lytic granules, oxidative burst, and other
effector functions, whereas the sole inhibitory receptor FcyRIIB (IIB) regulates and down-
modulates these effects. The high affinity FcyRIA is likely occupied by soluble IgG rather than
by immune complexes and is not thought to play a significant role in mediating cytotoxic effects
(1, 2). In contrast, RIIA, RIIB, and RIIIA have micromolar affinity constants for the various IgG
subclasses and are triggered by opsonized antigen. For a given IgG, the ratio of affinities to
activating FcyRs over the inhibitory FcyR, termed the A/I ratio, is hypothesized to correlate with
antibody efficacy, with the rank order of IgG subclass activity in a murine model reflecting the
rank. order of A/I ratios (3).
Several lines of evidence suggest that increasing the A/I ratio could be a promising
approach to increasing the efficacy of antibody therapeutics. A single nucleotide polymorphism
of RIIIA has been correlated with differential outcome in several antibody cancer therapy
clinical trials. The 158V form, which has a higher affinity for IgG1 compared to 158F, is
associated with better response to rituximab (4-7) and trastuzumab (8), both IgG1 therapeutics.
Knockout mice lacking RIIB can be treated with much lower antibody concentrations to reduce
tumor growth and metastasis as compared to wild type mice (9). Dhodapkar et. al demonstrated
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that selective blockade of RIIB on dendritic cells causes them to mature and to induce T cell
immunity much more efficiently when exposed to opsonized tumor cells (10). These studies
show the beneficial effects of increasing the A/I ratio by altering the receptor part of the equation,
and it is not surprising that several groups have applied protein engineering principles in attempts
to achieve the same goal by modifying the IgGs (2).
Mutations in the Fc portion of IgGs that improve A/I ratios have been found by alanine
scanning (11), algorithmic prediction (12), and yeast surface display (13, 14). While improved
activities in in vitro antibody-dependent cellular-mediated cytotoxicity (ADCC) assays were
demonstrated, the best clones improved the A/I ratios (either RIIA/RIIB or RIIIA/IIB) by only
around 10-fold (12, 13). For one protein surface to achieve simultaneous gains in binding affinity
to RIIA and RIIIA while maintaining or decreasing affinity to RIIB is intrinsically difficult; it is
made all the more challenging because the extracellular domains of RIIA and RIIB are 93%
homologous (2). Instead of Fc engineering, an alternative approach is to create bispecific
antibodies where one "arm" engages an activating FcR, as has been achieved with her2-RIIIA
specificity in both scFv (15) and IgG (16) formats. In the IgG format, RIIB affinity is
undiminished, whereas in the scFv format, RIIB binding is abolished at the cost of also
eliminating RIIA binding. For single agent therapy, it would be ideal not to have to choose
between activating either RIIA or RIIIA. On one hand, NK cells, which are almost entirely
responsible for lysis during in vitro ADCC assays using peripheral blood mononuclear cells
(PBMCs), express RIIIA but not RIIA or RIIB (2). On the other hand, in vivo, the anti-tumor
activity of the most effective murine IgG subclass, IgG2a, is primarily dependent on the balance
between FcyRIV and FcyRIIB, making it unlikely that NK cells are responsible as they express
neither receptor (1, 3).
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Here, we present a novel approach for developing IgG-based anti-tumor therapeutics with
greatly enhanced A/I ratios by fusing IgGs to two different fibronectin (Fn3) domains, one
engineered to bind selectively to RIIA over RIIB and the other to bind selectively to RIIIA. The
Fc portion of the IgG is prevented from engaging any of the FcyRs by eliminating the required
N-linked glycosylation using the N297Q mutation (14, 17). Aglycosylated Fc, however, retains
binding to the neonatal Fc receptor FcRn that recycles IgGs and is responsible for their unusually
long serum half-lives (11). The tenth type III domain of human Fn3 is small (-10 kDa), stable,
and is a validated scaffold for performing directed evolution to bind to a variety of targets (18-
27). Fn3 is a P-sandwich with an immunoglobulin-like fold; three exposed loops termed BC, DE,
and FG are structurally analogous to antibody complementarity-determining regions (CDRs).
Since each Fn3 domain is engineered separately, the RIIA-binding domain and the RIIIA-
binding domain need not bind to the same surface of the FcRs, with the potential to achieve
higher A/I ratios than achievable with a single molecule. Another advantage over directly
engineering the Fc portion is the ability to "sample" differences in amino acid sequence between
RIIA and RIIB that lie outside the Fc-FcR interface, potentially permitting greater discrimination
between the highly homologous pair of FcRs.
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D.2 Materials and Methods
D.2.1 Narve Yeast Libraries and Culture Conditions
Three yeast surface display libraries of Fn3 were combined for screening. The G2 library
has BC, DE, and FG loops randomized in both length and composition (27); in the G4 library,
the amino acid composition of the loops is also biased towards that in antibody CDRs (Hackel,
BJ, unpublished). In the YS library, the BC and FG loops consist solely of Tyr and Ser residues
(BJ Hackel, unpublished). In general, yeast libraries and individual clones were cultured in SD-
CAA (2% dextrose, 0.67% yeast nitrogen base, 0.5% casamino acids, 0.07 M sodium citrate, pH
4.5) at 300 C, 250 rpm to an OD600 of 2-7 and induced in SG-CAA (SD-CAA with galactose
replacing dextrose) at an initial OD600 of-I for 12-16 h at 300C, 250 rpm.
D.2.2 Library Screening using Magnetic Beads
Soluble, singly biotinylated human FcRs were provided by the Ravetch group, the
Rockefeller University, NY. The method of screening yeast surface display libraries for weak
binders using antigen-loaded magnetic beads was developed and validated by Ackerman and
colleagues in the Wittrup group (unpublished). Stoichiometric amounts of each FcR were
incubated individually with 4 x 106 Biotin Binder Dynabeads (Invitrogen, Carlsbad, CA, -6 x
106 biotin binding site per bead) overnight at 40C, then washed twice using the Dynal MPC
magnet. Every library sort against an FcR was preceded by two negative sorts to deplete
streptavidin and biotin binders. Briefly, yeast cells were incubated for 45 min at 40C with 8 x 106
untreated beads or beads partially coated with biotin and/or biotin-PEG (Laysan Bio, Arab, AL)
in 2 ml PBS + 0.1% bovine serum albumin (PBSA), after which the tube was placed in the
magnet for 5 min and the free yeast collected. For positive selection, the depleted library was
incubated for 3 h at 40C with the FcR-coated beads before magnetic separation. The bead-bound
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yeast were washed, with the number of wash steps (1-3), duration (1 - 15 min) and temperature
(40 C or 200 C) varying as the sorts progressed to maintain the number of retrieved yeast cells at
around 105 - 5 x 106. The retrieved yeast cells (with beads) were cultured in 50 ml SD-CAA and
the beads were removed using the magnet prior to induction.
In the initial sorts, 8 x 109 yeast cells from the naive Fn3 libraries were screened against
RIIA in a single tube, after which the unbound yeast were screened against RIIIA. For
subsequent sorts, enough cells were screened such that the number of expressing cells was
approximately ten-fold larger than the maximum library diversity. In addition to varying the
washing procedure, the stringency of the selections was also increased by reducing the avidity.
From the sixth sort onwards, the number of moles of biotinylated FcR was reduced to -20% of
the number of biotin-binding sites on the beads (although the number of beads used was
doubled), which was further reduced to 5% for the final sort against RIIIA. The remaining
binding sites were occupied by excess biotin-PEG to reduce streptavidin exposure. Also from the
sixth sort onwards, the induction time was reduced to 2.5 h to reduce the number of Fn3 domains
expressed per yeast cell. After a total of eight sorts interspersed with four rounds of mutagenesis
as described below, the resulting yeast libraries exhibited clear labeling by the respective FcR (in
tetrameric form bound to streptavidin) and magnetic bead sorts were abandoned in favor of
fluorescence activated cell sorting (FACS).
D.2.3 Fn3 Mutagenesis and Electroporation
After every two sorts (or three in the case of RIIA FACS sorts), the plasmid DNA was
rescued from the yeast libraries and subjected to error-prone PCR essentially as described
previously (27). Briefly, a 50 gl 15-cycle error-prone PCR reaction was performed to amplify the
entire Fn3 gene using 0.5 igM of each primer (see Table D.1), 0.2 mM of each dNTP, 2 mM each
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of 8-oxo-dGTP and dPTP (TriLink, San Diego, CA), Taq enzyme and Thermopol buffer (New
England Biolabs, Ipswich, MA) and plasmid DNA recovered from 2 x 107 yeast cells (Zymoprep
II kit, Zymo Research, Orange, CA). At the same time, three other PCR reactions were
performed to mutagenize the BC, DE, and FG loops individually using the appropriate primers
(Table D.1) and 20 mM each of 8-oxo-dGTP and dPTP. The error-prone PCR products were
extracted from agarose gel and amplified by conventional PCR reactions (400 la per product)
using shortened (23-27 bp) versions of the above primers. The three loop products were
precipitated using PelletPaint (Novagen, Madison, WI), dissolved together in 3 il of water, and
mixed with 2 lg of plasmid vector digested to remove the BG loop through the FG loop
(NcoIISmaIINdeI-cut pCT-Fn3-Loop). The gene product was likewise concentrated down to 1 gl
in water and mixed with 2 plg of plasmid vector digested to remove the entire Fn3 gene as well as
the (G4S)3 linker (PstI/NdeI/BamHI-cut pCT-Fn3-Gene). From the fourth round of mutagenesis
onwards, the mutagenized loops were also mixed with 1-2% of loops derived from the naive
libraries to increase loop diversity. Each DNA mix was electroporated into 100 pl
electrocompetent EBY100 yeast (from 25 ml of culture) divided between two cuvettes as
described previously (28).
Table D.1. Mutagenesis primers and shortened amplification primers (underlined)
Name Sequence Target
W5 CGACGATTGAAGGTAGATACCCATACGACGTTCCAGACTACGCTCTGCAG
W3 ATCTCGAGCTATTACAAGTCCTCTTCAGAAATAAGCTTTTGTTCGGATCCFn3gene
BC5new GGGACCTGGAAGTTGTTGCTGCGACCCCCACCAGCCTACTGATCAGCTGG
Lbc3 TGAACTCCTGGACAGGGCTATTTCCTCCTGTTTCTCCGTAAGTGATCCTGTAATA BCloop
Lde5 CAQGATCACTTACGGAGAAACAGGAGGAAATAGCCCTGTCCAGGAGTTCACTGTG
Lde3 CATACACAGTATGGTATAATCAACTCCAGGTTTAAGGCCGCTATGGTAG DE loop
Lfg5 ACCATCAGCGGCCTTAAACCTGGAGTTGATTATACCATCACTGTGTATGCTGTC
FG3new GATCCCTGGGATGGTTTGTCAATTTCTGTTCGGTAATTAATGGAAATTGG FG loop
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D.2.4 Library Screening by FACS
For flow cytometry, biotinylated FcRs were incubated with streptavidin-PE (premium
grade, Invitrogen) or streptavidin-Alexa Fluor 647 at a 4:1 molar ratio for at least 30 min at room
temperature (RT) before use. After the eighth magnetic bead sort, the library evolved to bind to
RIIIA did not display any binding to RIIB tetramer, thus further selections by FACS were
focused only on improving affinity to RIIIA. Yeast libraries were incubated with PE-tagged
RIIIA tetramer (at decreasing concentrations with successive sorts) in a volume of PBSA
ensuring at least 3-fold excess of RIIIA over Fn3 domains for 1 h at RT. The yeast was then
centrifuged and all the supernatant except for 0.1-0.5 ml was removed. Chicken a-c-myc-Alexa
Fluor 647 (made by using the Microscale Protein Labeling Kit on the unconjugated IgY, both
from Invitrogen) was then added prior to incubation on ice for 30 min. The yeast cells were
sorted on a BD FACSAria, selecting 0.1-0.5% of the cells with the highest PE to Alexa Fluor
647 fluorescence ratio, which were collected and grown up in 5 ml SD-CAA.
For the library evolved to bind to RIIA, some binding to RIIB tetramer was also seen
after magnetic sorting. Therefore, FACS selections for decreased affinity to RIIB were carried
out in alternation with selections for increased affinity to RIIA (performed analogously to the
RIIIA affinity sorts). For these selectivity sorts, yeast cells were incubated with Alexa Fluor 647-
tagged RIIA tetramer and a higher concentration of PE-tagged RIIB tetramer for 1 h at RT prior
to FACS. The cells exhibiting high RIIA binding with little or no RIIB binding were selected.
D.2.5 Characterization ofIndividual Clones
Plasmid DNA was recovered from the later library generations (Zymoprep II kit) and
transformed into competent DH5a bacteria (Invitrogen). Individual colonies (usually ten) were
grown, miniprepped, and sequenced, as well as re-transformed into EBY100 yeast (EZ Yeast
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Transformation Kit, Zymo Research). The resulting clones were cultured in SD-CAA and
induced in SG-CAA for analysis. To rapidly compare different clones, 0.1 OD.ml aliquots of
yeast were labeled with a low and a high concentration of PE-tagged RIIA (1 nM, 30 nM) or
RIIIA (0.3 nM, 10 nM) tetramer for 1 h at RT prior to flow cytometry (Coulter Epics XL). The
apparent tetramer Kd was estimated from the ratio of the two mean fluorescence readings. To
measure the apparent tetramer Kd more accurately for selected clones, yeast cells were washed
and incubated with 7-8 different concentrations of PE-tagged tetramer spanning 3-4 orders of
magnitude for 2 h at RT. The labeling volumes (in PBSA) were chosen to give at least a 10-fold
excess of FcR over Fn3. The yeast cells were centrifuged and washed with 0.5 ml PBSA for
analysis by flow cytometry. The Kd value was determined by fitting the data to the equation y =
A[tetramer]/([tetramer] + Kd) + B.
D. 2.6 Expression and Purification ofMBP-Fn3 Fusion Proteins
Selected Fn3 domains were subcloned into the pMal-c2x vector (New England Biolabs)
for expression in E. coli as a C-terminal fusion to maltose-binding protein (MBP). A forward
primer adding a flanking AvaI restriction site followed by the TEV protease site LGENLYFQS
and a reverse primer adding a Stop codon and a XbaI site were used to amplify each Fn3 gene
sequence. The AvaI/XbaI-digested PCR product was ligated to the similarly digested pMal-c2x
backbone. After sequence confirmation, the resulting plasmid was transformed into either
Rosetta(DE3) or Rosetta-gami 2(DE3) (Stratagene, La Jolla, CA) for expression. Freshly
transformed colonies were cultured to saturation in 5 ml antibiotic-supplemented LB + glucose
(10 g tryptone, 5 g yeast extract, 5 g NaC1, 2 g glucose in 1 L water) at 370C, 250 rpm. These
starter cultures were used to inoculate 100 ml (Rosetta) or 200 ml (Rosetta-gami) of antibiotic-
free LB + glucose at a 1:100 ratio, which were then induced with 0.3 mM IPTG when the OD600
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reached 0.6. The bacteria were pelleted by centrifugation and frozen after 1 h induction at 370 C.
The thawed pellets were resuspended in 5 ml cold column buffer (20 mM Tris-HC1, pH 7.4, 200
mM NaCl, 1 mM EDTA) with Complete Protease Inhibitor Cocktail (Roche Applied Science,
Indianapolis, IN) and lysed by sonication. After centrifuging at 20,000 x g, 15 min, 4°C, the
supernatant was loaded onto 2 ml amylose resin (New England Biolabs) pre-equilibrated with
column buffer, washed with 50 ml column buffer, and eluted with column buffer containing 10
mM maltose. The eluate was concentrated and buffer-exchanged into PBS using an Amicon
Ultra-15 device (Millipore, Billerica, MA).
D.2. 7 Surface Plasmon Resonance Analysis
Steady state affinity measurements were performed on a Biacore T100 biosensor by Rene
Ott of the Ravetch group. MBP-Fn3 fusion proteins were immobilized to CM5 sensor chips
(Biacore) by standard amine coupling. Soluble RIIA, RIIB or RIIIA were injected in 5 different
concentrations through flow cells at room temperature in HBS-EP running buffer (Biacore) for 3
min at a flow rate of 30 jl/ min and dissociation was observed for 10 min. Dissociation constants
were calculated after subtraction of background binding to a control flow cell using Biacore
T100 Evaluation software.
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D.3 Results
D.3.1 Selection and Affinity/Selectivity Maturation ofFn3 Binders to FcRs
To select for Fn3 domains that bind weakly to RIIA and RIIIA from na've yeast surface
display libraries, we performed magnetic bead sorting using streptavidin-coated beads loaded
with biotinylated FcR, capitalizing on the highly multivalent interactions between yeast cells and
beads. The libraries were mutagenized by error-prone PCR (the entire Fn3 gene as well as
focused mutagenesis of the BC, DE, and FG loops) on average after every two sorts. As the
selections progressed, in addition to increasing the wash stringency, the avidity was reduced by
decreasing the surface density of both Fn3 and FcR. Unless otherwise stated, the 131R allele of
RIIA and the 158F 176F allele of RIIIA were used. After eight magnetic sorts and four rounds of
mutagenesis, both libraries were highly enriched for yeast cells that were clearly labeled by 25
nM of their respective FcR target in tetrameric form (complexed with streptavidin-PE). The
RIIIA-binding library showed no binding to RIIB tetramer at 100 nM (not shown); therefore,
continued affinity maturation by FACS was performed by standard methods (28, 29). To avoid
unwanted side reactions between FcR and any mammalian IgG, a fluorescently tagged chicken
IgY was used for expression labeling. The RIIA-targeted library displayed some binding to RIIB
tetramer, albeit at a reduced level compared to RIIA tetramer (not shown), which was
unsurprising given the high level of homology between the two receptors. Alternating sorts for
affinity maturation and selectivity were performed. For the selectivity sorts, libraries were co-
labeled with a high concentration of PE-tagged RIIB tetramer and a low concentration of Alexa
Fluor 647-tagged RIIA tetramer to enrich clones that discriminated between the two receptors.
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D.3.2 Analysis of Selected Clones
Our goal was to engineer Fn3 domains with roughly the same affinity for RIIA and RIIB
as native IgGs (Kd - 10-5-10-6 M), such that the eventual IgG-Fn3 fusions would activate immune
cells after antigen opsonization but not in soluble form. After four FACS sorts (with one round
of mutagenesis), the RIIIA-binding library was clearly labeled by 1 jiM of monovalent RIIIA
(not shown) and the Kd was estimated to be in the range of 0.5-5 gM (necessarily a poor estimate
since saturation could not be reached and dissociation was rapid compared to handling time).
Individual clones from this and previous libraries were sequenced and their relative affinities
were estimated by determining the ratio of mean fluorescence intensities when labeled with a
low versus high concentration of FcR tetramer. The tightest binder was IIIA626 (sequence in Fig.
D.1A), which was then further characterized by titration to yield an apparent Kd of 0.13 nM for
RIIIA tetramer (Fig. D.1B). Another clone with roughly five-fold lower tetramer affinity was
also selected for further characterization in case the monovalent Kd of IIIA626 turned out to be
too low. The apparent Kd of IIIA537 for RIIIA tetramer was found to be 0.67 nM (Fig. D.1B).
For the RIIA-binding library, no improvement in apparent Kd was seen during the eighth
FACS sort (an affinity sort). Of the individual clones that were analyzed, IIA726 from the
seventh FACS sort had the highest affinity for RIIA tetramer. From the titration curve, the
apparent Kd for RIIA tetramer was 1.2 nM, whereas binding to RIIB tetramer was undetectable
even at 100 nM (Fig. D.1C). A new library was subsequently created by mutagenizing IIA726.
After two sorts, clone IIA827 with a single mutation (188S) was identified as having improved
affinity for RIIA tetramer (0.54 nM apparent Kd) while retaining undetectable binding for 100
nM RIIB tetramer (not shown). Unlike the cysteine-free RIIIA binders, IIA726 and IIA827
contain a pair of Cys residues in the BC and DE loops (Fig. D.1A).
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Fig. D.1, Sequences and binding curves of selected Fn3 domains to target FcRs.A, Sequence alignment with wild type Fn3. Dots indicate conserved positions whereas dashesindicate deletions.
B, Yeast surface-displaying clones IIIA537 and IIIA626 were incubated with variousconcentrations of RIIIA F tetramer (complexed to streptavidin-PE) for 2 h at RT. The yeastcells were washed and analyzed by flow cytometry. The mean PE fluorescence intensities werefitted to binding isotherms (with proportionality and background constants) to give apparentRIIIA tetramer Kd values of 0.67 nM for IIIA537 and 0.13 nM for IIIA626.C, Yeast surface-displaying clone IIA726 were incubated with various concentrations of eitherRIIA 13 1R or RIIB tetramer (complexed to streptavidin-PE) for 2 h at RT. The yeast cells werewashed and analyzed by flow cytometry. The curve fit for the RIIA data points is to a bindingisotherm (apparent Kd = 1.2 nM) with proportionality and background constants.D, Each Fn3 domain was produced as a C-terminal fusion to MBP and biotinylated. Pre-incubated mixtures of each biotinylated MBP-Fn3 with streptavidin-PE were used to labelhuman PBMCs for analysis by flow cytometry. Cells were gated by forward and side scatter toexclude lymphocytes. Gray fill histogram: MBP alone, black line: MBP-IIA726, gray line: MBP-IIIA537, dotted line: MBP-IIIA626.
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D.3.3 Soluble MBP-Fn3 Fusion Proteins
The selected Fn3 domains were each produced as C-terminal fusions to MBP for
determining the affinities for FcRs using surface plasmon resonance (SPR). MBP was chosen as
a fusion partner because it contains many lysine residues available for amine coupling and acts
as a chaperone, increasing the yields of soluble protein expressed in E. coli (30). MBP fusions of
IIIA537, IIIA626 and IIA726 were initially expressed in the strain Rosetta(DE3) at high yields
(3-5 mg from 100 ml of culture) and purified by amylose affinity chromatography. MBP-IIIA537
and MBP-IIIA626 were able to block the binding of PE-tagged RIIIA tetramer to yeast surface-
displaying IIIA537 (not shown). The ability of MBP-IIA726 to block RIIA tetramer binding to
yeast surface-displaying IIA726 was much lower (not shown), leading us to hypothesize that
disulfide bond formation between the BC and DE loops was important for binding activity but
had failed to occur. Accordingly, after MBP-IIA726 was incubated with 10 pM of CuSO4 for 1 h
at RT (cupric-catalyzed oxidation (31)), the blocking ability was significantly enhanced (not
shown). MBP-IIA726 was then produced in Rosetta-gami 2, a strain containing mutations to
promote disulfide bond formation in the cytosol. The blocking ability of this preparation was
high and not significantly improved by incubation with CuSO4 (not shown).
To determine whether the Fn3 domains were able to recognize FcRs expressed on cell
surfaces, each MBP-Fn3 fusion protein was biotinylated, complexed with streptavidin-PE and
used to label human peripheral blood mononuclear cells (PBMCs). Since B and T cells do not
express RIIA or RIIIA, lymphocytes were excluded by forward and side scatter during flow
cytometry analysis. MBP-IIA726 labeled the non-lymphocyte PBMCs more than the control of
MBP alone, and a subpopulation of cells were distinctly labeled by MBP-IIIA537 and MBP-
IIIA626 (Fig. D.1D). Although the shift in fluorescence intensity for MBP-IIA726 was small
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(not unexpected because of the low avidity of streptavidin complexes), it was unlikely to be non-
specific because no such shift was observed with the lymphocytes (not shown).
These three MBP-Fn3 fusion proteins as well as MBP-IIA827 (also produced in Rosetta-
gami 2) were subjected to SPR analysis to determine the monovalent dissociation constants for
the FcRs (Table D.1). MBP-IIIA537 and MBP-IIA626 each have single-digit micromolar
affinities for their respective antigens, similar to the affinity of IgG1 for the activating FcRs,
whereas MBP-IIIA626 and MBP-IIA827 (for RIIA 131R) have sub-micromolar dissociation
constants. The RIIIA binders showed no binding to RIIA and RIIB, and the RIIA binders were
also highly selective for RIIA over RIIB. Except for MBP-IIA827, the proteins had similar
affinities for the two tested isoforms of their target FcR.
Table D.1. Dissociation constants of MBP-Fn3 fusion proteins for FcRs.
Protein Kd (gM) for FcR
RIIA RIIA RIIB RIIIA RIIIA
131H 131R 158F 176F 158F 176V
MBP-IIIA537 nb nb nb 4.9 3.9
MBP-IIIA626 nb nb nb 0.53 0.54
MBP-IIA726 3.3 3.2 nb nb nb
MBP-IIA826 6.2 0.85 ud nb ud
nb: no binding observed ud: binding was too weak for Kd to be determined (>10 gM)
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D.4 Conclusion and Future Work
Using yeast surface display, we have engineered Fn3 domains that selectively bind to the
activating FcRs RIIA or RIIIA with little or no binding to the inhibitory RIIB receptor. Fusing
these to antibodies represents a promising strategy to produce cancer therapeutics with
heightened abilities to recruit immune effectors.
The B16-F10 melanoma lung metastasis mouse model has been used by Ravetch and
colleagues to study tumor cytotoxicity effects mediated by antibodies and FcRs (3, 9, 32). The
injected melanoma cells express the gp75 antigen, which is recognized by the TA99 monoclonal
antibody. The Ravetch group is currently developing FcyR humanized mice (transgenic mice
with individual human FcRs are already available), which will allow human IgGs and our human
FcR-binding Fn3 domains to be investigated in vivo (33). We have already grafted the TA99
heavy and light variable regions onto human aglycosylated IgG1 (N297Q) heavy and light chain
expression vectors. We have also created light chain-Fn3 expression cassettes for each of the
four selected Fn3 domains. We plan to co-transfect two light chain-Fn3 plasmids (IIIA537 paired
with IIA726 or IIIA626 paired with IIA827) and the heavy chain plasmid into HEK293 cells to
secrete assembled IgG fusion proteins with the ability to bind gp75, RIIA and RIIIA. Since
complexes with two identical light chain-Fn3 fusions will also be formed, purification of the
trispecific complex will be facilitated by using different tags on on the IIA binders versus the
IIIA binders (His6 and Strep-tag II). A control IgG-Fn3 fusion protein bearing irrelevant
lysozyme-binding Fn3 domains will also be produced. An alternative format for attaching two
different Fn3 domains to one IgG molecule is to fuse each Fn3 to the C-terminus of one heavy
chain. Heterodimeric assembly of the heavy chains can be promoted using the "knobs-into-
holes" technique (complementary mutations in the CH3 domains) (34).
145
We have shown that the selected Fn3 domains bind epitopes of the FcRs that are
accessible on the cell surface, but is is as yet unknown if the topology of either IgG-Fn3 format
in an immune complex is amenable to productively engaging and cross-linking FcRs. Therefore,
it is likely that in vitro experiments will be performed on either human immune cells (using a
donor with the appropriate FcR alleles), cells derived from the FcR humanized mouse, or cell
lines transgenic for the FcRs. Dendritic cell maturation can also be studied in vitro to investigate
the consequences of engaging activating FcRs without applying the RIIB brakes.
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